# AUTHOR INDEX


Abeloff M, *see* Allred DC
Abeloff MD, *see* Clark GM
— *see* Tormey DC
Acaba L, *see* Gulati S
Achterrath W, *see* Gatzemeier U
Ackery D, *see* Lashford LS
Acord P, *see* MacKenzie MR
Ad Hoc Committee on Cancer Pain of the American Society of Clinical Oncology. Cancer pain assessment and treatment curriculum guidelines, 1976
Adamo DO, *see* Sarosy G
Adamson PC, Balis FM, McCully CL, Godwin KS, Poplack DG. Methotrexate pharmacokinetics following administration of recombinant carboxypeptidase-$G_2$ in rhesus monkeys, 1359
— *see* Smith MA
Adler KM, *see* Lum BL
— *see* Yahanda AM
Adrover E, *see* Martín M
Advanced colorectal cancer meta-analysis project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate, 896
Agerlin N, *see* Bach F
Ahn C, *see* Margolin KA
Aisner J, Goutsou M, Maurer LH, Cooper R, Chahinian P, Carey R, Skarin A, Slawson R, Perry MC, Green MR. Intensive combination chemotherapy, concurrent chest irradiation, and warfarin for the treatment of limited-disease small-cell lung cancer: A Cancer and Leukemia Group B pilot study, 1230
Akman SA, *see* Margolin KA
Albertioni F, *see* Liliemark J
Alberts DS, Green S, Hannigan EV, O'Toole R, Stock-Novack D, Anderson P, Surwit EA, Malvlya VK, Nahhas WA, Jolles CJ. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: Final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer, 706
Alexander E III, *see* Loeffler JS
Alexanian R, *see* Dimopoulos MA
Alison RE, *see* Sturgeon JFG
Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff M, Eudey L, McGuire WL. HER-2/*neu* in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma, 599
Almadrones L, *see* Markman M
Altschuler G, *see* Castleberry RP
Alvord WG, *see* Smith JW II
Ambinder R, *see* Wagner JE
Ames FC, *see* Buzdar AU
Anastasopoulos E, *see* Kosmidis PA
Anbazhagan R, *see* Gusterson BA
Andersen J, *see* Nichols CR
Andersen JW, Harrington D. Meta-analyses need new publication standards (editorial), 878
— *see* Rubin EH
— *see* Weisdorf DJ
Anderson KC, *see* Soiffer RJ
Anderson L, *see* Hancock BW
Anderson P, *see* Alberts DS
Andrien F, *see* Bosly A
Andrieu J-M, *see* Tourani J-M
Andriole GL. Serum prostate-specific antigen: The most useful tumor marker (editorial), 1205
Andrulis I, *see* Levine MN
Anselmo AP, *see* Biti GP
Antman K, Ayash L, Elias A, Wheeler C, Hunt M, Eder JP, Teicher BA, Critchlow J, Bibbo J, Schnipper LE, Frei E III. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy, 102
— *see* Ayash LJ
Appelbaum F, *see* Chopra R
Appelbaum FR, *see* Bensinger WI
— *see* Clift RA
Applewhite A, *see* Meyers PA
Ariyoshi Y, *see* Fukuoka M
Armand JP, *see* Robert J
Aronson FR, *see* Weiss GR
Aronson L, *see* Smith MA
Arriagada R, Kramar A, Le Chevalier T, De Cremoux H. Competing events determining relapse-free survival in limited small-cell lung carcinoma, 447
Artim R, *see* MacKenzie MR
Assendelft A, *see* Niiranen A
Atiq OT, *see* Kelsen D
Atkins MB, Vachino G, Tilg HJ, Karp DD, Robert NJ, Kappler K, Mier JW. Phase I evaluation of thrice-daily intravenous bolus interleukin-4 in patients with refractory malignancy, 1802
— *see* Weiss GR
Atkinson CH, *see* Ellis PA
Atkinson K, *see* Copelan EA
Attisano C, *see* Foa R
Attubato M, *see* Speyer JL
Audy J-CR, *see* Rougier P
Auzanneau G, *see* Bosly A
Avalos BR, *see* Copelan EA
Ayash L, *see* Antman K
Ayash LJ, Wright JE, Tretyakov O, Gonin R, Elias A, Wheeler C, Eder JP, Rosowsky A, Antman K, Frei E III. Cyclophosphamide pharmacokinetics: Correlation with cardiac toxicity and tumor response, 995

Bacchi M, *see* Cocconi G
Bach F, Agerlin N, Sørensen JB, Rasmussen TB, Dombernowsky P, Sørensen PS, Hansen HH. Metastatic spinal cord compression secondary to lung cancer, 1781
Bachaud JM, *see* de Forni M
Bacoyiannis C, *see* Kosmidis PA
Bader JL, *see* Lichter AS
Bafaloukos D, *see* Kosmidis PA

Bagnulo S, *see* De Bernardi B
Baiocchi G, *see* Scambia G
Bajorin DF, *see* Ilson DH
Baker DK, Relling MV, Pui C-H, Christensen ML, Evans WE, Rodman JH. Increased teniposide clearance with concomitant anticonvulsant therapy, 311
Balis FM, *see* Adamson PC
— *see* Berg SL
— *see* Smith MA
Banks PLC, *see* Vogler WR
Bar MH, *see* Weiss GR
Barakat R, *see* Markman M
Barbui T, *see* Vitolo U
Barna B, *see* Budd GT
Barr RD, *see* Feeny D
Bartolucci AA, *see* Vogler WR
Barylak EJ, *see* Tormey DC
Bast RC Jr, *see* Daly L
Bastert G, *see* Diel IJ
Bastian A, *see* Foss FM
Battaglia F, *see* Scambia G
Bauters F, *see* Detourmignies L
— *see* Morel P
Baxevanis CN, *see* Kosmidis PA
Beatty P, *see* Bensinger WI
Beck TM, Hesketh PJ, Madajewicz S, Navari RM, Pendergrass K, Lester EP, Kish JA, Murphy WK, Hainsworth JD, Gandara DR, Bricker LJ, Keller AM, Mortimer J, Galvin DV, House KW, Bryson JC. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting, 1969
Behar C, *see* Oberlin O
Belanger C, *see* Michel G
Belfort R Jr, *see* Sanda MG
Belhani M, *see* Tourani J-M
Bell S, *see* Dropcho EJ
Belldegrun A, *see* Figlin RA
Bellesi GP, *see* Biti GP
Bellone G, *see* Foa R
Belt RJ, *see* Ravdin PM
Benedet JL, *see* Hoskins PJ
Benjamin RS, *see* Kleinerman ES
— *see* Vadhan-Raj S
Bennett MH, *see* Hancock BW
Bensinger WI, Buckner CD, Clift RA, Petersen FB, Bianco JA, Singer JW, Appelbaum FR, Dalton W, Beatty P, Fefer A, Storb R, Thomas ED, Hansen JA. Phase I study of busulfan and cyclophosphamide in preparation for allogeneic marrow transplant for patients with multiple myeloma, 1492
— *see* Clift RA
Benyunes MC, *see* Thompson JA
Benz LA, *see* Thompson JA
Beran M, *see* Kantarjian HM
Berchuck A, *see* Rodriguez GC
Berg DT, *see* Rubin EH
Berg SL, Balis FM, Zimm S, Murphy RF, Holcenberg J, Sato J, Reaman G, Steinherz P, Gillespie A, Doherty K, Poplack DG. Phase I/II trial and pharmacokinetics of intrathecal diaziquone in refractory meningeal malignancies, 143
Berger R, *see* Detourmignies L
Bergeron C, *see* Michel G
Bergsagel DE, Myeloma, melphalan, and meta-analysis (editorial), 178
Bernadet P, *see* de Forni M
Bernasconi C, *see* Vitolo U
Bernaudin F, *see* Michel G
Bernstein ML, Leclerc JM, Bunin G, Brisson L, Robison L, Shuster J, Byrne T, Gregory D, Hill G, Dougherty G, Scriver C, Lemieux B, Tuchman M, Woods WG. A population-based study of neuroblastoma incidence, survival, and mortality in North America, 323
Bertini M, *see* Vitolo U
Bertrand Y, *see* Oberlin O
Bettelheim R, *see* Gusterson BA
— *see* Neville AM
Beutler E, *see* Kay AC
Bevilacqua P, *see* Gasparini G
Bey P, *see* Oberlin O
Biagini C, *see* Biti GP
Bianco JA, *see* Bensinger WI
Bibbo J, *see* Antman K
Biddinger PW, *see* Yahalom J
Biesma B, *see* Postmus PE
Biggs JC, *see* Copelan EA
Biondi A, *see* Rovelli A
Bisagni G, *see* Cocconi G
Biti GP, Cimino G, Cartoni C, Magrini SM, Anselmo AP, Maurizi Enrici RM, Bellesi GP, Bosi A, Papa G, Giannarelli D, Ponticelli P, Papi MG, Rossi Ferrini PL, Biagini C, Mandelli F. Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin's disease: Eight-year update of an Italian prospective randomized study, 378
Bitran JD, *see* Williams SF
Black PMcL, *see* Loeffler JS
Blackstein ME, *see* Burkes RL
Blaise D, *see* Michel G
Blake K, *see* Soiffer RJ
Blakley RL, *see* Santana VM
Blanchette VS, *see* Coppes MJ
Blend MJ, Ronan SG, Salk DJ, Das Gupta TK. Role of technetium 99m-labeled monoclonal antibody in the management of melanoma patients, 1330
Blend R, *see* Sturgeon JFG
Blevins C, *see* Margolin KA
Blum RH, *see* Speyer JL
Blumenstein B, *see* Loehrer PJ Sr
Bobo H, *see* Goffman TE
Boldt DH, *see* Weiss GR
Bolufer P, Ricart E, Lluch A, Vazquez C, Rodriguez A, Ruiz A, Llopis F, Garcia-Conde J, Romero R. Aromatase activity and estradiol in human breast cancer: Its relationship to estradiol and epidermal growth factor receptors and to tumor-node-metastasis staging, 438
Bonadonna G, *see* Gianni AM
Boni C, *see* Cocconi G

Boni L, *see* De Bernardi B
Boracchi P, *see* Gasparini G
Borden EC, *see* Greiner JW
Bordigoni P, *see* Michel G
Borowitz M, *see* Trueworthy R
Borst JR, *see* Ravdin PM
Bosi A, *see* Biti GP
Bosl GJ, The late effects of germ cell tumor chemotherapy: More data are needed (editorial), 1375
— *see* Ilson DH
Bosly A, Coiffier B, Gisselbrecht C, Tilly H, Auzanneau G, Andrien F, Herbrecht R, Legros M, Devaux Y, Jaubert J, Pignon B, Michaux J-L, Humblet Y, Dupriez B, Thyss A, Lederlin P for the Group d'Etudes des Lymphomes de l'Adulte. Bone marrow transplantation prolongs survival after relapse in aggressive-lymphoma patients treated with the LNH-84 regimen, 1615
Botet J, *see* Kemeny N
Boudjema B, *see* de Forni M
Bouffet E, *see* Frappaz D
Bova FJ, *see* Ellis ER
Boyett J, *see* Budd GT
Brahimi S, *see* Tourani J-M
Braine HG, *see* Graham ML
Bramwell VHC, Burgers M, Sneath R, Souhami R, van Oosterom AT, Voûte PA, Rouesse J, Spooner D, Craft AW, Somers R, Pringle J, Malcolm AJ, van der Eijken J, Thomas D, Uscinska B, Machin D, van Glabbeke M. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: The first study of the European Osteosarcoma Intergroup, 1579
Bregni M, *see* Gianni AM
Breneman DL, *see* Foss FM
Breneman JC, *see* Foss FM
Brennan M, *see* Kelsen D
Brennan MF, *see* Gaynor JJ
Brescia FJ, Portenoy RK, Ryan M, Krasnoff L, Gray G. Pain, opioid use, and survival in hospitalized patients with advanced cancer, 149
Breslin M, *see* Shea TC
Brice P, *see* Morel P
Bricker LJ, *see* Beck TM
Brisigotti M, *see* De Bernardi B
Brisson L, *see* Bernstein ML
Brodsky I, *see* Lazarus HM
Brophy NA, *see* Lum BL
— *see* Yahanda AM
Brothers M, *see* Dropcho EJ
Broun GO, *see* Roth BJ
Broxmeyer HE, *see* Vadhan-Raj S
Brugger W, Frisch J, Schulz G, Pressler K, Mertelsmann R, Kanz L. Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following standard-dose combination chemotherapy with etoposide, ifosfamide, and cisplatin, 1452
Brugia M, *see* Cocconi G
Brugiere L, *see* Frappaz D
Brunat-Mentigny M, *see* Oberlin O
Brusamolino E, *see* Vitolo U
Bruzzi P, *see* De Bernardi B
Bryant G, *see* Wilson WH
Bryson JC, *see* Beck TM
Buchanan GR, *see* Wofford MM
Buckley M, *see* Kelsen D
Buckner CD, *see* Bensinger WI
— *see* Clift RA
Budd GT, Murthy S, Finke J, Sergi J, Gibson V, Medendorp S, Barna B, Boyett J, Bukowski RM. Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy, 804
Buescher ES, *see* Vadhan-Raj S
Bugat R, *see* de Forni M
Bukman A, *see* Osanto S
Bukowski RM, Tangen C, Lee R, Macdonald JS, Einstein AB Jr, Peterson R, Fleming TR. Phase II trial of chlorozotocin and fluorouracil in islet cell carcinoma: A Southwest Oncology Group study, 1914
— *see* Budd GT
Bulova SI, *see* Lazarus HM
Bundow D, *see* Krown SE
Bunin G, *see* Bernstein ML
Burger P, *see* Friedman HS
Burgers M, *see* Bramwell VHC
Burkes RL, Ginsberg RJ, Shepherd FA, Blackstein ME, Goldberg ME, Waters PF, Patterson GA, Todd T, Pearson FG, Cooper JD, Jones D, Lockwood G. Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non–small-cell lung cancer: Results of the Toronto phase II trial, 580
Bürki K, *see* Gusterson BA
Burns W, *see* Wagner JE
Burroughs J, *see* Jacobs C
Burroughs JN, *see* Jodrell DI
Burrows W, *see* Speyer JL
Bush WH Jr, *see* Thompson JA
Buter J, *see* Sleijfer DTh
Buzdar AU, Hortobagyi GN, Kau S-WC, Smith TL, Fraschini G, Holmes FA, Gutterman JU, Hug VM, Singletary SE, Ames FC, McNeese MD. Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte $\alpha$-interferon for stage II or III breast cancer, 1540
— *see* Jaiyesimi IA
Byrne M, *see* Coates A
Byrne T, *see* Bernstein ML

Cabanillas F, *see* Redman JR
Caillot D, *see* Solary E
Callender DPE, *see* Mueller BU
Canal P, *see* de Forni M
Canellos GP, The second chance for advanced Hodgkin's disease (editorial), 175
Canetta R, *see* Swenerton K
Canetta RM, *see* Jodrell DI
Caputo C, *see* Lerman C
Carbone A, *see* Foa R
— *see* Tirelli U
Carey R, *see* Aisner J
Carey RW, *see* Strauss GM

Carli M, *see* De Bernardi B
Carmichael J, *see* Swenerton K
Carpi A, *see* Cocconi G
Carrera CJ, *see* Kay AC
Carrié C, *see* Oberlin O
Carrié D, *see* de Forni M
Carroll A, *see* Trueworthy R
Carson DA, *see* Kay AC
Carter C, *see* Wilson WH
Carter D, *see* Haffty BG
Carter M, *see* Mulhern RK
— *see* Schell MJ
Carter RD, *see* Ravdin PM
Cartoni C, *see* Biti GP
Carver CS, *see* Pozo C
Casado A, *see* Martín M
Casale F, *see* De Bernardi B
Casasnovas R-O, *see* Solary E
Casper ES, *see* Gaynor JJ
Cassidy J, *see* Myers C
Cassileth PA, *see* Hochster HS
Cassuto-Viguier E, *see* Milano G
Castaigne S, *see* Detourmignies L
Castiglione M, *see* Gusterson BA
— *see* Neville AM
Castleberry RP, Shuster JJ, Altschuler G, Smith IE, Nitschke R, Winick N, McWilliams N, Joshi V, Hayes FA. Infants with neuroblastoma and regional lymph node metastases have a favorable outlook after limited postoperative chemotherapy: A Pediatric Oncology Group study, 1299
Cavallero GB, *see* Vitolo U
Ceci G, *see* Cocconi G
Chabner BA, Camptothecins (editorial), 3
Chahinian P, *see* Aisner J
Champlin RE, *see* Schiller GJ
Chapman D, *see* Kelsen D
Chappell RJ, *see* Ritter MA
Chastagner P, *see* Frappaz D
Chauffert B, *see* Solary E
Chawla SP, *see* Vadhan-Raj S
Cherng N, *see* Jacobs C
Cherng NC, *see* Roth BJ
Cheson BD, The purine analogs—A therapeutic beauty contest (editorial), 352, 868
— *see* Smith MA
Chevreau C, *see* de Forni M
Childs A, *see* Raghavan D
— *see* Sanda MG
Chisesi T, *see* Foa R
Chlebowski RT, Sayre J, Frank-Stromborg M, Lillington LB. Current attitudes and practice of American Society of Clinical Oncology-member clinical oncologists regarding cancer prevention and control, 164
Choi NC, *see* Strauss GM
Chomienne C, *see* Detourmignies L
Chompret A, *see* Oberlin O
Chopra R, Goldstone AH, Pearce R, Philip T, Petersen F, Appelbaum F, De Vol E, Ernst P. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: A case-controlled analysis of the European Bone Marrow Transplant Group registry data, 1690
Choyke P, *see* Myers C
Christensen ML, *see* Baker DK
Christian M, *see* Shea TC
Cicale MJ, *see* Ellis ER
Cimino G, *see* Biti GP
Ciobanu N, *see* Lazarus HM
Ciocca DR, *see* Osborne CK
Civin CI, *see* Graham ML
— *see* Kuerbitz SJ
Claessens RAMJ, *see* Oyen WJG
Clark GM, Mathieu M-C, Owens MA, Dressler LG, Eudey L, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff MD, McGuire WL. Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients, 428
— *see* Allred DC
Clark KC, *see* Pozo C
Clark PI, *see* Girling DJ
Clarke DH, Martinez AA. Identification of patients who are at high risk for locoregional breast cancer recurrence after conservative surgery and radiotherapy: A review article for surgeons, pathologists, and radiation and medical oncologists, 474
Clarke-Pearson DL, *see* Rodriguez GC
Clift RA, Buckner CD, Appelbaum FR, Schoch G, Petersen FB, Bensinger WI, Sanders J, Sullivan KM, Storb R, Singer J, Hansen JA, Thomas ED. Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia, 1723
— *see* Bensinger WI
Coates A, Gebski V, Signorini D, Murray P, McNeil D, Byrne M, Forbes JF for the Australian New Zealand Breast Cancer Trials Group. Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer, 1833
Cocconi G, Bisagni G, Ceci G, Bacchi M, Boni C, Brugia M, Carpi A, Di Costanzo F, Franciosi V, Gori S, Indelli M, Passalacqua R. Low-dose aminoglutethimide with and without hydrocortisone replacement as a first-line endocrine treatment in advanced breast cancer: A prospective randomized trial of the Italian Oncology Group for Clinical Research, 984
Cohen AM, *see* Minsky BD
Cohen HJ, *see* Roth BJ
Coiffier B, *see* Bosly A
Collin CF, *see* Gaynor JJ
Collins C, *see* Thompson JA
Collins J, *see* Gusterson BA
— *see* Neville AM
Colls BM, *see* Ellis PA
Colombani PM, *see* Graham ML
Colonna P, *see* Tourani J-M
Comis R, *see* Hudes GR
Comotti B, *see* Vitolo U
Conlon KC, *see* Smith JW II
Connaghan GD, *see* Smith MA
Conter V, *see* Rovelli A
Conti F, *see* Francini G
Conti JA, *see* Kemeny N

Cook J, *see* Goffman TE
Cook PA, *see* Mead GM
— *see* Read G
Coombes RC, *see* Jones AL
Cooper BW, *see* Lazarus HM
Cooper JD, *see* Burkes RL
Cooper M, *see* Myers C
Cooper R, *see* Aisner J
Cooper S, *see* Vadhan-Raj S
Copelan EA, Biggs JC, Avalos BR, Szer J, Cunningham I, Klein JP, Atkinson K, Kapoor N, Klein JL, Downs K, Tutschka PJ. Radiation-free preparation for allogeneic bone marrow transplantation in adults with acute lymphoblastic leukemia, 237
Coppes MJ, Zandvoort SWH, Sparling CR, Poon AO, Weitzman S, Blanchette VS. Acquired von Willebrand disease in Wilms' tumor patients, 422
Coral F, *see* Soiffer RJ
Corciulo P, *see* De Bernardi B
Corn BW, Goldwein JW, Evans I, D'Angio GJ. Outcomes in low-risk babies treated with half-dose chemotherapy according to the Third National Wilms' Tumor Study, 1305
Corstens FHM, *see* Oyen WJG
Costa P, *see* Kemeny N
Costa SD, *see* Diel IJ
Cotelingam JD, *see* Foss FM
Cottler-Fox M, *see* Wilson WH
Cowan K, *see* Lichter AS
Cowan KH, *see* Wilson WH
Cox K, *see* Raghavan D
Craft AW, *see* Bramwell VHC
Cram GP Jr, *see* Daly L
Crawford ED, *see* Loehrer PJ Sr
Crawford J, *see* Roth BJ
Creekmore SP, *see* Smith JW II
Creger RJ, *see* Lazarus HM
Crilley P, *see* Lazarus HM
Crist W, *see* Trueworthy R
Crist WM, *see* Kuerbitz SJ
Critchlow J, *see* Antman K
Crom W, *see* Santana VM
Crown J, *see* Gulati S
Cullen MH, *see* Read G
Cunningham D, *see* Mansi J
Cunningham I, *see* Copelan EA
Cunningham J, *see* Ziegler LD
Cunnion RE, *see* Sarosy G
Curti BD, *see* Smith JW II
Curtin J, *see* Markman M

da Costa F, *see* Mansi J
Dachowski LJ, *see* Goffman TE
D'Agay M-F, *see* Morel P
Dalton T, *see* Jacobs C
Dalton W, *see* Bensinger WI
Daly L, Ferguson J, Cram GP Jr, Hars V, George SL, McCarty KS Jr, Bast RC Jr. Comparison of a novel assay for breast cancer mucin to CA15-3 and carcinoembryonic antigen, 1057
Damsma O, *see* Postmus PE
Danforth DN Jr, *see* Lichter AS
d'Angelo T, *see* Lichter AS
D'Angio GJ, *see* Corn BW
— *see* Maity A
Das Gupta TK, *see* Blend MJ
Davidson H, *see* MacKenzie MR
Davidson NE. Out of the courtroom and into the clinic (editorial), 517
Davis BW, *see* Neville AM
Dawson N, *see* Myers C
De Bernardi B, Carli M, Casale F, Corciulo P, di Montezemolo LC, De Laurentis C, Bagnulo S, Brisigotti M, Marchese N, Garaventa A, Felici L, Lo Curto M, Viscoli C, Tamaro P, Rogers D, Boni L, Dini G, Bruzzi P. Standard-dose and high-dose peptichemio and cisplatin in children with disseminated poor-risk neuroblastoma: Two studies by the Italian Cooperative Group for Neuroblastoma, 1870
De Cicco M, *see* Tirelli U
De Cremoux H, *see* Arriagada R
de Forni M, Malet-Marino MC, Jaillais P, Shubinski RE, Bachaud JM, Lemaire L, Canal P, Chevreau C, Carrié D, Soulié P, Roché H, Boudjema B, Mihura J, Martino R, Bernadet P, Bugat R. Cardiotoxicity of high-dose continuous infusion fluorouracil: A prospective clinical study, 1795
de Gast GC, *see* Verdonck LF
de Jong J, Geijssen GJ, Munniksma CN, Vermorken JB, van der Vijgh JF. Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-/-leucyldoxorubicin and its metabolites in a phase I clinical trial, 1897
De Laat JAPM, *see* Osanto S
De Laurentis C, *see* De Bernardi B
de Pauw BE, *see* Oyen WJG
de Smet MD, *see* Sanda MG
De Vincenzo R, *see* Scambia G
De Vol E, *see* Chopra R
de Vries EGE, *see* Postmus PE
— *see* Sleijfer DTh
DeAngelis LM, Yahalom J, Thaler HT, Kher U. Combined modality therapy for primary CNS lymphoma, 635
DeBoer G, *see* Sagman U
DeGregorio MW, *see* Osborne CK
— *see* Wiebe VJ
Deisseroth A, *see* Kantarjian HM
deKernion J, *see* Figlin RA
Dekker AW, *see* Lokhorst HM
— *see* Verdonck LF
Delasalle K, *see* Dimopoulos MA
Delmoor E, *see* Lerman C
Delmotte J-J, *see* Lienard D
DelRosario RB, *see* Kaminski MS
Demard F, *see* Milano G
Demchak PA, *see* Weiss GR
Demers L, *see* Leitzel K
Demory JL, *see* Detourmignies L
deMoss E, *see* Lichter AS
Denham JW, *see* Gill PG
Dennin R, *see* Ziegler LD
Dershaw DD, *see* Yahalom J
Desablens B, *see* Tourani J-M

Desch CE, Lasala MR, Smith TJ, Hillner BE. The optimal timing of autologous bone marrow transplantation in Hodgkin's disease patients after a chemotherapy relapse, 200
Deshmukh AA, *see* Lee CR
Detourmignies L, Castaigne S, Stoppa AM, Harousseau JL, Sadoun A, Janvier M, Demory JL, Sanz M, Berger R, Bauters F, Chomienne C, Fenaux P. Therapy-related acute promyelocytic leukemia: A report on 16 cases, 1430
Devaux Y, *see* Bosly A
DeVita VT Jr, *see* Longo DL
Devitt PG, *see* Gill PG
di Celle PF, *see* Foa R
Di Costanzo F, *see* Cocconi G
di Montezemolo LC, *see* De Bernardi B
Di Nicola M, *see* Gianni AM
Díaz-Rubio E, *see* Martín M
Diel IJ, Kaufmann M, Goerner R, Costa SD, Kaul S, Bastert G. Detection of tumor cells in bone marrow of patients with primary breast cancer: A prognostic factor for distant metastasis, 1534
Dimopoulos MA, Goldstein J, Fuller L, Delasalle K, Alexanian R. Curability of solitary bone plasmacytoma, 587
Dini G, *see* De Bernardi B
DiPetrillo T, *see* Wazer DE
Djuric L, *see* Jeremic B
Dnistrian A, *see* Rusch VW
Dodge R, *see* Rodriguez GC
Doherty K, *see* Berg SL
Doherty M, *see* Gulati S
Dombernowsky P, *see* Bach F
— *see* Pedersen-Bjergaard J
Donehower RC, *see* Rowinsky EK
Donovan A, *see* Leichman L
Doroshow JH, *see* Margolin KA
— *see* Weiss GR
Dorr TM, *see* Ravdin PM
Dougherty G, *see* Bernstein ML
Downs K, *see* Copelan EA
Dressler LG, *see* Clark GM
Dropcho EJ, Rosenfeld SS, Morawetz RB, Vitek J, Brothers M, Gorum T, Bell S, Gillespie GY, Glantz M, Mahaley MS Jr, Schold SC Jr for the CNS Cancer Consortium. Preradiation intracarotid cisplatin treatment of newly diagnosed anaplastic gliomas, 452
Drouin P, *see* Swenerton K
Du M, *see* Grunewald R
Dubousset J, *see* Oberlin O
Dubowy RL, *see* Graham ML
Duffey PL, *see* Longo DL
Dumas M, *see* Solary E
Duncan W, *see* Sturgeon JFG
Dupriez B, *see* Bosly A
— *see* Morel P
Dutcher JP, *see* Weiss GR

Easton D, *see* Jones AL
Eddy DM. High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer, 657
Eder JP, *see* Antman K
— *see* Ayash LJ
Egorin MJ, *see* Jodrell DI
Ehsan MN, *see* Lum BL
Einhorn LH, *see* Jacobs C
— *see* Loehrer PJ Sr
— *see* Nichols CR
— *see* Roth BJ
Einstein AB Jr, *see* Bukowski RM
Einzig AI, Wiernik PH, Sasloff J, Runowicz CD, Goldberg GL. Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma, 1748
Eisenberg PD, *see* LeVeque FG
Elias A, *see* Antman K
— *see* Ayash LJ
Elias AD, *see* Strauss GM
Elias D, *see* Rougier P
Ellis ER, Marcus RB Jr, Cicale MJ, Springfield DS, Bova FJ, Graham-Pole J, Enneking WF, Spanier SS, Million RR. Pulmonary function tests after whole-lung irradiation and doxorubicin in patients with osteogenic sarcoma, 459
Ellis PA, Fitzharris BM, George PM, Robinson BA, Atkinson CH, Colls BM. Fasting plasma lipid measurements following cisplatin chemotherapy in patients with germ cell tumors, 1609
Elson PJ, *see* Loehrer PJ Sr
Elwood LJ, *see* Smith JW II
Engstrom P, *see* Lerman C
Enker WE, *see* Minsky BD
Enneking WF, *see* Ellis ER
Ensley JF, *see* Forastiere AA
Ernst P, *see* Chopra R
Errante D, *see* Tirelli U
Escat J, *see* Rougier P
Esperou-Bourdeau H, *see* Michel G
Estey EH, *see* Kantarjian HM
Etienne MC, Milano G, Frenay M, Renee N, Francois E, Thyss A, Schneider M, Namer M. Pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate in advanced breast cancer patients, 1176
— *see* Milano G
Ettinger DS, *see* Rowinsky EK
Eudey L, *see* Allred DC
— *see* Clark GM
Evans I, *see* Corn BW
Evans WE, *see* Baker DK
Evans WK, *see* Feld R
— *see* Sagman U
— *see* Shepherd FA
Evrard D, *see* Mattson K
Ewalenko P, *see* Lienard D

Fabian C, *see* Ravdin PM
Fairclough D, *see* Mulhern RK
Fairey RN, *see* Hoskins PJ
Falkson G, *see* Raats JI
— *see* Sesterhenn IA
— *see* Tormey DC
Falkson HC, *see* Raats JI
Falletta JM, *see* Friedman HS

Farinacci GC, *see* LeVeque FG
Faucher K, *see* Grunewald R
Feeny D, Furlong W, Barr RD, Torrance GW, Rosenbaum P, Weitzman S. A comprehensive multiattribute system for classifying the health status of survivors of childhood cancer, 923
Fefer A, *see* Bensinger WI
— *see* Thompson JA
Feit F, *see* Speyer JL
Feld R, Wierzbicki R, Walde PLD, Shepherd FA, Evans WK, Gupta S, Shannon P, Lassus M. Phase I-II study of high-dose epirubicin in advanced non–small-cell lung cancer, 297
— *see* Sagman U
Feldman E, *see* Kantarjian HM
Felici L, *see* De Bernardi B
Fenaux P, *see* Detourmignies L
— *see* Morel P
Fenoglio C, *see* Vadhan-Raj S
Fenton RG, *see* Smith JW II
Fenton RM, *see* Smith MA
Ferguson J, *see* Daly L
Ferrandina G, *see* Scambia G
Ferrans V, *see* Speyer JL
Ferretti GA, *see* LeVeque FG
Feusner J, *see* Smith MA
Fielding SL, *see* Lashford LS
Fig LM, *see* Kaminski MS
Figlin RA, Belldegrun A, Moldawer N, Zeffren J, deKernion J. Concomitant Administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: An active outpatient regimen in metastatic renal cell carcinoma, 414
Finberg R, *see* Talcott JA
Findlay PA, *see* Lichter AS
Fine HA, *see* Loeffler JS
Finke J, *see* Budd GT
Fischer D, *see* Haffty BG
Fischmann AB, *see* Foss FM
Fisher GA, *see* Yahanda AM
Fisher H, *see* Nichols CR
Fisher RI, *see* Weiss GR
Fitzharris BM, *see* Ellis PA
Flaum MA, *see* Vogler WR
Fleming TR, *see* Bukowski RM
Fletcher B, *see* Meyer WH
Flomenberg N, *see* Krown SE
Flower MA, *see* Lashford LS
Flynn S, *see* Haffty BG
Foa R, Guarini A, di Celle PF, Trentin L, Gillio Tos A, Bellone G, Carbone A, Attisano C, Massaia M, Raspadori D, Pizzolo G, Chisesi T, Lauria F, Semenzato G. Constitutive production of tumor necrosis factor-alpha in hairy cell leukemia: Possible role in the pathogenesis of the cytopenia(s) and effect of treatment with interferon-alpha, 954
Forastiere AA, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, Kish JA, McClure S, VonFeldt E, Williamson SK, Von Hoff DD. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group study, 1245
— *see* Rowinsky EK
Forbes JF, *see* Coates A
Ford HT, *see* Jones AL
Foss FM, Ihde DC, Breneman DL, Phelps RM, Fischmann AB, Schechter GP, Linnoila I, Breneman JC, Cotelingam JD, Ghosh BC, Steinberg SM, Lynch JW, Phares JC, Stocker JL, Bastian A, Sausville EA. Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome, 1907
Fossâ SD, Qvist H, Stenwig AE, Lien HH, Ous S, Giercksky KE. Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses? 569
Fossa SD, *see* Mead GM
Fox RM, *see* Lazarus HM
Fox S, *see* Hudes GR
Francini G, Gonnelli S, Petrioli R, Conti F, Paffetti P, Gennari C. Treatment of bone metastases with dichloromethylene bisphosphonate, 591
Franciosi V, *see* Cocconi G
Francis IR, *see* Kaminski MS
Francois E, *see* Etienne MC
Frankel J, *see* Minsky BD
Frankel L, *see* Trueworthy R
Frank-Stromborg M, *see* Chlebowski RT
Franzén L, *see* Henriksson R
Frappaz D, Michon J, Hartmann O, Bouffet E, Lejars O, Rubie H, Gentet JC, Chastagner P, Sariban E, Brugiere L, Zucker JM, Lemerle J, Philip T. Etoposide and carboplatin in neuroblastoma: A French Society of Pediatric Oncology phase II study, 1592
— *see* Michel G
Fraschini G, *see* Buzdar AU
Fraumeni JF Jr, *see* Li FP
Freedman AS, *see* Soiffer RJ
Freeman A, *see* Soiffer RJ
Frei E III, *see* Antman K
— *see* Ayash LJ
Frenay M, *see* Etienne MC
— *see* Milano G
Frenck RW Jr, *see* Vadhan-Raj S
Fridman M, *see* Silber JH
Friedman HS, Krischer JP, Burger P, Oakes WJ, Hockenberger B, Weiner MD, Falletta JM, Norris D, Ragab AH, Mahoney DH Jr, Whitehead MV, Kun LE. Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: A Pediatric Oncology Group randomized phase II study, 249
Friedman MA, *see* Smith MA
Friedrich C, *see* Gaynor JJ
Frisch J, *see* Brugger W
Fuerst M, *see* Leichman L
Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S, Masuda N, Nakajima S, Taguchi T for the CPT-11 Lung Cancer Study Group. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non–small-cell lung cancer, 16

— *see* Masuda N
Fuller L, *see* Dimopoulos MA
Furlong W, *see* Feeny D

Gadia M, *see* Gregg RW
Gajewski JL, *see* Schiller GJ
Galili N, *see* Wasserman R
Gallo E, *see* Vitolo U
Gallot D, *see* Rougier P
Galvin DV, *see* Beck TM
Gandara D, *see* MacKenzie MR
Gandara DR, *see* Beck TM
Garaventa A, *see* De Bernardi B
Garcia-Conde J, *see* Bolufer P
Gardembas-Pain M, *see* Michel G
Gasparini G, Gullick WJ, Bevilacqua P, Sainsbury JRC, Meli S, Boracchi P, Testolin A, La Malfa G, Pozza F. Human breast cancer: Prognostic significance of the expression of the c-*erb*-B-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features, 686
Gastrointestinal Tumor Study Group. Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum, 549
Gatzemeier U, Hossfeld DK, Neuhauss R, Reck M, Achterrath W, Lenaz L. Combination chemotherapy with carboplatin, etoposide, and vincristine as first-line treatment in small-cell lung cancer, 818
Gaynor ER, *see* Weiss GR
Gaynor JJ, Tan CC, Casper ES, Collin CF, Friedrich C, Shiu M, Hajdu SI, Brennan MF. Refinement of clinicopathologic staging for localized soft tissue sarcoma of the extremity: A study of 423 adults, 1317
Gazet JC, *see* Jones AL
Gebski V, *see* Coates A
Geertsen PF, Hermann GG, von der Maase H, Steven K. Treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2: A single-center phase II study, 753
Gehan E, *see* Heyn R
Geijssen GJ, *see* de Jong J
Gelber RD, *see* Gusterson BA
— *see* Neville AM
— *see* Waber DP
Geller RB, *see* Wagner JE
Gennari C, *see* Francini G
Gentet JC, *see* Frappaz D
Gentet J-C, *see* Oberlin O
George C, *see* MacKenzie MR
George PM, *see* Ellis PA
George SL, *see* Daly L
Gerber LH, *see* Lichter AS
Gerber MC, *see* Vogler WR
Ghio R, *see* Vitolo U
Ghosh BC, *see* Foss FM
Giaccone G, *see* Mattson K
Giannarelli D, *see* Biti GP
Gianni AM, Bregni M, Siena S, Magni M, Di Nicola M, Lombardi F, Tarella C, Pileri A, Bonadonna G. Granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor infusion makes high-dose etoposide a safe outpatient regimen that is effective in lymphoma and myeloma patients, 1955
Gibson V, *see* Budd GT
Gierckskey KE, *see* Fosså SD
Gietema JA, *see* Postmus PE
Gilchrist KW, *see* Allred DC
— *see* Clark GM
— *see* Tormey DC
Gilewski T, *see* Williams SF
Gill I, *see* Nichols CR
Gill PG, Denham JW, Jamieson GG, Devitt PG, Yeoh E, Olweny C. Patterns of treatment failure and prognostic factors associated with the treatment of esophageal carcinoma with chemotherapy and radiotherapy either as sole treatment or followed by surgery, 1037
Gillespie A, *see* Berg SL
Gillespie GY, *see* Dropcho EJ
Gillio Tos A, *see* Foa R
Ginn D, *see* Kelsen D
Ginsberg R, *see* Sagman U
Ginsberg RJ, *see* Burkes RL
Girling DJ, Clark PI. Randomized trials in the treatment of cancer of the esophagus (editorial), 1031
Gisselbrecht C, *see* Bosly A
— *see* Morel P
Giudici G, *see* Rovelli A
Gjedde SB, *see* Pedersen-Bjergaard J
Glantz M, *see* Dropcho EJ
Glatstein E, *see* Goffman TE
— *see* Lichter AS
— *see* Longo DL
— *see* Rothenberg ML
Glick JH, *see* Weisdorf DJ
Gluckman E, *see* Michel G
Godwin KS, *see* Adamson PC
Goerner R, *see* Diel IJ
Goffman TE, Dachowski LJ, Bobo H, Oldfield EH, Steinberg SM, Cook J, Mitchell JB, Katz D, Smith R, Glatstein E. Long-term follow-up on National Cancer Institute phase I/II study of glioblastoma multiforme treated with iododeoxyuridine and hyperfractionated irradiation, 264
Gold JWM, *see* Krown SE
Goldberg GL, *see* Einzig AI
Goldberg ME, *see* Burkes RL
Goldbloom EP, *see* Jodrell DI
Goldhirsch A, *see* Gusterson BA
— *see* Neville AM
Goldman L, *see* Talcott JA
Goldspiel B, *see* Wilson WH
Goldstein D, *see* Greiner JW
Goldstein J, *see* Dimopoulos MA
Goldstone AH, *see* Chopra R
Goldwein JW, *see* Corn BW
— *see* Maity A
— *see* Silber JH
Golembe BL, *see* Wofford MM
Golouh R, *see* Gusterson BA
— *see* Neville AM

Gonin R, *see* Ayash LJ
— *see* Lerner A
— *see* Soiffer RJ
Gonnelli S, *see* Francini G
Gonzales G, *see* Leith CP
Goodlow JL, *see* Jodrell DI
— *see* Roth BJ
Goodnough LT, *see* Jacobs C
Gore M, *see* Mansi J
Gori S, *see* Cocconi G
Gorrell CR, *see* Lichter AS
Gorum T, *see* Dropcho EJ
Gosland MP, *see* Lum BL
— *see* Yahanda AM
Gospodarowicz MK, *see* Sturgeon JFG
Goss PE, *see* Shepherd FA
Gosselin B, *see* Morel P
Goutsou M, *see* Aisner J
Gouvernet J, *see* Michel G
Gouzi JL, *see* Rougier P
Graham ML, Yeager AM, Leventhal BG, Wiley JM, Civin CI, Strauss LC, Hurwitz CA, Dubowy RL, Wharam MD Jr, Colombani PM, Rowley SD, Braine HG, Santos GW. Treatment of recurrent and refractory pediatric solid tumors with high-dose busulfan and cyclophosphamide followed by autologous bone marrow rescue, 1857
Graham-Pole J, *see* Ellis ER
Gralla RJ, *see* Grant SC
Grant SC, Gralla RJ, Kris MG, Orazem J, Kitsis EA. Single-agent chemotherapy trials in small-cell lung cancer, 1970 to 1990: The case for studies in previously treated patients, 484
Gratecos N, *see* Michel G
Gray G, *see* Brescia FJ
Gray R, *see* Tormey DC
Greco FA, *see* Hainsworth JD
— *see* Roth BJ
— *see* Waits TM
Green MD, *see* Hochster HS
— *see* Speyer JL
Green MR, *see* Aisner J
— *see* Strauss GM
Green S, *see* Alberts DS
— *see* Ravdin PM
Greenberg R, *see* Hudes GR
Greer J, *see* Nichols CR
Gregg RW, Molepo JM, Monpetit VJA, Mikael NZ, Redmond D, Gadia M, Stewart DJ. Cisplatin neurotoxicity: The relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity, 795
Greggi S, *see* Scambia G
Gregory D. *see* Bernstein ML
Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: An overview of published trials, 334
Greiner JW, Guadagni F, Goldstein D, Smalley RV, Borden EC, Simpson JF, Molinolo A, Schlom J. Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells, 735
Gresik MV, *see* Kuerbitz SJ
Gress J, *see* Mueller BU
Gribble M, *see* MacKenzie MR
Griffin C, *see* Wagner JE
Griffin J, *see* Kleinerman ES
Grigolato P, *see* Gusterson BA
Grochow LB, *see* Rowinsky EK
Grogan TM, *see* Leith CP
Groshen S, *see* Leichman L
— *see* Mitchell MS
Groves ES, *see* Sanda MG
Grujicic D, *see* Jeremic B
Grunewald R, Kantarjian H, Du M, Faucher K, Tarassoff P, Plunkett W. Gemcitabine in leukemia: A phase I clinical, plasma, and cellular pharmacology study, 406
Grygiel J, *see* Raghavan D
Guadagni F, *see* Greiner JW
Guarini A, *see* Foa R
Gucalp R, Ritch P, Wiernik PH, Sarma PR, Keller A, Richman SP, Tauer K, Neidhart J, Mallette LE, Siegel R, VandePol CJ. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia, 134
— *see* Lazarus HM
— *see* Weiss GR
Guilhot F, *see* Tourani J-M
Gulati S, Yahalom J, Acaba L, Reich L, Motzer R, Crown J, Toia M, Igarashi T, Lemoli R, Hanninen E, Doherty M. Treatment of patients with relapsed and resistant non-Hodgkin's lymphoma using total body irradiation, etoposide, and cyclophosphamide and autologous bone marrow transplantation, 936
Gullick WJ, *see* Gasparini G
Gupta S, *see* Feld R
Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Säve-Söderbergh J, Anbazhagan R, Styles J, Rudenstam C-M, Golouh R, Reed R, Martinez-Tello F, Tiltman A, Torhorst J, Grigolato P, Bettelheim R, Neville AM, Bürki K, Castiglione M, Collins J, Lindtner J, Senn, H-J for the International (Ludwig) Breast Cancer Study Group. Prognostic importance of c-*erb*B-2 expression in breast cancer, 1049
Gutin PH, *see* Wilson CB
Gutterman J, *see* Kantarjian HM
Gutterman JU, *see* Buzdar AU
— *see* Vadhan-Raj S
Guy H, *see* Solary E

Habrand JL, *see* Oberlin O
Habrand J-L, *see* Oberlin O
Haddad R, *see* Sagman U
Haffty BG, Toth M, Flynn S, Fischer D, Carter D. Prognostic value of DNA flow cytometry in the locally recurrent, conservatively treated breast cancer patient, 1839
Hagemeister FB, *see* Redman JR
Haggard M, *see* Trueworthy R

Haggard ME, *see* Wofford MM
Hahka-Kemppinen M, *see* Pyrhönen S
Hainsworth JD, Johnson DH, Greco FA. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: Results of a 12-year experience, 912
— *see* Beck TM
— *see* Waits TM
Hajdu SI, *see* Gaynor JJ
Hakes T, *see* Markman M
Halsey J, *see* Lum BL
— *see* Yahanda AM
Hammond GD, *see* Smith MA
Hancock BW, Hudson GV, Hudson BV, Bennett MH, MacLennan KA, Haybittle JL, Anderson L, Linch DC. LOPP alternating with EVAP is superior to LOPP alone in the initial treatment of advanced Hodgkin's disease: Results of a British National Lymphoma Investigation trial, 1252
Hande KR, *see* Waits TM
Hanjani P, *see* Lerman C
Hannigan EV, *see* Alberts DS
Hannigan J, *see* MacKenzie MR
Hanninen E, *see* Gulati S
Hansen HH, *see* Bach F
— *see* Kristensen CA
Hansen JA, *see* Bensinger WI
— *see* Clift RA
Hansen M, *see* Pedersen-Bjergaard J
Hanson CA, *see* Kaminski MS
Hardy RI, *see* Yahanda AM
Harel W, *see* Mitchell MS
Harousseau JL, *see* Detourmignies L
Harrington D, *see* Andersen JW
Harris M, *see* Trueworthy R
Harris SD, *see* Pozo C
Hars V, *see* Daly L
Hartmann O, *see* Frappaz D
Harvey H, *see* Leitzel K
Hasegawa K, *see* Fukuoka M
Hassan M, *see* Liliemark J
Hawkins MJ, *see* Weiss GR
Hay JM, *see* Rougier P
Hayakawa K, *see* Ziegler LD
Haybittle JL, *see* Hancock BW
Hayes FA, *see* Castleberry RP
Hays DM, Landsverk J, Sallan SE, Hewett KD, Patenaude AF, Schoonover D, Zilber SL, Ruccione K, Siegel SE. Educational, occupational, and insurance status of childhood cancer survivors in their fourth and fifth decades of life, 1397
— *see* Heyn R
Healey J, *see* Meyers PA
Heelan R, *see* Kelsen D
Heimans JJ, *see* van Rijswijk REN
Helfrich SG, *see* Herrmann F
Helin H, *see* Toikkanen S
Heller G, *see* Meyers PA
Hellstrom I, *see* Ziegler LD
Hellstrom KE, *see* Ziegler LD
Hendricks CB, *see* Rowinsky EK
Henriksson R, Franzén L, Littbrand B. Effects of sucralfate on acute and late bowel discomfort following radiotherapy of pelvic cancer, 969
Herbrecht R, *see* Bosly A
Herman S, *see* Sturgeon JFG
Hermann GG, *see* Geertsen PF
Hermans J, *see* Osanto S
Herndier B, *see* Shiramizu B
Herndon JE, *see* Strauss GM
Herrmann F, Helfrich SG, Lindermann A, Schleiermacher E, Huber Ch, Mertelsmann R. Elevated circulating levels of tumor necrosis factor predict unresponsiveness to treatment with interferon alfa-2b in chronic myelogenous leukemia, 631
Herve P, *see* Michel G
Hesketh PJ, *see* Beck TM
Hestdal K, *see* Smith JW II
Hewett KD, *see* Hays DM
Heyn R, Raney RB Jr, Hays DM, Tefft M, Gehan E, Webber B, Mauer HM. Late effects of therapy in patients with paratesticular rhabdomyosarcoma, 614
Heyne KH, Lippman SM, Lee JJ, Lee JS, Hong WK. The incidence of second primary tumors in long-term survivors of small-cell lung cancer, 1519
Hill G, *see* Bernstein ML
Hillner BE, *see* Desch CE
Hittelman WN, *see* Smith MA
— *see* Vadhan-Raj S
Ho WG, *see* Schiller GJ
Hochster H, *see* Jacobs C
— *see* Speyer JL
Hochster HS, Kim K, Green MD, Mann RB, Neiman RS, Oken MM, Cassileth PA, Stott P, Ritch P, O'Connell MJ. Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: Results of an Eastern Cooperative Oncology Group study, 28
Hockenberger B, *see* Friedman HS
Holcenberg J, *see* Berg SL
Holian A, *see* Vadhan-Raj S
Holmes FA, *see* Buzdar AU
Hong WK, *see* Heyne KH
Horowitz ME, *see* Smith MA
Hortobagyi G, *see* Jaiyesimi IA
Hortobagyi GN, *see* Buzdar AU
Horwich A, *see* Mead GM
— *see* Read G
Hoskins PJ, O'Reilly SE, Swenerton KD, Spinelli JJ, Fairey RN, Benedet JL. Ten-year outcome of patients with advanced epithelial ovarian carcinoma treated with cisplatin-based multimodality therapy, 1561
Hoskins W, *see* Markman M
Hossfeld DK, *see* Gatzemeier U
House KW, *see* Beck TM
Hovgaard DJ, Nissen NI. Effect of recombinant human granulocyte-macrophage colony-stimulating factor in patients with Hodgkin's disease: A phase I/II study, 390
Hubbard SM, *see* Longo DL
Huber Ch, *see* Herrmann F
Hudes GR, Greenberg R, Krigel RL, Fox S, Scher R, Litwin

S, Watts P, Speicher L, Tew K, Comis R. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer, 1754
— *see* O'Dwyer PJ
Hudson BV, *see* Hancock BW
Hudson GV, *see* Hancock BW
Huet S, *see* Robert J
Hug VM, *see* Buzdar AU
Huguier M, *see* Rougier P
Humblet Y, *see* Bosly A
Hunger SP, Sklar J, Link MP. Acute lymphoblastic leukemia occurring as a second malignant neoplasm in childhood: Report of three cases and review of the literature, 156
Hunt M, *see* Antman K
Hurowitz L, *see* Markman M
Hurowitz LA, *see* Rowinsky EK
Hurteloup P, *see* Robert J
Hurwitz CA, *see* Graham ML
Hutchins LF, *see* Forastiere AA
Huvos A, *see* Meyers PA

Ifrah N, *see* Tourani J-M
Igarashi T, *see* Gulati S
Ihde DC, Tucker MA. Second primary malignancies in small-cell lung cancer: A major consequence of modest success (editorial), 1511
— *see* Foss FM
— *see* Longo DL
Ilson DH, Motzer RJ, Kradin RL, Vogelzang NJ, Bajorin DF, Scher HI, Nanus D, O'Moore P, Marathias K, Bosl GJ. A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma, 1124
Indelli M, *see* Cocconi G
Isley M, *see* Neville AM
Isola J, *see* Toikkanen S
Ito Y, *see* Wasserman R
Itoh K, *see* Ziegler LD

Jacob J, *see* Sarosy G
Jacobs C, Lyman G, Velez-García E, Sridhar KS, Knight W, Hochster H, Goodnough LT, Mortimer JE, Einhorn LH, Schacter L, Cherng N, Dalton T, Burroughs J, Rozencweig M. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck, 257
Jaffe ES, *see* Longo DL
Jaffe N, *see* Kleinerman ES
Jaillais P, *see* de Forni M
Jain V, *see* Wilson WH
Jaiyesimi IA, Buzdar AU, Hortobagyi G. Inflammatory breast cancer: A review, 1014
Jamieson GG, *see* Gill PG
Janik JE, *see* Smith JW II
Jankovic M, *see* Rovelli A
Janssen RAJ, *see* Sleijfer DTh
Janus M, *see* Ziegler LD
Janvier M, *see* Detourmignies L
Jaubert J, *see* Bosly A
Jeffrey J, *see* Swenerton K
Jeremic B, Grujicic D, Jevremovic S, Stanisavljevic B, Milojevic L, Djuric L, Mijatovic L. Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: A phase II study, 1074
Jevremovic S, *see* Jeremic B
Jew L, *see* Lum BL
Jewett MAS, *see* Sturgeon JFG
Jia S-F, *see* Kleinerman ES
Jodrell DI, Egorin MJ, Canetta RM, Langenberg P, Goldbloom EP, Burroughs JN, Goodlow JL, Tan S, Wiltshaw E. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer, 520
Joensuu H, *see* Toikkanen S
Johansen E, *see* Shepherd FA
Johnson DH, *see* Hainsworth JD
— *see* Roth BJ
— *see* Waits TM
Johnson JT, *see* LeVeque FG
Johnson W, *see* Wofford MM
Jolles CJ, *see* Alberts DS
Jones AL, Powles TJ, Law M, Tidy A, Easton D, Coombes RC, Smith IE, McKinna JA, Nash A, Ford HT, Gazet JC. Adjuvant aminoglutethimide for postmenopausal patients with primary breast cancer: Analysis at 8 years, 1547
Jones D, *see* Burkes RL
Jones R, *see* Wagner JE
Jones W, *see* Markman M
Joshi V, *see* Castleberry RP
Jouet JP, *see* Michel G
Judson I, *see* Mansi J
Julien M, *see* Rougier P
Juliusson G, *see* Liliemark J

Kahn CM, *see* Waber DP
Kaminski MS, Fig LM, Zasadny KR, Koral KF, DelRosario RB, Francis IR, Hanson CA, Normolle DP, Mudgett E, Liu CP, Moon S, Scott P, Miller RA, Wahl RL. Imaging, dosimetry, and radioimmunotherapy with iodine 131–labeled anti-CD37 antibody in B-cell lymphoma, 1696
Kantarjian H, *see* Grunewald R
Kantarjian HM, Keating MJ, Estey EH, O'Brien S, Pierce S, Beran M, Koller C, Feldman E, Talpaz M. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-$\alpha$ and low-dose cytarabine, 772
—, Talpaz M, Kontoyiannis D, Gutterman J, Keating MJ, Estey EH, O'Brien S, Rios MB, Beran M, Deisseroth A. Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor, 398
Kanz L, *see* Brugger W
Kaplan L, *see* Shiramizu B
Kapoor N, *see* Copelan EA
Kappler K, *see* Atkins MB
Karabelis A, *see* Kosmidis PA

Karp DD, *see* Atkins MB
Karvounis N, *see* Kosmidis PA
Katz D, *see* Goffman TE
Kau S-WC, *see* Buzdar AU
Kaubisch S, *see* Lum BL
Kaufmann M, *see* Diel IJ
Kaufmann SH, *see* Rowinsky EK
Kaul S, *see* Diel IJ
Kawashima Y, *see* Kobayashi H
Kay AC, Saven A, Carrera CJ, Carson DA, Thurston D, Beutler E, Piro LD. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas, 371
Kaye SB, *see* Mead GM
— *see* Read G
Kearns C, *see* Santana VM
Keating MJ, *see* Kantarjian HM
— *see* Redman JR
Keller A, *see* Gucalp R
Keller AM, *see* Beck TM
Keller JR, *see* Smith JW II
Kelsen D, Atiq OT, Saltz L, Niedzwiecki D, Ginn D, Chapman D, Heelan R, Lightdale C, Vinciguerra V, Brennan M. FAMTX versus etoposide, doxorubicin, and cisplatin: A random assignment trial in gastric cancer, 541
—, Lovett D, Wong J, Saltz L, Buckley M, Murray P, Heelan R, Lightdale C. Interferon alfa-2a and fluorouracil in the treatment of patients with advanced esophageal cancer, 269
— *see* Rusch VW
Kelsen DP, *see* Minsky BD
Kemeny N, Conti JA, Seiter K, Niedzwiecki D, Botet J, Martin D, Costa P, Wiseberg J, McCulloch W. Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer, 747
— *see* Minsky BD
Kemshead JT, *see* Lashford LS
Kessler S, *see* Yahalom J
Ketcham AS, *see* Pozo C
Khamsi F, *see* Shepherd FA
Kher U, *see* DeAngelis LM
Kim K, *see* Hochster HS
Kinne DA, *see* Yahalom J
Kinsella TJ, *see* Ritter MA
Kirk ME, *see* Swenerton K
Kirkpatrick A, *see* Mattson K
Kish JA, *see* Beck TM
— *see* Forastiere AA
Kishimoto S, *see* Masuda N
Kishnani P, *see* Silber JH
Kitsis EA, *see* Grant SC
Kiyabu M, *see* Leichman L
Klein JL, *see* Copelan EA
Klein JP, *see* Copelan EA
Kleinerman ES, Jia S-F, Griffin J, Seibel NL, Benjamin RS, Jaffe N. Phase II study of liposomal muramyl tripeptide in osteosarcoma: The cytokine cascade and monocyte activation following administration, 1310
Klink-Alakl M, *see* Robert J
Knight W, *see* Jacobs C
Kobayashi H, Terao T, Kawashima Y. Serum sialyl Tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer, 95
Kodish E, Stocking C, Ratain MJ, Kohrman A, Siegler M. Ethical issues in phase I oncology research: A comparison of investigators and institutional review board chairpersons, 1810
Kohler DR, *see* Myers C
Kohn E, *see* Sarosy G
Kohrman A, *see* Kodish E
Koller C, *see* Kantarjian HM
Kontoyiannis D, *see* Kantarjian HM
Kooy HM, *see* Loeffler JS
Koral KF, *see* Kaminski MS
Koski B, *see* Swenerton K
Kosmidis PA, Baxevanis CN, Tsavaris N, Papanastasiou M, Anastasopoulos E, Bacoyiannis C, Mylonakis N, Karvounis N, Bafaloukos D, Karabelis A, Papamichail M. The prognostic significance of immune changes in patients with renal cell carcinoma treated with interferon alfa-2b, 1153
Kouri M, *see* Niiranen A
Kovnar E, *see* Mulhern RK
Kradin RL, *see* Ilson DH
Kramar A, *see* Arriagada R
Kramer E, *see* Speyer JL
Krasnoff L, *see* Brescia FJ
Krepart G, *see* Swenerton K
Krigel RL, *see* Hudes GR
Kris MG, *see* Grant SC
Krischer JP, *see* Friedman HS
— *see* Kuerbitz SJ
Kristensen CA, Kristijansen PEG, Hansen HH. Systemic chemotherapy of brain metastases from small-cell lung cancer: A review, 1498
Kristijansen PEG, *see* Kristensen CA
Krown SE, Paredes J, Bundow D, Polsky B, Gold JWM, Flomenberg N. Interferon-$\alpha$, zidovudine, and granulocyte-macrophage colony-stimulating factor: A phase I AIDS Clinical Trials Group study in patients with Kaposi's sarcoma associated with AIDS, 1344
Kudoh S, *see* Masuda N
Kuebler P, *see* Loehrer PJ Sr
Kuentz M, *see* Michel G
Kuerbitz SJ, Civin CI, Krischer JP, Ravindranath Y, Steuber CP, Weinstein HJ, Winick N, Ragab AH, Gresik MV, Crist WM. Expression of myeloid-associated and lymphoid-associated cell-surface antigens in acute myeloid leukemia of childhood: A Pediatric Oncology Group study, 1419
Kun L, *see* Meyer WH
Kun LE, *see* Friedman HS
— *see* Mulhern RK
Kuriyama T, *see* Fukuoka M
Kusunoki Y, *see* Masuda N

La Malfa G, *see* Gasparini G
Lacaine F, *see* Rougier P
LaCreta FP, *see* O'Dwyer PJ
Laine L, *see* Leichman L
Land V, *see* Trueworthy R
Landsverk J, *see* Hays DM

Lane J, *see* Meyers PA
Lange B, *see* Maity A
— *see* Wasserman R
Lange PH, *see* Thompson JA
Langenberg P, *see* Jodrell DI
Langer MP, *see* Strauss GM
Langston J, *see* Mulhern RK
Langton BC, *see* Leitzel K
Laplanche A, *see* Rougier P
LaRocca R, *see* Myers C
Larsen SO, *see* Pedersen-Bjergaard J
Larson DA, *see* Wilson CB
Lasala MR, *see* Desch CE
Lashford LS, Lewis IJ, Fielding SL, Flower MA, Meller S, Kemshead JT, Ackery D. Phase I/II study of iodine 131 metalodobenzylguanidine in chemoresistant neuroblastoma: A United Kingdom Children's Cancer Study Group investigation, 1889
Laskey J, *see* Shepherd FA
Lasser P, *see* Rougier P
Lassus M, *see* Feld R
Lauria F, *see* Foa R
Law M, *see* Jones AL
Lazarus HM, Crilley P, Ciobanu N, Creger RJ, Fox RM, Shina DC, Bulova SI, Gucalp R, Cooper BW, Topolsky D, Soegiarso W, Brodsky I. High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma, 1682
— *see* Nichols CR
Le Chevalier T, *see* Arriagada R
Le Maignan C, *see* Tourani J-M
Leclerc JM, *see* Bernstein ML
Lederlin P, *see* Bosly A
Lee CR, Nicholson PW, Souhami RL, Deshmukh AA. Patient compliance with oral chemotherapy as assessed by a novel electronic technique, 1007
Lee JJ, *see* Heyne KH
Lee JS, *see* Heyne KH
Lee R, *see* Bukowski RM
Legaspi A, *see* Pozo C
Legros M, *see* Bosly A
Leichman CG, *see* Leichman L
Leichman L, Silberman H, Leichman CG, Spears CP, Ray M, Muggia FM, Kiyabu M, Radin R, Laine L, Stain S, Fuerst M, Groshen S, Donovan A. Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: A University of Southern California pilot program, 1933
Leigh L, *see* Mulhern RK
Leith CP, Spier CM, Grogan TM, Gonzales G, Rangel CS, Rybski JA, Matzner M, Miller TP. Diffuse small cleaved-cell lymphoma: A heterogeneous disease with distinct immunobiologic subsets, 1259
Leitzel K, Teramoto Y, Sampson E, Mauceri J, Langton BC, Demers L, Podczaski E, Harvey H, Shambaugh S, Volas G, Weaver S, Lipton A. Elevated soluble c-*erb*B-2 antigen levels in the serum and effusions of a proportion of breast cancer patients, 1436
Lejars O, *see* Frappaz D
Lejeune FJ, *see* Lienard D
Lemaire L, *see* de Forni M
Lemerle J, *see* Frappaz D
— *see* Oberlin O
Lemevel A, *see* Tourani J-M
Lemieux B, *see* Bernstein ML
Lemoli R, *see* Gulati S
Lenaz L, *see* Gatzemeier U
— *see* Martín M
Leong LA, *see* Margolin KA
Lepage E, *see* Morel P
Leprise P-Y, *see* Tourani J-M
Lerman C, Hanjani P, Caputo C, Miller S, Delmoor E, Nolte S, Engstrom P. Telephone counseling improves adherence to colposcopy among lower-income minority women, 330
Lerner A, Gonin R, Steele GD Jr, Mayer RJ. Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric adenocarcinoma: Results of a phase II trial, 536
Lester EP, *see* Beck TM
Leventhal BG, *see* Graham ML
LeVeque FG, Parzuchowski JB, Farinacci GC, Redding SW, Rodu B, Johnson JT, Ferretti GA, Eisenberg PD, Zimmer MB. Clinical evaluation of MGI 209, an anesthetic, film-forming agent for relief from painful oral ulcers associated with chemotherapy, 1963
Leverger G, *see* Oberlin O
Levin VA, Prados MD. Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosourea resistance, 766
Levine MN, Andrulis I. The HER-2/*neu* oncogene in breast cancer: So what is new? (editorial), 1034
Levis A, *see* Vitolo U
Levy R, *see* Tourani J-M
Lewis IJ, *see* Lashford LS
Lewis JL Jr, *see* Markman M
Li FP, Fraumeni JF Jr. Predictive testing for inherited mutations in cancer-susceptibility genes (editorial), 1203
Lichter AS. Lumpectomy and radiation: Improving the outcome (editorial), 349
—, Lippman ME, Danforth DN Jr, d'Angelo T, Steinberg SM, deMoss E, MacDonald HD, Reichert CM, Merino M, Swain SM, Cowan K, Gerber LH, Bader JL, Findlay PA, Schain W, Gorrell CR, Straus K, Rosenberg SA, Glatstein E. Mastectomy versus breast-conserving therapy in the treatment of stage I and II carcinoma of the breast: A randomized trial at the National Cancer Institute, 976
Lien HH, *see* Fossâ SD
Lienard D, Ewalenko P, Delmotte J-J, Renard N, Lejeune FJ. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma, 52
Lightdale C, *see* Kelsen D
Liliemark J, Albertioni F, Hassan M, Juliusson G. On the bioavailability of oral and subcutaneous 2-chloro-2'-deoxyadenosine in humans: Alternative routes of administration, 1514
Lillington LB, *see* Chlebowski RT

Limburg PC, *see* Postmus PE
Linch DC, *see* Hancock BW
Lindermann A, *see* Herrmann F
Lindgren CG, *see* Thompson JA
Lindtner J, *see* Gusterson BA
Linehan WM, *see* Myers C
Link MP, *see* Hunger SP
— *see* Simone JV
Linnoila I, *see* Foss FM
Lioure B, *see* Michel G
Lippman ME, *see* Lichter AS
Lippman SM, *see* Heyne KH
Lipton A, *see* Leitzel K
Lishner M, *see* Sagman U
Littbrand B, *see* Henriksson R
Litwin S, *see* Hudes GR
Liu CP, *see* Kaminski MS
Llopis F, *see* Bolufer P
Lluch A, *see* Bolufer P
Lo Curto M, *see* De Bernardi B
Locasciulli A, *see* Rovelli A
Lockwood G, *see* Burkes RL
Loeffler JS, Alexander E III, Shea WM, Wen PY, Fine HA, Kooy HM, Black PMcL. Radiosurgery as part of the initial management of patients with malignant gliomas, 1379
Loehrer PJ, *see* Nichols CR
Loehrer PJ Sr, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, Raghavan D, Stuart-Harris R, Sarosdy MF, Lowe BA, Blumenstein B, Trump D. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study, 1066
Lokhorst HM, Meuwissen OJATh, Verdonck LF, Dekker AW. High-risk multiple myeloma treated with high-dose melphalan, 47
— *see* Verdonck LF
Lombardi F, *see* Gianni AM
Longo D, *see* Mueller BU
Longo DL, Duffey PL, Young RC, Hubbard SM, Ihde DC, Glatstein E, Phares JC, Jaffe ES, Urba WJ, DeVita VT Jr. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability for cure, 210
— *see* Smith JW II
— *see* Wilson WH
Look T, *see* Trueworthy R
Lopez R, *see* van Rijswijk REN
Lotz J-P, *see* Tourani J-M
Lotze MT, *see* Sanda MG
Lovett D, *see* Kelsen D
Lowe BA, *see* Loehrer PJ Sr
Lubejko BG, *see* Rowinsky EK
Luboinski M, *see* Rougier P
Lum BL, Kaubisch S, Yahanda AM, Adler KM, Jew L, Ehsan MN, Brophy NA, Halsey J, Gosland MP, Sikic BI. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance, 1635
— *see* Yahanda AM
Luxi G, *see* Vitolo U
Lyman G, *see* Jacobs C
Lynch JW, *see* Foss FM

MacDonald HD, *see* Lichter AS
Macdonald JS, *see* Bukowski RM
Machin D, *see* Bramwell VHC
MacKenzie MR, Wold H, George C, Gandara D, Ray G, Schiff S, Shields J, Artim R, Davidson H, Meyers F, Hannigan J, Gribble M, Acord P, Phillips TL. Consolidation hemibody radiotherapy following induction combination chemotherapy in high-tumor-burden multiple myeloma, 1769
MacLean G, *see* Swenerton K
MacLennan KA, *see* Hancock BW
Madajewicz S, *see* Beck TM
Magni M, *see* Gianni AM
Magrini SM, *see* Biti GP
Mahaley MS Jr, *see* Dropcho EJ
Mahoney DH Jr, *see* Friedman HS
Maity A, Goldwein JW, Lange B, D'Angio GJ. Comparison of high-dose and low-dose radiation with and without chemotherapy for children with Hodgkin's disease: An analysis of the experience at the Children's Hospital of Philadelphia and the Hospital of the University of Pennsylvania, 929
Maki E, *see* Sagman U
Malcolm AJ, *see* Bramwell VHC
Malet-Marino MC, *see* de Forni M
Mallette LE, *see* Gucalp R
Malpas JS, *see* Gregory WM
Malvlya VK, *see* Alberts DS
Mancuso S, *see* Scambia G
Mandelli F, *see* Biti GP
Mangalik A, *see* Neidhart JA
Mann RB, *see* Hochster HS
Mansi J, da Costa F, Viner C, Judson I, Gore M, Cunningham D. High-dose busulfan in patients with myeloma, 1569
Mansour EG, *see* Allred DC
— *see* Clark GM
Maraninchi D, *see* Michel G
Marathias K, *see* Ilson DH
Marchant DJ, *see* Wazer DE
Marchese N, *see* De Bernardi B
Marcove R, *see* Meyers PA
Marcus RB Jr, *see* Ellis ER
Margolin KA, Doroshow JH, Akman SA, Leong LA, Morgan RJ, Raschko JW, Somlo G, Blevins C. Effective initial therapy of advanced breast cancer with fluorouracil and high-dose, continuous infusion calcium leucovorin, 1278
—, Doroshow JH, Akman SA, Leong LA, Morgan RJ, Somlo G, Raschko J, Pereira C, Yonemoto L, Ahn C. Phase II trial of cisplatin and $\alpha$-interferon in advanced malignant melanoma, 1574
— *see* Weiss GR
Marina N, *see* Meyer WH
Markman M, Hakes T, Reichman B, Lewis JL Jr, Rubin S, Jones W, Almadrones L, Pizzuto F, Hoskins W. Ifos-

famide and mesna in previously treated advanced epithelial ovarian cancer: Activity in platinum-resistant disease, 243
—, Hoskins W. Responses to salvage chemotherapy in ovarian cancer: A critical need for precise definitions of the treated population (editorial), 513
—, Reichman B, Hakes T, Lewis JL Jr, Jones W, Rubin S, Barakat R, Curtin J, Almadrones L, Hoskins W. Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer, 1479
—, Rowinsky E, Hakes T, Reichman B, Jones W, Lewis JL Jr, Rubin S, Curtin J, Barakat R, Phillips M, Hurowitz L, Almadrones L, Hoskins W. Phase I trial of intraperitoneal taxol: A Gynecologic Oncology Group study, 1485
— *see* Rusch VW
Marshall D, *see* Mueller BU
Martin D, *see* Kemeny N
Martín M, Díaz-Rubio E, Casado A, Santabárbara P, Vega JML, Adrover E, Lenaz L. Carboplatin: An active drug in metastatic breast cancer, 433
Martinez AA, *see* Clarke DH
Martinez-Tello F, *see* Gusterson BA
Martino R, *see* de Forni M
Masera G, *see* Rovelli A
Mason JR, *see* Shea TC
Massaia M, *see* Foa R
Masuda N, Fukuoka M, Takada M, Kusunoki Y, Negoro S, Matsui K, Kudoh S, Takifuji N, Nakagawa K, Kishimoto S. CPT-11 in combination with cisplatin for advanced non–small-cell lung cancer, 1775
—, Fukuoka M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, Negoro S, Nishioka M, Nakagawa K, Takada M. CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer, 1225
— *see* Fukuoka M
Mathieu M-C, *see* Clark GM
Mathisen DJ, *see* Strauss GM
Matsui K, *see* Masuda N
Mattson K, Giaccone G, Kirkpatrick A, Evrard D, Tammilehto L, van Breukelen FJM, Planteydt HT, van Zandwijk N. Epirubicin in malignant mesothelioma: A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group, 824
— *see* Niiranen A
Matzner M, *see* Leith CP
Mauceri J, *see* Leitzel K
Mauch P, *see* Soiffer RJ
Mauch PM, *see* Shapiro CL
Mauer HM, *see* Heyn R
Maurer LH, *see* Aisner J
Maurizi Enrici RM, *see* Biti GP
May WS, *see* Wagner JE
Mayer RJ, *see* Lerner A
— *see* Rubin EH
Maynadie M, *see* Solary E
McAleer C, *see* O'Dwyer PJ
McCarty KS Jr, *see* Daly L
McClure S, *see* Forastiere AA
McCormick B, *see* Yahalom J
McCulloch W, *see* Kemeny N
McCully CL, *see* Adamson PC
McGrath M, *see* Shiramizu B
McGuire WL, *see* Allred DC
— *see* Clark GM
— *see* Osborne CK
— *see* Ravdin PM
— *see* Wiebe VJ
McGuire WP, *see* Rowinsky EK
McKinna JA, *see* Jones AL
McLaughlin P, *see* Redman JR
McNeese MD, *see* Buzdar AU
McNeil D, *see* Coates A
McWilliams N, *see* Castleberry RP
Mead GM, Stenning SP, Parkinson MC, Horwich A, Fossa SD, Wilkinson PM, Kaye SB, Newlands ES, Cook PA. The second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors, 85
Meadows AT, *see* Silber JH
Medendorp S, *see* Budd GT
Meeker T, *see* Shiramizu B
Mehta N, *see* Richards JM
Meijer E, *see* van Rijswijk REN
Meli S, *see* Gasparini G
Meller S, *see* Lashford LS
Meneghini V, *see* Vitolo U
Menendez-Botet C, *see* Rusch VW
Merino M, *see* Lichter AS
Mertelsmann R, *see* Brugger W
— *see* Herrmann F
Messing EM, *see* Ritter MA
Metch B, *see* Forastiere AA
— *see* Ravdin PM
Meuwissen OJATh, *see* Lokhorst HM
Meyer WH, Kun L, Marina N, Roberson P, Parham D, Rao B, Fletcher B, Pratt CB. Ifosfamide plus etoposide in newly diagnosed Ewing's sarcoma of bone, 1737
— *see* Simone JV
Meyers F, *see* MacKenzie MR
Meyers M, *see* Speyer JL
Meyers PA, Heller G, Healey J, Huvos A, Lane J, Marcove R, Applewhite A, Vlamis V, Rosen G. Chemotherapy for nonmetastatic osteogenic sarcoma: The Memorial Sloan-Kettering experience, 5
Michaux J-L, *see* Bosly A
Michel G, Gluckman E, Blaise D, Esperou-Bourdeau H, Vernant JP, Kuentz M, Bordigoni P, Milpied N, Rubie H, Thuret I, Troussard X, Frappaz D, Herve P, Plouvier E, Gratecos N, Bernaudin F, Lioure B, Bergeron C, Jouet JP, Gardembas-Pain M, Belanger C, Gouvernet J, Perrimond H, Maraninchi D. Improvement in outcome for children receiving allogeneic bone marrow transplantation in first remission of acute myeloid leukemia: A report from the Groupe d'Etude des Greffes de Moelle Osseuse, 1865
Michon J, *see* Frappaz D
Mick R, *see* Williams SF
Mier JW, *see* Atkins MB

Mihura J, *see* de Forni M
Mijatovic L, *see* Jeremic B
Mikael NZ, *see* Gregg RW
Milano G, Etienne MC, Cassuto-Viguier E, Thyss A, Santini J, Frenay M, Renee N, Schneider M, Demard F. Influence of sex and age on fluorouracil clearance, 1171
— *see* Etienne MC
Miller KB, *see* Soiffer RJ
Miller L, *see* Shea TC
Miller LL, *see* O'Dwyer PJ
— *see* Smith JW II
Miller RA, *see* Kaminski MS
Miller S, *see* Lerman C
Miller TP, *see* Leith CP
Million RR, *see* Ellis ER
Milojevic L, *see* Jeremic B
Milpied N, *see* Michel G
Minsky BD, Cohen AM, Kemeny N, Enker WE, Kelsen DP, Reichman B, Saltz L, Sigurdson ER, Frankel J. Combined modality therapy of rectal cancer: Decreased acute toxicity with the preoperative approach, 1218
—, Cohen AM, Kemeny N, Enker WE, Kelsen DP, Reichman B, Saltz L, Sigurdson ER, Frankel J. Enhancement of radiation-induced downstaging of rectal cancer by fluorouracil and high-dose leucovorin chemotherapy, 79
Mirro J Jr, *see* Santana VM
Mitchell JB, *see* Goffman TE
Mitchell MS, Harel W, Groshen S. Association of HLA phenotype with response to active specific immunotherapy of melanoma, 1158
Modeas C, *see* Strauss GM
Moffat FL Jr, *see* Pozo C
Moldawer N, *see* Figlin RA
Molepo JM, *see* Gregg RW
Molina R, *see* Allred DC
Molinolo A, *see* Greiner JW
Monfardini S, *see* Tirelli U
Monpetit VJA, *see* Gregg RW
Montana G, *see* Rodriguez GC
Moon S, *see* Kaminski MS
Morawetz RB, *see* Dropcho EJ
Morel P, Lepage E, Brice P, Dupriez B, D'Agay M-F, Fenaux P, Gosselin B, Bauters F, Gisselbrecht C. Prognosis and treatment of lymphoblastic lymphoma in adults: A report on 80 patients, 1078
Morgan RJ, *see* Margolin KA
Mortimer J, *see* Beck TM
Mortimer JE, *see* Jacobs C
Mosijczuk A, *see* Trueworthy R
Mostofi FK, *see* Sesterhenn IA
Motomiya M, *see* Fukuoka M
Motzer R, *see* Gulati S
Motzer RJ, *see* Ilson DH
Mouridsen H, *see* Pedersen-Bjergaard J
Mudgett E, *see* Kaminski MS
Mueller BU, Skelton J, Callender DPE, Marshall D, Gress J, Longo D, Norton J, Rubin M, Venzon D, Pizzo PA. A prospective randomized trial comparing the infectious and noninfectious complications of an externalized catheter versus a subcutaneously implanted device in cancer patients, 1943
Muggia F. Search for the optimal treatment of ovarian cancer: Heavy metals, "belly baths," and yew trees (editorial), 683
Muggia FM, *see* Leichman L
— *see* Nichols CR
— *see* Speyer JL
Muhonen T, *see* Pyrhönen S
Mulder NH, *see* Sleijfer DTh
Mulhern RK, Kovnar E, Langston J, Carter M, Fairclough D, Leigh L, Kun LE. Long-term survivors of leukemia treated in infancy: Factors associated with neuropsychologic status, 1095
Mullen M, *see* Shea TC
Munniksma CN, *see* de Jong J
Munro A, *see* Sturgeon JFG
Murphy RF, *see* Berg SL
— *see* Smith MA
Murphy WK, *see* Beck TM
Murray C, *see* Soiffer RJ
Murray JL, *see* Ziegler LD
Murray P, *see* Coates A
— *see* Kelsen D
Murthy S, *see* Budd GT
Myers C, Cooper M, Stein C, LaRocca R, Walther MM, Weiss G, Choyke P, Dawson N, Steinberg S, Uhrich MM, Cassidy J, Kohler DR, Trepel J, Linehan WM. Suramin: A novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer, 881
Mylonakis N, *see* Kosmidis PA

Nadler LM, *see* Soiffer RJ
Nahhas WA, *see* Alberts DS
Nakagawa K, *see* Masuda N
Nakajima S, *see* Fukuoka M
Namer M, *see* Etienne MC
Nanus D, *see* Ilson DH
Nash A, *see* Jones AL
Nash S, *see* O'Dwyer PJ
Navari RM, *see* Beck TM
Negoro S, *see* Fukuoka M
— *see* Masuda N
Neidhart J, *see* Gucalp R
Neidhart JA, Mangalik A, Stidley CA, Tebich SL, Sarmiento LE, Pfile JE, Oette DH, Oldham FB. Dosing regimen of granulocyte-macrophage colony-stimulating factor to support dose-intensive chemotherapy, 1460
Neiman RS, *see* Hochster HS
Neuhauss R, *see* Gatzemeier U
Neville AM, Bettelheim R, Gelber RD, Säve-Söderbergh J, Davis BW, Reed R, Torhorst J, Golouh R, Peterson HF, Price KN, Isley M, Rudenstam C-M, Collins J, Castiglione M, Senn H-J, Goldhirsch A for the International Breast Study Group. Factors predicting treatment responsiveness and prognosis in node-negative breast cancer, 696
— *see* Gusterson BA
Newlands ES, *see* Mead GM

Newton B, *see* Shea TC
Nicaise C, *see* Ziegler LD
Nichols CR, Andersen J, Lazarus HM, Fisher H, Greer J, Stadtmauer EA, Loehrer PJ, Trump DL. High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: An Eastern Cooperative Oncology Group protocol, 558
—, Roth BJ, Williams SD, Gill I, Muggia FM, Stablein DM, Weiss RB, Einhorn LH. No evidence of acute cardiovascular complications of chemotherapy for testicular cancer: An analysis of the Testicular Cancer Intergroup study, 760
Nicholson PW, *see* Lee CR
Niedzwiecki D, *see* Kelsen D
— *see* Kemeny N
— *see* Rusch VW
Nielsen D, *see* Pedersen-Bjergaard J
Nieuwenhuis HK, *see* Verdonck LF
Niiranen A, Niitamo-Korhonen S, Kouri M, Assendelft A, Mattson K, Pyrhönen S. Adjuvant chemotherapy after radical surgery for non–small-cell lung cancer: A randomized study, 1927
Niitamo-Korhonen S, *see* Niiranen A
Niitani H, *see* Fukuoka M
Nimer SD, *see* Schiller GJ
Nishioka M, *see* Masuda N
Nishiwaki Y, *see* Fukuoka M
Nissen NI, *see* Hovgaard DJ
Nitschke R, *see* Castleberry RP
Nolte S, *see* Lerman C
Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: A randomized trial, 904
Noriega V, *see* Pozo C
Normolle DP, *see* Kaminski MS
Norris D, *see* Friedman HS
Norton J, *see* Mueller BU
Novero D, *see* Vitolo U

Oakes WJ, *see* Friedman HS
Oberlin O, Habrand J-L, Zucker JM, Brunat-Mentigny M, Terrier-Lacombe M-J, Dubousset J, Gentet J-C, Schmitt C, Ponvert D, Carrié C, Lemerle J. No benefit of ifosfamide in Ewing's sarcoma: A nonrandomized study of the French Society of Pediatric Oncology, 1407
—, Leverger G, Pacquement H, Raquin MA, Chompret A, Habrand JL, Terrier-Lacombe MJ, Bey P, Bertrand Y, Rubie H, Behar C, Zucker JM, Schaison G, Lemerle J. Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin's disease: The experience of the French Society of Pediatric Oncology, 1602
O'Brien S, *see* Kantarjian HM
Ochs JJ, *see* Schell MJ
O'Connell G, *see* Swenerton K
O'Connell MJ. Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric cancer: An old lesson revisited (editorial), 515
— *see* Hochster HS
O'Dwyer PJ, LaCreta FP, Schilder R, Nash S, McAleer C, Miller LL, Hudes GR, Ozols RF. Phase I trial of thiotepa in combination with recombinant human granulocyte-macrophage colony-stimulating factor, 1352
Oette DH, *see* Neidhart JA
Ognibene FP, *see* Sarosy G
Oken MM, *see* Hochster HS
— *see* Weisdorf DJ
Oldfield EH, *see* Goffman TE
Oldham FB, *see* Neidhart JA
Oleson J, *see* Rodriguez GC
Ollivier JM, *see* Rougier P
Olweny C, *see* Gill PG
O'Moore P, *see* Ilson DH
Omura GA, *see* Roth BJ
— *see* Vogler WR
Oppenheim JJ, *see* Smith JW II
Orazem J, *see* Grant SC
O'Reilly SE, *see* Hoskins PJ
Orsucci L, *see* Vitolo U
Osanto S, Bukman A, Van Hoek F, Sterk PJ, De Laat JAPM, Hermans J. Long-term effects of chemotherapy in patients with testicular cancer, 574
Osborne CK. Prognostic factors for breast cancer: Have they met their promise? (editorial), 679
— William Leo McGuire, MD, 1937–1992 (in memoriam), 1377
—, Wiebe VJ, McGuire WL, Ciocca DR, DeGregorio MW. Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients, 304
— *see* Allred DC
— *see* Clark GM
— *see* Ravdin PM
— *see* Wiebe VJ
Osborne MP, *see* Yahalom J
O'Toole R, *see* Alberts DS
Ous S, *see* Fossâ SD
Owens MA, *see* Clark GM
Oyen WJG, Claessens RAMJ, Raemaekers JMM, de Pauw BE, van der Meer JWM, Corstens FHM. Diagnosing infection in febrile granulocytopenic patients with indium-111–labeled human immunoglobulin G, 61
Ozols RF, *see* O'Dwyer PJ
— *see* Rothenberg ML

Pacquement H, *see* Oberlin O
Paffetti P, *see* Francini G
Pailler JL, *see* Rougier P
Palazzolo P, *see* Ziegler LD
Panici PB, *see* Scambia G
Papa G, *see* Biti GP
Papadopoulos NE, *see* Vadhan-Raj S
Papamichail M, *see* Kosmidis PA
Papanastasiou M, *see* Kosmidis PA
Papi MG, *see* Biti GP
Paredes J, *see* Krown SE

Parham D, *see* Meyer WH
Parkinson DR, *see* Smith MA
Parkinson MC, *see* Mead GM
— *see* Read G
Parzuchowski JB, *see* LeVeque FG
Passalacqua R, *see* Cocconi G
Patenaude AF, *see* Hays DM
Pater J, *see* Swenerton K
Patterson GA, *see* Burkes RL
Payne D, *see* Sagman U
— *see* Warde P
Pearce R, *see* Chopra R
Pearson FG, *see* Burkes RL
Peckham V, *see* Silber JH
Pedersen-Bjergaard J, Sigsgaard TC, Nielsen D, Gjedde SB, Philip P, Hansen M, Larsen SO, Rørth M, Mouridsen H, Dombernowsky P. Acute monocytic or myelomonocytic leukemia with balanced chromosome translocations to band 11q23 after therapy with 4-epi-doxorubicin and cisplatin or cyclophosphamide for breast cancer, 1444
Pendergrass K, *see* Beck TM
Pereira C, *see* Margolin KA
Perilongo G, *see* Silber JH
Perkins RC, *see* Vadhan-Raj S
Perona G, *see* Vitolo U
Perrimond H, *see* Michel G
Perry MC, *see* Aisner J
Petersen F, *see* Chopra R
Petersen FB, *see* Bensinger WI
— *see* Clift RA
Peterson HF, *see* Neville AM
Peterson R, *see* Bukowski RM
Petrek JA, *see* Yahalom J
Petrioli R, *see* Francini G
Pfile JE, *see* Neidhart JA
Phares JC, *see* Foss FM
— *see* Longo DL
Phelps RM, *see* Foss FM
Philip P, *see* Pedersen-Bjergaard J
Philip T, *see* Chopra R
— *see* Frappaz D
Phillips M, *see* Markman M
Phillips TL, *see* MacKenzie MR
Piantadosi S, *see* Wagner JE
Pierce S, *see* Kantarjian HM
Pignon B, *see* Bosly A
Pileri A, *see* Gianni AM
— *see* Vitolo U
Pinedo HM, van Rijswijk REN. Suramin awakes? (editorial), 875
— *see* van Rijswijk REN
Piro LD. 2-Chlorodeoxyadenosine: Drug development priorities (editorial), 1507
— *see* Kay AC
Pizzo PA, *see* Mueller BU
Pizzolo G, *see* Foa R
Pizzuto F, *see* Markman M
Planteydt HT, *see* Mattson K
Plouvier E, *see* Michel G
Plunkett W, *see* Grunewald R
Plunkett WK, *see* Redman JR
Podczaski E, *see* Leitzel K
Polsky B, *see* Krown SE
Ponticelli P, *see* Biti GP
Ponvert D, *see* Oberlin O
Poon AO, *see* Coppes MJ
Poplack DG, *see* Adamson PC
— *see* Berg SL
— *see* Smith MA
Portenoy RK. Cancer pain: From curriculum to practice change (editorial), 1830
— *see* Brescia FJ
Postmus PE, Gietema JA, Damsma O, Biesma B, Limburg PC, Vellenga E, de Vries EGE. Effects of recombinant human interleukin-3 in patients with relapsed small-cell lung cancer treated with chemotherapy: A dose-finding study, 1131
Potts S, *see* Ritter MA
Powles TJ, *see* Jones AL
Pozo C, Carver CS, Noriega V, Harris SD, Robinson DS, Ketcham AS, Legaspi A, Moffat FL Jr, Clark KC. Effects of mastectomy versus lumpectomy on emotional adjustment to breast cancer: A prospective study of the first year postsurgery, 1292
Pozza F, *see* Gasparini G
Prados MD, *see* Levin VA
Pratt CB, *see* Meyer WH
Pressler K, *see* Brugger W
Price KN, *see* Gusterson BA
— *see* Neville AM
Pringle J, *see* Bramwell VHC
Pringle JF, *see* Sagman U
Pugh RP, *see* Ravdin PM
Pui C-H, *see* Baker DK
Pullen J, *see* Trueworthy R
Pyrhönen S, Hahka-Kemppinen M, Muhonen T. A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma, 1919
— *see* Niiranen A

Qvist H, *see* Fosså SD

Raats JI, Falkson G, Falkson HC. A study of fadrozole, a new aromatase inhibitor, in postmenopausal women with advanced metastatic breast cancer, 111
Rabinowe SN, *see* Soiffer RJ
Radcliffe J, *see* Silber JH
Radin R, *see* Leichman L
Raemaekers JMM, *see* Oyen WJG
Ragab AH, *see* Friedman HS
— *see* Kuerbitz SJ
Raghavan D, Cox K, Childs A, Grygiel J, Sullivan D. Hypercholesterolemia after chemotherapy for testis cancer, 1386
— *see* Loehrer PJ Sr
Rajnoldi AC, *see* Rovelli A
Ramming K, *see* Richards JM
Randolph JA, *see* Roth BJ
Raney RB Jr, *see* Heyn R
Rangel CS, *see* Leith CP
Rao B, *see* Meyer WH

Raquin MA, *see* Oberlin O
Raschko J, *see* Margolin KA
Raschko JW, *see* Margolin KA
Rasmussen TB, *see* Bach F
Raspadori D, *see* Foa R
Ratain MJ, *see* Kodish E
Ravdin PM, Green S, Dorr TM, McGuire WL, Fabian C, Pugh RP, Carter RD, Rivkin SE, Borst JR, Belt RJ, Metch B, Osborne CK. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: Results of a prospective Southwest Oncology Group study, 1284
Ravindranath Y, *see* Kuerbitz SJ
Ray G, *see* MacKenzie MR
Ray M, *see* Leichman L
Read G, Stenning SP, Cullen MH, Parkinson MC, Horwich A, Kaye SB, Cook PA for the Medical Research Council Testicular Tumors Working Party. Medical Research Council prospective study of surveillance for stage I testicular teratoma, 1762
Reaman G, *see* Berg SL
— *see* Smith MA
Reck M, *see* Gatzemeier U
Recondo G, *see* Robert J
Redding SW, *see* LeVeque FG
Redman JR, Cabanillas F, Velasquez WS, McLaughlin P, Hagemeister FB, Swan F Jr, Rodriguez MA, Plunkett WK, Keating MJ. Phase II trial of fludarabine phosphate in lymphoma: An effective new agent in low-grade lymphoma, 790
Redmond D, *see* Gregg RW
Reed E, *see* Rothenberg ML
— *see* Sarosy G
Reed R, *see* Gusterson BA
— *see* Neville AM
Rege VB, *see* Strauss GM
Reich L, *see* Gulati S
Reichard BA, *see* Wasserman R
Reichert CM, *see* Lichter AS
Reichman B, *see* Markman M
— *see* Minsky BD
Relling MV, *see* Baker DK
Renard N, *see* Lienard D
Renee N, *see* Etienne MC
— *see* Milano G
Resegotti L, *see* Vitolo U
Rey M, *see* Speyer JL
Ricart E, *see* Bolufer P
Richards JM, Mehta N, Ramming K, Skosey P. Sequential chemoimmunotherapy in the treatment of metastatic melanoma, 1338
Richards MA, *see* Gregory WM
Richman SP, *see* Gucalp R
Richmond H, *see* Sturgeon JFG
Rios MB, *see* Kantarjian HM
Ritch P, *see* Gucalp R
— *see* Hochster HS
Ritchey AK, *see* Wofford MM
Ritter MA, Messing EM, Shanahan TG, Potts S, Chappell RJ, Kinsella TJ. Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer, 1208
Ritz J, *see* Soiffer RJ
Rivera GK, *see* Wofford MM
Rivkin SE, *see* Ravdin PM
Rivkind SE, *see* Sesterhenn IA
Rizzari C, *see* Rovelli A
Roberson P, *see* Meyer WH
Robert J, Armand JP, Huet S, Klink-Alakl M, Recondo G, Hurteloup P. Pharmacokinetics and metabolism of 4′-iodo-4′-deoxy-doxorubicin in humans, 1183
Robert NJ, *see* Atkins MB
— *see* Wazer DE
Robertson MJ, *see* Soiffer RJ
Robinson BA, *see* Ellis PA
Robinson DS, *see* Pozo C
Robison L, *see* Bernstein ML
Roché H, *see* de Forni M
Rodman JH, *see* Baker DK
Rodriguez A, *see* Bolufer P
Rodriguez GC, Soper JT, Berchuck A, Oleson J, Dodge R, Montana G, Clarke-Pearson DL. Improved palliation of cerebral metastases in epithelial ovarian cancer using a combined modality approach including radiation therapy, chemotherapy, and surgery, 1553
Rodriguez MA, *see* Redman JR
Rodu B, *see* LeVeque FG
Rogers D, *see* De Bernardi B
Romero R, *see* Bolufer P
Romitti L, *see* Rovelli A
Ronan SG, *see* Blend MJ
Roos S, *see* Rougier P
Rørth M, *see* Pedersen-Bjergaard J
Roseman DL, *see* Tormey DC
Rosen D, *see* Wofford MM
Rosen G, *see* Meyers PA
Rosen PP, *see* Yahalom J
Rosenbaum P, *see* Feeny D
Rosenberg SA. The immunotherapy and gene therapy of cancer (Karnofsky Memorial Lecture), 180
— *see* Lichter AS
— *see* Sanda MG
— *see* Weber JS
Rosenfeld SS, *see* Dropcho EJ
Rosowsky A, *see* Ayash LJ
Rossi Ferrini PL, *see* Biti GP
Rossi MR, *see* Rovelli A
Rossio J, *see* Smith JW II
Rota-Scalabrini D, *see* Vitolo U
Roth BJ, Johnson DH, Einhorn LH, Schacter LP, Cherng NC, Cohen HJ, Crawford J, Randolph JA, Goodlow JL, Broun GO, Omura GA, Greco FA. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group, 282
— *see* Nichols CR
Rothenberg M, *see* Sarosy G
Rothenberg ML, Ozols RF, Glatstein E, Steinberg SM, Reed

E, Young RC. Dose-intensive induction therapy with cyclophosphamide, cisplatin, and consolidative abdominal radiation in advanced-stage epithelial ovarian cancer, 727
Rotman N, *see* Rougier P
Rouesse J, *see* Bramwell VHC
Rougier P, Laplanche A, Huguier M, Hay JM, Ollivier JM, Escat J, Salmon R, Julien M, Audy J-CR, Gallot D, Gouzi JL, Pailler JL, Elias D, Lacaine F, Roos S, Rotman N, Luboinski M, Lasser P. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: Long-term results of a prospective randomized trial, 1112
Rovelli A, Biondi A, Rajnoldi AC, Conter V, Giudici G, Jankovic M, Locasciulli A, Rizzari C, Romitti L, Rossi MR, Schirò R, Tosi S, Uderzo C, Masera G. Microgranular variant of acute promyelocytic leukemia in children, 1413
Rovera G, *see* Wasserman R
Rowinsky E, *see* Markman M
Rowinsky EK, Grochow LB, Hendricks CB, Ettinger DS, Forastiere AA, Hurowitz LA, McGuire WP, Sartorius SE, Lubejko BG, Kaufmann SH, Donehower RC. Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor, 647
Rowland RG, *see* Sesterhenn IA
Rowley S, *see* Wagner JE
Rowley SD, *see* Graham ML
Roy M, *see* Swenerton K
Rozencweig M, *see* Jacobs C
Rubie H, *see* Frappaz D
— *see* Michel G
— *see* Oberlin O
Rubin EH, Andersen JW, Berg DT, Schiffer CA, Mayer RJ, Stone RM. Risk factors for high-dose cytarabine neurotoxicity: An analysis of a Cancer and Leukemia Group B trial in patients with acute myeloid leukemia, 948
Rubin M, *see* Mueller BU
Rubin S, *see* Markman M
Ruccione K, *see* Hays DM
Rudders RA, *see* Soiffer RJ
Rudenstam C-M, *see* Gusterson BA
— *see* Neville AM
Ruiz A, *see* Bolufer P
Runowicz CD, *see* Einzig AI
Ruscetti FW, *see* Smith JW II
Rusch VW, Niedzwiecki D, Tao Y, Menendez-Botet C, Dnistrian A, Kelsen D, Saltz L, Markman M. Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: Pharmacokinetic studies, 1001
Ryan M, *see* Brescia FJ
Rybski JA, *see* Leith CP

Sadoun A, *see* Detourmignies L
Sagman U, Lishner M, Maki E, Shepherd FA, Haddad R, Evans WK, DeBoer G, Payne D, Pringle JF, Yeoh JL, Ginsberg R, Feld R. Second primary malignancies following diagnosis of small-cell lung cancer, 1525
Sainsbury JRC, *see* Gasparini G
Salem P, *see* Vadhan-Raj S
Salk DJ, *see* Blend MJ
Sallan SE, *see* Hays DM
— *see* Waber DP
Salmon R, *see* Rougier P
Saltz L, *see* Kelsen D
— *see* Minsky BD
— *see* Rusch VW
Sampson E, *see* Leitzel K
Sanda MG, Yang JC, Topalian SL, Groves ES, Childs A, Belfort R Jr, de Smet MD, Schwartzentruber DJ, White DE, Lotze MT, Rosenberg SA. Intravenous administration of recombinant human macrophage colony-stimulating factor to patients with metastatic cancer: A phase I study, 1643
Sanders J, *see* Clift RA
Sanger J, *see* Speyer JL
Santabárbara P, *see* Martín M
Santana VM, Mirro J Jr, Kearns C, Schell MJ, Crom W, Blakley RL. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia, 364
Santini J, *see* Milano G
Santos GW, *see* Graham ML
— *see* Wagner JE
Sanz M, *see* Detourmignies L
Saral R, *see* Wagner JE
Sariban E, *see* Frappaz D
Sarma PR, *see* Gucalp R
Sarmiento LE, *see* Neidhart JA
Sarosdy MF, *see* Loehrer PJ Sr
Sarosy G, Kohn E, Stone DA, Rothenberg M, Jacob J, Adamo DO, Ognibene FP, Cunnion RE, Reed E. Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer, 1165
Sartorius SE, *see* Rowinsky EK
Sasloff J, *see* Einzig AI
Sato J, *see* Berg SL
Sausville EA, *see* Foss FM
Saven A, *see* Kay AC
Säve-Söderbergh J, *see* Gusterson BA
— *see* Neville AM
Sayre J, *see* Chlebowski RT
Scambia G, Panici PB, Battaglia F, Ferrandina G, Baiocchi G, Greggi S, De Vincenzo R, Mancuso S. Significance of epidermal growth factor receptor in advanced ovarian cancer, 529
Schacter L, *see* Jacobs C
Schacter LP, *see* Roth BJ
Schain W, *see* Lichter AS
Schaison G, *see* Oberlin O
Schechter GP, *see* Foss FM
Schell MJ, Ochs JJ, Schriock EA, Carter M. A Method of predicting adult height and obesity in long-term survivors of childhood acute lymphoblastic leukemia, 128
— *see* Santana VM
Scher HI, *see* Ilson DH
Scher R, *see* Hudes GR
Scheule RK, *see* Vadhan-Raj S

Schiff S, *see* MacKenzie MR
Schiffer CA, *see* Rubin EH
Schilder R, *see* O'Dwyer PJ
Schiller GJ, Nimer SD, Territo MC, Ho WG, Champlin RE, Gajewski JL. Bone marrow transplantation versus high-dose cytarabine-based consolidation chemotherapy for acute myelogenous leukemia in first remission, 41
Schirò R, *see* Rovelli A
Schleiermacher E, *see* Herrmann F
Schlom J, *see* Greiner JW
Schmidt-Ullrich R, *see* Wazer DE
Schmitt C, *see* Oberlin O
Schneider M, *see* Etienne MC
— *see* Milano G
Schnipper LE, *see* Antman K
Schoch G, *see* Clift RA
Schold SC Jr, *see* Dropcho EJ
Schoonover D, *see* Hays DM
Schriock EA, *see* Schell MJ
Schuller DE, *see* Forastiere AA
Schulz G, *see* Brugger W
Schwartzentruber DJ, *see* Sanda MG
— *see* Weber JS
Scott P, *see* Kaminski MS
Scriver C, *see* Bernstein ML
Seibel NL, *see* Kleinerman ES
Seiter K, *see* Kemeny N
Semenzato G, *see* Foa R
Senn H-J, *see* Neville AM
— *see* Gusterson BA
Sensebe L, *see* Tourani J-M
Sergi J, *see* Budd GT
Serraino D, *see* Tirelli U
Sesterhenn IA, Weiss RB, Mostofi FK, Stablein DM, Rowland RG, Falkson G, Rivkind SE, Vogelzang NJ. Prognosis and other clinical correlates of pathologic review in stage I and II testicular carcinoma: A report from the Testicular Cancer Intergroup study, 69
Shah N, *see* Wagner JE
Shambaugh S, *see* Leitzel K
Shanahan TG, *see* Ritter MA
Shane S, *see* Wasserman R
Shannon P, *see* Feld R
Shapiro CL, Mauch PM. Radiation-associated breast cancer after Hodgkin's disease: Risks and screening in perspective, 1662
Sharfman WH, *see* Smith JW II
Shea TC, Mason JR, Storniolo AM, Newton B, Breslin M, Mullen M, Ward DM, Miller L, Christian M, Taetle R. Sequential cycles of high-dose carboplatin administered with recombinant human granulocyte-macrophage colony-stimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: A novel and effective method for delivering multiple courses of dose-intensive therapy, 464
Shea WM, *see* Loeffler JS
Shelley W, *see* Swenerton K
Shepherd FA, Laskey J, Evans WK, Goss PE, Johansen E, Khamsi F. Cushing's syndrome associated with ectopic corticotropin production and small-cell lung cancer, 21
— *see* Burkes RL
— *see* Feld R
— *see* Sagman U
Sherman DD, *see* Strauss GM
Shields J, *see* MacKenzie MR
Shimizu M, *see* Smith JW II
Shina DC, *see* Lazarus HM
Shiramizu B, Herndier B, Meeker T, Kaplan L, McGrath M. Molecular and immunophenotypic characterization of AIDS-associated, Epstein-Barr virus-negative, polyclonal lymphoma, 383
Shiu M, *see* Gaynor JJ
Shubinski RE, *see* de Forni M
Shulman KL, *see* Thompson JA
Shuster J, *see* Bernstein ML
— *see* Trueworthy R
Shuster JJ, *see* Castleberry RP
— *see* Wofford MM
Siegel R, *see* Gucalp R
Siegel RD, *see* Talcott JA
Siegel SE, *see* Hays DM
Siegler M, *see* Kodish E
Siena S, *see* Gianni AM
Signorini D, *see* Coates A
Sigsgaard TC, *see* Pedersen-Bjergaard J
Sigurdson ER, *see* Minsky BD
Sikic BI, *see* Lum BL
— *see* Yahanda AM
Silber JH, Radcliffe J, Peckham V, Perilongo G, Kishnani P, Fridman M, Goldwein JW, Meadows AT. Whole-brain irradiation and decline in intelligence: The influence of dose and age on IQ score, 1390
— *see* Wasserman R
Silberman H, *see* Leichman L
Simone JV, Meyer WH, Link MP. Osteosarcoma: Good news despite crude tools (editorial), 1
Simpson JF, *see* Greiner JW
Singer J, *see* Clift RA
Singer JW, *see* Bensinger WI
Singletary SE, *see* Buzdar AU
Skarin A, *see* Aisner J
Skarin AT, *see* Strauss GM
Skelton J, *see* Mueller BU
Sklar J, *see* Hunger SP
Skosey P, *see* Richards JM
Slawson R, *see* Aisner J
Sleijfer DTh, Janssen RAJ, Buter J, de Vries EGE, Willemse PHB, Mulder NH. Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis, 1119
Smalley RV, *see* Greiner JW
Smith DC, Tucker JA, Trump DL. Hypercalcemia and neuroendocrine carcinoma of the prostate: A report of three cases and a review of the literature, 499
Smith IE, *see* Castleberry RP
— *see* Jones AL
Smith JW II, Urba WJ, Curti BD, Elwood LJ, Steis RG, Janik JE, Sharfman WH, Miller LL, Fenton RG, Conlon KC, Sznol M, Creekmore SP, Wells NF, Rus-

cetti FW, Keller JR, Hestdal K, Shimizu M, Rossio J, Alvord WG, Oppenheim JJ, Longo DL.The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies, 1141
Smith MA, Adamson PC, Balis FM, Feusner J, Aronson L, Murphy RF, Horowitz ME, Reaman G, Hammond GD, Fenton RM, Connaghan GD, Hittelman WN, Poplack DG. Phase I and pharmacokinetic evaluation of all-*trans*-retinoic acid in pediatric patients with cancer, 1666
— , Parkinson DR, Cheson BD, Friedman MA. Retinoids in cancer therapy, 839
Smith R, *see* Goffman TE
Smith SD, *see* Wofford MM
Smith TJ, *see* Desch CE
— *see* Wazer DE
Smith TL, *see* Buzdar AU
Sneath R, *see* Bramwell VHC
Soegiarso W, *see* Lazarus HM
Soiffer RJ, Murray C, Mauch P, Anderson KC, Freedman AS, Rabinowe SN, Takvorian T, Robertson MJ, Spector N, Gonin R, Miller KB, Rudders RA, Freeman A, Blake K, Coral F, Nadler LM, Ritz J. Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow, 1191
Solary E, Caillot D, Chauffert B, Casasnovas R-O, Dumas M, Maynadie M, Guy H. Feasibility of using quinine, a potential multidrug resistance–reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia, 1730
Somers R, *see* Bramwell VHC
Somlo G, *see* Margolin KA
Soper JT, *see* Rodriguez GC
Sørensen JB, *see* Bach F
Sørensen PS, *see* Bach F
Souhami R, *see* Bramwell VHC
Souhami RL, *see* Lee CR
Soulié P, *see* de Forni M
Spanier SS, *see* Ellis ER
Sparling CR, *see* Coppes MJ
Spears CP, *see* Leichman L
Spector N, *see* Soiffer RJ
Speicher L, *see* Hudes GR
Speyer JL, Green MD, Zeleniuch-Jacquotte A, Wernz JC, Rey M, Sanger J, Kramer E, Ferrans V, Hochster H, Meyers M, Blum RH, Feit F, Attubato M, Burrows W, Muggia FM. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer, 117
Spier CM, *see* Leith CP
Spinelli JJ, *see* Hoskins PJ
Spooner D, *see* Bramwell VHC
Springfield DS, *see* Ellis ER
Sridhar KS, *see* Jacobs C
Stablein DM, *see* Nichols CR
— *see* Sesterhenn IA
Stadtmauer EA, *see* Nichols CR
Stain S, *see* Leichman L
Stanimir R, *see* Swenerton K
Stanisavljevic B, *see* Jeremic B
Steele GD Jr, *see* Lerner A
Stein C, *see* Myers C
Steinberg S, *see* Myers C
Steinberg SM, *see* Foss FM
— *see* Goffman TE
— *see* Lichter AS
— *see* Rothenberg ML
— *see* Wilson WH
Steinherz P, *see* Berg SL
Steis RG, *see* Smith JW II
Stenning SP, *see* Mead GM
— *see* Read G
Stenwig AE, *see* Fosså SD
Sterk PJ, *see* Osanto S
Steuber CP, *see* Kuerbitz SJ
Steuber P, *see* Trueworthy R
Steven K, *see* Geertsen PF
Stewart DJ, *see* Gregg RW
Stidley CA, *see* Neidhart JA
Stocker JL, *see* Foss FM
Stocking C, *see* Kodish E
Stock-Novack D, *see* Alberts DS
Stone DA, *see* Sarosy G
Stone RM, *see* Rubin EH
Stoppa AM, *see* Detourmignies L
Storb R, *see* Bensinger WI
— *see* Clift RA
Storniolo AM, *see* Shea TC
Stott P, *see* Hochster HS
— *see* Tormey DC
Straus K, *see* Lichter AS
Strauss GM, Herndon JE, Sherman DD, Mathisen DJ, Carey RW, Choi NC, Rege VB, Modeas C, Green MR. Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non–small-cell carcinoma of the lung: Report of a Cancer and Leukemia Group B phase II study, 1237
—, Langer MP, Elias AD, Skarin AT, Sugarbaker DJ. Multimodality treatment of stage IIIA non–small-cell carcinoma of the lung: A critical review of the literature and strategies for future research, 829
Strauss LC, *see* Graham ML
Stuart G, *see* Swenerton K
Stuart-Harris R, *see* Loehrer PJ Sr
Sturgeon JFG, Jewett MAS, Alison RE, Gospodarowicz MK, Blend R, Herman S, Richmond H, Thomas G, Duncan W, Munro A. Surveillance after orchidectomy for patients with clinical stage I nonseminomatous testis tumors, 564
Styles J, *see* Gusterson BA
Sugarbaker DJ, *see* Strauss GM
Sullivan D, *see* Raghavan D
Sullivan KM, *see* Clift RA
Surwit EA, *see* Alberts DS
Suzuki A, *see* Fukuoka M
Swain SM, *see* Lichter AS
Swan F Jr, *see* Redman JR
Swenerton K, Jeffrey J, Stuart G, Roy M, Krepart G, Carmichael J, Drouin P, Stanimir R, O'Connell G, MacLean G, Kirk ME, Canetta R, Koski B, Shelley W, Zee B, Pater J. Cisplatin-cyclophosphamide versus

carboplatin-cyclophosphamide in advanced ovarian cancer: A randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group, 718
Swenerton KD, *see* Hoskins PJ
Szer J, *see* Copelan EA
Sznol M, *see* Smith JW II
— *see* Weiss GR

Taetle R, *see* Shea TC
Taguchi, T, *see* Fukuoka M
Takada M, *see* Masuda N
Takifuji N, *see* Masuda N
Takvorian T, *see* Soiffer RJ
Talamini R, *see* Tirelli U
Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: A prospective, two-center validation of a prediction rule, 316
Talpaz M, *see* Kantarjian HM
Tamaro P, *see* De Bernardi B
Tammilehto L, *see* Mattson K
Tan CC, *see* Gaynor JJ
Tan S, *see* Jodrell DI
Tandon AK, *see* Allred DC
Tangen C, *see* Bukowski RM
Tannock I, *see* Loehrer PJ Sr
Tao Y, *see* Rusch VW
Tarassoff P, *see* Grunewald R
Tarbell NJ, *see* Waber DP
Tarella C, *see* Gianni AM
— *see* Vitolo U
Tauer K, *see* Gucalp R
Tebich SL, *see* Neidhart JA
Tefft M, *see* Heyn R
Teicher BA, *see* Antman K
Teramoto Y, *see* Leitzel K
Terao T, *see* Kobayashi H
Terrier-Lacombe MJ, *see* Oberlin O
Terrier-Lacombe M-J, *see* Oberlin O
Territo MC, *see* Schiller GJ
Testolin A, *see* Gasparini G
Tew K, *see* Hudes GR
Thaler HT, *see* DeAngelis LM
Thomas D, *see* Bramwell VHC
Thomas ED, *see* Bensinger WI
— *see* Clift RA
Thomas G, *see* Sturgeon JFG
Thomas M, *see* Waits TM
Thompson JA, Shulman KL, Benyunes MC, Lindgren CG, Collins C, Lange PH, Bush WH Jr, Benz LA, Fefer A. Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma, 960
Thuret I, *see* Michel G
Thurston D, *see* Kay AC
Thyss A, *see* Bosly A
— *see* Etienne MC
— *see* Milano G
Tidy A, *see* Jones AL
Tilg HJ, *see* Atkins MB
Tilly H, *see* Bosly A
Tiltman A, *see* Gusterson BA
Tirelli U, Zagonel V, Errante D, Serraino D, Talamini R, De Cicco M, Carbone A, Monfardini S. A prospective study of a new combination chemotherapy regimen in patients older than 70 years with unfavorable non-Hodgkin's lymphoma, 228
Todd T, *see* Burkes RL
Todeschini G, *see* Vitolo U
Toia M, *see* Gulati S
Toikkanen S, Helin H, Isola J, Joensuu H. Prognostic significance of HER-2 oncoprotein expression in breast cancer: A 30-year follow-up, 1044
Topalian SL, *see* Sanda MG
— *see* Weber JS
Topolsky D, *see* Lazarus HM
Torhorst J, *see* Gusterson BA
— *see* Neville AM
Tormey DC, Gray R, Abeloff MD, Roseman DL, Gilchrist KW, Barylak EJ, Stott P, Falkson G. Adjuvant therapy with a doxorubicin regimen and long-term tamoxifen in premenopausal breast cancer patients: An Eastern Cooperative Oncology Group trial, 1848
— *see* Allred DC
— *see* Clark GM
Torrance GW, *see* Feeny D
Tosi S, *see* Rovelli A
Toth M, *see* Haffty BG
Tourani J-M, Levy R, Colonna P, Desablens B, Leprise P-Y, Guilhot F, Brahimi S, Belhani M, Ifrah N, Sensebe L, Lemevel A, Lotz J-P, Le Maignan C, Andrieu J-M. High-dose salvage chemotherapy without bone marrow transplantation for adult patients with refractory Hodgkin's disease, 1086
Trentin L, *see* Foa R
Trepel J, *see* Myers C
Tretyakov O, *see* Ayash LJ
Triozzi P, *see* Forastiere AA
Troussard X, *see* Michel G
Trueworthy R, Shuster J, Look T, Crist W, Borowitz M, Carroll A, Frankel L, Harris M, Wagner H, Haggard M, Mosijczuk A, Pullen J, Steuber P, Land V. Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: A Pediatric Oncology Group study, 606
Trump D, *see* Loehrer PJ Sr
Trump DL, *see* Nichols CR
— *see* Smith DC
Tsavaris N, *see* Kosmidis PA
Tuchman M, *see* Bernstein ML
Tucker JA, *see* Smith DC
Tucker MA, *see* Ihde DC
Tutschka PJ, *see* Copelan EA

Uderzo C, *see* Rovelli A
Uhrich MM, *see* Myers C
Urba WJ, *see* Longo DL
— *see* Smith JW II
Uscinska B, *see* Bramwell VHC

Vachino G, *see* Atkins MB
Vadhan-Raj S, Broxmeyer HE, Hittelman WN, Papadopoulos NE, Chawla SP, Fenoglio C, Cooper S, Buescher ES, Frenck RW Jr, Holian A, Perkins RC, Scheule RK, Gutterman JU, Salem P, Benjamin RS. Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor: Protection at the progenitor cell level, 1266
van Breukelen FJM, *see* Mattson K
van der Eijken J, *see* Bramwell VHC
van der Meer JWM, *see* Oyen WJG
van der Vijgh JF, *see* de Jong J
van Glabbeke M, *see* Bramwell VHC
van Groeningen CJ, *see* van Rijswijk REN
Van Hoek F, *see* Osanto S
van Kempen ML, *see* Verdonck LF
van Loenen AC, *see* van Rijswijk REN
van Oosterom AT, *see* Bramwell VHC
van Rijswijk REN, van Loenen AC, Wagstaff J, Meijer E, Lopez R, van Groeningen CJ, Heimans JJ, Pinedo HM. Suramin: Rapid loading and weekly maintenance regimens for cancer patients, 1788
— *see* Pinedo HM
van Zandwijk N, *see* Mattson K
VandePol CJ, *see* Gucalp R
Vazquez C, *see* Bolufer P
Vega JML, *see* Martín M
Velasquez WS, *see* Redman JR
Velez-García E, *see* Jacobs C
— *see* Vogler WR
Vellenga E, *see* Postmus PE
Venzon D, *see* Mueller BU
Verdonck LF, Dekker AW, de Gast GC, Lokhorst HM, Nieuwenhuis HK. Autologous bone marrow transplantation for adult poor-risk lymphoblastic lymphoma in first remission, 644
—, Dekker AW, de Gast GC, van Kempen ML, Lokhorst HM, Nieuwenhuis HK. Salvage therapy with ProMACE-MOPP followed by intensive chemoradiotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma who failed to respond to first-line CHOP, 1949
— *see* Lokhorst HM
Vermorken JB, *see* de Jong J
Vernant JP, *see* Michel G
Viero P, *see* Vitolo U
Vinciguerra V, *see* Kelsen D
Viner C, *see* Mansi J
Viscoli C, *see* De Bernardi B
Vitek J, *see* Dropcho EJ
Vitolo U, Bertini M, Brusamolino E, Cavallero GB, Comotti B, Gallo E, Ghio R, Levis A, Luxi G, Meneghini V, Novero D, Orsucci L, Rota-Scalabrini D, Tarella C, Todeschini G, Viero P, Barbui T, Bernasconi C, Perona G, Pileri A, Resegotti L. MACOP-B treatment in diffuse large-cell lymphoma: Identification of prognostic groups in an Italian multicenter study, 219
Vlamis V, *see* Meyers PA
Vogelsang GB, *see* Wagner JE
Vogelzang NJ, *see* Ilson DH
— *see* Sesterhenn IA
Vogler WR, Velez-Garcia E, Weiner RS, Flaum MA, Bartolucci AA, Omura GA, Gerber MC, Banks PLC. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: A Southeastern Cancer Group study, 1103
Volas G, *see* Leitzel K
von der Maase H, *see* Geertsen PF
Von Hoff DD, *see* Forastiere AA
VonFeldt E, *see* Forastiere AA
Voûte PA, *see* Bramwell VHC

Waber DP, Tarbell NJ, Kahn CM, Gelber RD, Sallan SE. The relationship of sex and treatment modality to neuropsychologic outcome in childhood acute lymphoblastic leukemia, 810
Wagner H, *see* Trueworthy R
Wagner JE, Zahurak M, Piantadosi S, Geller RB, Vogelsang GB, Wingard JR, Saral R, Griffin C, Shah N, Zehnbauer BA, Ambinder R, Burns W, Jones R, May WS, Rowley S, Yeager A, Santos GW. Bone marrow transplantation of chronic myelogenous leukemia in chronic phase: Evaluation of risks and benefits, 779
Wagstaff J, *see* van Rijswijk REN
Wahl RL, *see* Kaminski MS
Waits TM, Johnson DH, Hainsworth JD, Hande KR, Thomas M, Greco FA. Prolonged administration of oral etoposide in non–small-cell lung cancer: A phase II trial, 292
Walde PLD, *see* Feld R
Walther MM, *see* Myers C
Ward DM, *see* Shea TC
Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis, 890
Warrell RP Jr. All-*trans*-retinoic acid: What is it good for? (editorial), 1659
Wasserman R, Galili N, Ito Y, Silber JH, Reichard BA, Shane S, Womer RB, Lange B, Rovera G. Residual disease at the end of induction therapy as a predictor of relapse during therapy in childhood B-lineage acute lymphoblastic leukemia, 1879
Waters PF, *see* Burkes RL
Watts P, *see* Hudes GR
Wazer DE, DiPetrillo T, Schmidt-Ullrich R, Weld L, Smith TJ, Marchant DJ, Robert NJ. Factors influencing cosmetic outcome and complication risk after conservative surgery and radiotherapy for early-stage breast carcinoma, 356
Weaver S, *see* Leitzel K
Webber B, *see* Heyn R
Weber JS, Yang JC, Topalian SL, Schwartzentruber DJ, White DE, Rosenberg SA. The use of interleukin-2 and lymphokine-activated killer cells for the treatment of patients with non-Hodgkin's lymphoma, 33
Weeks J. Quality-of-life assessment: Performance status upstaged? (editorial), 1827
Weiner MD, *see* Friedman HS
Weiner RS, *see* Vogler WR

Weinstein HJ, *see* Kuerbitz SJ
Weisdorf DJ, Andersen JW, Glick JH, Oken MM. Survival after relapse of low-grade non-Hodgkin's lymphoma: Implications for marrow transplantation, 942
Weiss G, *see* Myers C
Weiss GR, Margolin KA, Aronson FR, Sznol M, Atkins MB, Dutcher JP, Gaynor ER, Boldt DH, Doroshow JH, Bar MH, Hawkins MJ, Demchak PA, Gucalp R, Fisher RI. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma, 275
Weiss RB, *see* Nichols CR
— *see* Sesterhenn IA
Weitzman S, *see* Coppes MJ
— *see* Feeny D
Weld L, *see* Wazer DE
Wells NF, *see* Smith JW II
Wen PY, *see* Loeffler JS
Wernz JC, *see* Speyer JL
Wharam MD, *see* Wofford MM
Wharam MD Jr, *see* Graham ML
Wheeler C, *see* Antman K
— *see* Ayash LJ
White DE, *see* Sanda MG
— *see* Weber JS
Whitehead MV, *see* Friedman HS
Wiebe VJ, Osborne CK, McGuire WL, DeGregorio MW. Identification of estrogenic tamoxifen metabolite(s) in tamoxifen-resistant human breast tumors, 990
— *see* Osborne CK
Wiernik PH, *see* Einzig AI
— *see* Gucalp R
Wierzbicki R, *see* Feld R
Wiley JM, *see* Graham ML
Wilkinson PM, *see* Mead GM
Willemse PHB, *see* Sleijfer DTh
Williams SD, *see* Nichols CR
Williams SF, Gilewski T, Mick R, Bitran JD. High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: Follow-up report, 1743
Williamson SK, *see* Forastiere AA
Wilson CB, Larson DA, Gutin PH. Radiosurgery: A new application? (editorial), 1373
Wilson WH, Jain V, Bryant G, Cowan KH, Carter C, Cottler-Fox M, Goldspiel B, Steinberg SM, Longo DL, Wittes RE. Phase I and II study of high-dose ifosfamide, carboplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid tumors, 1712
Wiltshaw E, *see* Jodrell DI
Wingard JR, *see* Wagner JE
Winick N, *see* Castleberry RP
— *see* Kuerbitz SJ
Wiseberg J, *see* Kemeny N
Wittes RE, *see* Wilson WH
Wofford MM, Smith SD, Shuster JJ, Johnson W, Buchanan GR, Wharam MD, Ritchey AK, Rosen D, Haggard ME, Golembe BL, Rivera GK. Treatment of occult or late overt testicular relapse in children with acute lymphoblastic leukemia: A Pediatric Oncology Group study, 624
Wold H, *see* MacKenzie MR
Womer RB, *see* Wasserman R
Wong J, *see* Kelsen D
Woods WG, *see* Bernstein ML
Wright JE, *see* Ayash LJ

Yahalom J, Petrek JA, Biddinger PW, Kessler S, Dershaw DD, McCormick B, Osborne MP, Kinne DA, Rosen PP. Breast cancer in patients irradiated for Hodgkin's disease: A clinical and pathologic analysis of 45 events in 37 patients, 1674
Yahalom J, *see* DeAngelis LM
— *see* Gulati S
Yahanda AM, Adler KM, Fisher GA, Brophy NA, Halsey J, Hardy RI, Gosland MP, Lum BL, Sikic BI. Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance, 1624
— *see* Lum BL
Yang JC, *see* Sanda MG
— *see* Weber JS
Yeager A, *see* Wagner JE
Yeager AM, *see* Graham ML
Yeoh E, *see* Gill PG
Yeoh JL, *see* Sagman U
Yonemoto L, *see* Margolin KA
Young RC, *see* Longo DL
— *see* Rothenberg ML

Zagonel V, *see* Tirelli U
Zahurak M, *see* Wagner JE
Zandvoort SWH, *see* Coppes MJ
Zasadny KR, *see* Kaminski MS
Zee B, *see* Swenerton K
Zeffren J, *see* Figlin RA
Zehnbauer BA, *see* Wagner JE
Zeleniuch-Jacquotte A, *see* Speyer JL
Ziegler LD, Palazzolo P, Cunningham J, Janus M, Itoh K, Hayakawa K, Hellstrom I, Hellstrom KE, Nicaise C, Dennin R, Murray JL. Phase I trial of murine monoclonal antibody L6 in combination with subcutaneous interleukin-2 in patients with advanced carcinoma of the breast, colorectum, and lung, 1470
Zilber SL, *see* Hays DM
Zimm S, *see* Berg SL
Zimmer MB, *see* LeVeque FG
Zucker JM, *see* Frappaz D
— *see* Oberlin O

# SUBJECT INDEX


Acquired immunodeficiency disease, polyclonal EBV-negative lymphoma associated with, 383-389
ACTH, *see* Adrenocorticotropic hormone
Adenocarcinoma, poorly differentiated
  chemotherapy responsiveness in, 919
  cisplatin-based combination chemotherapy for, 912-922
  pathology of, 915
  prognostic factors in, 916-918
  tumor site and, 919
Adrenocorticotropic hormone
  ectopic production of, combination chemotherapy response and, 23-25
  SCLC and, 21-27
Adults, lymphoblastic lymphoma in, 1078-1085
AFP, *see* Alpha-fetoprotein
Age
  in acute lymphoblastic leukemia, 606-613
  autologous *v* allogeneic BMT and, 1693
  5-FU clearance and, 1171-1175
  GVHD incidence and, 1194-1195
  young, relapsed breast cancer and, 476-477
AIDS, polyclonal EBV-negative lymphoma associated with, 383-389
ALL, *see* Leukemia, acute lymphocytic
All-*trans*-retinoic acid
  clinical responses to, 1669
  dose-limiting toxicities of, 1668
  in pediatric patients, 1666-1673
  pediatric pharmacokinetics of, 1670
  pharmacokinetics of, 1667, 1669-1670
  phase I trial of, 1666-1673
  utility of, 1659-1661
Alpha-fetoprotein, prelymphadenectomy levels of, in testicular cancer, 75
Aminoglutethimide
  adjuvant, in breast cancer, 1547-1552
  hydrocortisone plus
    in breast cancer, 984-989
    side effects of, 988
  toxicity of, 1551
Analgesic, for cancer pain, 1978-1979
Anti-CD37 imaging, in B-cell lymphoma, 1696-1711
Anti-T12 monoclonal antibody, in GVHD prevention, 1191-1200
21N Antibody, immunocytochemical staining with, 689
Antibody(ies)
  monoclonal, *see* Monoclonal antibody(ies)
  myeloid, diagnostic sensitivity of, 1422
Antibody-dependent cellular toxicity
  measurement of, 1471
  natural-killer–cell activity and, 1475
Anticonvulsant therapy, teniposide and, 311-315
Antigen(s)
  c-*erb*B-2, *see* c-*erb*B-2 antigen
  cell-surface, in acute myeloid leukemia, 1419-1429
  expression of, in childhood acute myeloid leukemia, 1421
  *see also specific types*
Apoptosis, retinoic acid and, 846-847
Area-under-the-curve
  for carboplatin, 520-528
  for mitomycin, 1004
Aromatase activity
  distant metastasis and, 442
  estradiol receptor status and, 443
  in breast cancer, 438-446
  tumor estradiol status and, 444
  tumor size and, 442
Asparaginase
  in combination chemotherapy, for lymphoblastic lymphoma, 1078-1085
  in LNH-84 regimen, for relapsing lymphomas, 1615-1623
Astrocytic neoplasm, low-grade, treatment of, 253
Astrocytoma, pilocytic, 252

B-cell lineage, in lymphoma, 1259-1265
B-lymphoid antigen, in acute myeloid leukemia, 1421
Basal cell carcinoma, retinoids in, 851
Bladder cancer, retinoids in, 853
Bleomycin
  cumulative doses of, 576
  in chemoimmunotherapy, for metastatic melanoma, 1919-1926
  in combination chemotherapy
    for childhood HD, 1602-1608
    for poorly differentiated carcinoma, 912-922
  in LNH-84 regimen, for relapsing lymphomas, 1615-1623
  long-term effects of, 574-579
BMT, *see* Bone marrow transplantation
Bone
  Ewing's sarcoma of, etoposide plus ifosfamide in, 1737-1742
  solitary plasmacytoma of, 587-590
Bone marrow
  autologous stem-cell rescue, in stage IV breast cancer, 1743-1747
  donor, CD6-positive T lymphocyte depletion from, 1191-1200
  in vitro treatment of, 1684
  tumor cell detection in, 1534-1539
Bone marrow transplantation
  allogeneic
    in acute lymphoblastic leukemia, 237-242
    in acute myeloid leukemia, 1865-1869
    busulfan plus cyclophosphamide for, 1492-1497
    for children, 1865-1869
    in chronic myelogenous leukemia, 779-789
    complications following, 239, 783-784
    in first leukemia relapse, 1723-1729
    GVHD prophylaxis in, 780-781
    GVHD treatment in, 781
    preparation for, 238
    procedure for, 780
    prognostic factors in, 784
    supportive care in, 781
    survival following, 782-785
  anti-T12 monoclonal antibody in, toxicity associated with, 1194-1195
  autologous
    busulfan plus, 1569-1573
    combination chemotherapy and, 102-110
    in HD, 200-209
    toxicity criteria and, 1715-1716
  autologous *v* allogeneic, for NHL, 1690-1695

Bone marrow transplantation (*Continued*)
busulfan plus
acute toxicity of, 1571
early deaths with, 1572
hematologic toxicity of, 1571
nonhematologic toxicity of, 1572
carmustine, etoposide, cisplatin regimen plus, 1682-1689
characteristics in, 43
in chemoimmunotherapy, for germ cell cancer, 558-563
chemoradiotherapy plus, for NHL, 1949-1954
chemotherapy following, 1861
chemotherapy *v*, in acute myelogenous leukemia, 41-46
chemotherapy without, in HD, 1086-1094
in combined modality therapy
for lymphoblastic lymphoma, 644-646
for pediatric solid tumors, 1857-1864
for resistant NHL, 936-941
GVHD and, 1726
GVHD prevention in, 1191-1200
high-dose chemotherapy plus
in breast cancer, 517-519
in inflammatory breast cancer, 1020-1021
ifosfamide, carboplatin, etoposide regimen plus, 1712-1722
LNH-84 regimen plus, in relapsing lymphomas, 1615-1623
mortality related to, 1694
preparative regimens for, 1724
protocol for, 1683
relapse probability in, 1725
in relapsed testicular cancer, 629
second, following relapse, 784
Bone metastases
clodronate for, 591-598
dichloromethylene bisphosphonate for, 591-598
Brachytherapy technique, intraoperative, 1220
Brain
irradiation of, IQ score following, 1390-1396
metastases to
chemotherapy of, 1498-1502
delayed, treatment of, 1501
initial, treatment of, 1500-1501
therapeutic cranial irradiation in, 1499
of ovarian cancer, palliation of, 1553-1560
prophylactic cranial irradiation and, 1242
Brain tumor
patients with, health status classification of, 926
pediatric, carboplatin *v* iproplatin for, 249-256
recurrent, chemoradiotherapy in, 766-771
Breast cancer
adjuvant aminoglutethimide in, 1547-1552
aminoglutethimide plus hydrocortisone in, 984-989
aromatase activity in, 438-446
bone marrow tumor cell detection in, 1534-1539
c-*erb*B-2 in, 1034-1036
chemoimmunotherapy in, 1540-1546
conservative surgery plus radiotherapy in, 356-363
cyclophosphamide, thiotepa, carboplatin regimen in, 102-110
doxorubicin, cyclophosphamide, leukocyte alpha-interferon regimen in, 1540-1546
early-stage, cosmetic outcome and, 356-363
4-epi-doxorubicin for, 1444-1451
Breast cancer (*Continued*)
epidermal growth factor receptor and aromatase activity in, 438-446
estradiol and aromatase activity in, 438-446
estrogen receptor-positive, with metastatic disease, 1284-1291
5-FU plus leucovorin in, 1278-1283
good-risk node-negative, S-phase prognostic significance for, 428-432
following HD
clinical information for, 1671
outcome of, 1677
pathology of, 1671-1672
treatment of, 1677
HER-2 oncoprotein in, 1044-1048
HER-2-*neu* oncogene expression in, 599-605
high-dose chemotherapy in
nonmortal side effects of, 665-666
overall survival of, 664-665
response duration of, 663-664
response rates of, 663
symptom relief of, 664-665
toxicity of, 665
high-dose chemotherapy plus BMT in, 517-519, 657-670
studies of, 659
high-dose cyclophosphamide in, 102-110
ICRF-187 plus doxorubicin in, 117-127
inflammatory, 1014-1024
classification of, 1015
clinical features of, 1015-1016
combined modality therapy of, 1018-1020
current status in, 1021-1022
epidemiology of, 1014-1015
future directions in, 1022
high-dose chemotherapy plus BMT in, 1020-1021
hormonal assay results in, 1017
hormonal manipulation in, 1018
pathology of, 1016-1017
prognostic factors in, 1017
surgery in, 1017
interval for developing, following HD, 1675
invasive lobular, 479-480
local recurrence of, prognosis following, 1845
locally recurrent
DNA flow cytometry in, 1839-1847
management of, 1841
lumpectomy plus radiation *v* mastectomy in, 976-983
mastectomy *v* lumpectomy in, 1292-1298
medroxyprogesterone acetate in, 1176-1182
metastatic
carboplatin in, 433-437
conventional-dose chemotherapy in, 660-662
fadrozole in, 111-116
mucin, serum marker for, 1057-1065
node-negative
HER-2-*neu* overexpression in, 599-605
perioperative chemotherapy in, 696-705
prognostic factors in, 696-705
postmenopausal, aromatase activity in, 438-446
in postmenopausal patients, aminoglutethimide for, 1547-1552
premenopausal, adjuvant therapy of, 1848-1856
progesterone receptor levels in, 1284-1291

Breast cancer (*Continued*)
prognostic factors in, 679-682, 686-695
psychologic measures in, 1294
psychologic well-being in, 1295-1297
radiation-associated, following HD, 1662-1665, 1674-1681
relapsed
adjuvant chemotherapy and, 480
aggressive therapy strategies and, 480-482
extensive intraductal component and, 474-475
high risk for, 474-483
histologic grade and, 476
histopathologic predictors for, 474-476
infiltrating lobular histology and, 476-479
intralymphatic extension and, 476
marked mononuclear cell reaction and, 476-479
S-phase prognostic significance for, 428-432
tumor necrosis and, 476
young age and, 476-477
retinoids in, 852
serum marker for, 1057-1065
serum of, c-*erb*B-2 antigen in, 1436-1443
stage IV
cyclophosphamide, doxorubicin, vincristine, methotrexate, leucovorin regimen in, 1743-1747
cyclophosphamide, thiotepa, autologous stem-cell rescue regimen in, 1743-1747
cyclophosphamide, thiotepa, carmustine regimen in, 1743-1747
5-FU, cisplatin, doxorubicin, cyclophosphamide regimen in, 1743-1747
high-dose consolidation therapy in, 1743-1747
high-dose therapy in, 107
systemic adjuvant chemotherapy in, 357
tamoxifen resistance in, 304-310
British classification, of testicular cancer, 69
Burst-forming unit-erythroid, 955-956
Busulfan
BMT plus
acute toxicity of, 1571
early deaths with, 1572
hematologic toxicity of, 1571
for myeloma, 1569-1573
nonhematologic toxicity of, 1572
cyclophosphamide plus
for allogeneic BMT, 1492-1497
dose escalation of, 1493
for multiple myeloma, 1492-1497
toxicity of, 1493-1494
high-dose, for myeloma, 1569-1573
Busulfan, cyclophosphamide, BMT regimen
for pediatric solid tumors, 1857-1864
toxicity of, 1859-1861
tumor response to, 1859-1861

CA15-3, *v* microparticle enzyme immunoassay, for breast cancer mucin, 1057-1065
Camptothecin-11
in NSCLC, 16-20
response to, 18
toxicities due to, 18
Cancer
childhood, health status classification of, 925
control of, clinical oncologists in, 164-168
pain of, 1830-1832
evaluation of, 1977
management of, barriers to, 1976-1977
pharmacologic approaches to, 1978-1981
procedure-related, 1981
treatment of, 1977-1978
survivors of, classifying health status of, 923-928
Carbon monoxide diffusing lung capacity, 460-462
Carboplatin
area-under-the-curve of, 520-528
in combination chemotherapy
for breast cancer, 102-110
IL-3 following, 1131-1140
for ovarian cancer, 715
phase II trials of, 821
in combined modality therapy, for lymphomas, 1712-1722
cyclophosphamide plus
in advanced ovarian cancer, 718-726
clinical response to, 722
efficacy of, 722-724
nausea and vomiting due to, 713
therapeutic index of, 706-717
toxicity of, 707-708
etoposide plus
disease site and, 1600
for neuroblastoma, 1592-1601
for recurrent malignant glioma, 1074-1077
phase II study of, 1074-1077
previous cisplatin dose and, 1599
previous treatment and, 1599
response to, 1075
scheduling of, 1599
toxicity of, 1076
5-FU plus
in head and neck cancer, 1245-1251
nonhematologic toxicity of, 1248
high-dose, 520-528
in metastatic breast cancer, 433-437
multiple course high-dose, delivery of, 464-473
nonhematologic toxicity due to, 467-468
toxicity of, 436
tumor response to, 520-528
Carboplatin, etoposide, BMT regimen
in germ cell cancer, 558-563
therapeutic outcome following, 560
toxicity of, 560
Carboplatin, etoposide, vincristine regimen
in SCLC, 818-823
SCLC studies with, 822
toxicity of, 820
worst toxicity of, 821
Carboplatin, GM-CSF, peripheral-blood progenitor cell regimen, 464-473
Carboxypeptidase-G2
antibody to, assay for, 1361
methotrexate pharmacokinetics following, 1359-1364
pharmacokinetics of, 1360

Carcinoembryonic antigen
expression of
following interferon-gamma, 735-746
measurement of, 738
*v* microparticle enzyme immunoassay, for breast cancer mucin, 1057-1065
Carcinoma, poorly differentiated
chemotherapy responsiveness in, 919
cisplatin-based combination chemotherapy for, 912-922
pathology of, 915
prognostic factors in, 916-918
tumor site and, 919
Cardiac toxicity
due to cyclophosphamide, 995-1000
of high-dose continuous infusion 5-FU, 1795-1801
of ICRF-187, 121-122
Carmustine
in chemoimmunotherapy, for melanoma, 1338-1343
in combination chemotherapy
for HD, 1086-1094
for stage IV breast cancer, 1743-1747
Carmustine, etoposide, cisplatin, BMT regimen
antitumor effect of, 1685-1686
hematopoietic recovery and, 1685
high-dose, in relapsed lymphoma, 1682-1689
lymphoma relapse sites following, 1693-1694
outcome of, 1686
toxicity of, 1684-1685
Catheter, venous, complications with, 1943-1948
CCSG 782 study, 14
Central nervous system
metastases to, of ovarian cancer, 1553-1560
tumor survivors of, 1400
c-*erb*B-2 antigen
ELISA for, 1436-1443
in breast cancer serum, 1436-1443
level of
in effusions, 1440-1441
in sera, 1440
*see also* HER-2
Chemoimmunotherapy
autoimmune toxicities of, 1341
in breast cancer, 1540-1546
immunologic changes following, 1341-1342
for Kaposi's sarcoma, 1344-1351
for metastatic melanoma, 1919-1926
sequential, for melanoma, 1338-1343
toxicity of, 1340-1341
Chemoradiotherapy
BMT plus, for NHL, 1949-1954
for primary CNS lymphoma, 635-643
in pediatric HD, 929-935
preoperative *v* postoperative, in rectal cancer, 1218-1224
in rectal cancer, 549-557
reduced, in childhood HD, 1602-1608
in SCLC, 1526, 892
in stage IIIA NSCLC, 832-833
surgery plus, in NSCLC, 1237-1244
surgery *v*, in NSCLC, 1240
toxicity of, 1220-1223, 1240
warfarin plus, in limited-disease SCLC, 1230-1236
Chemotherapy
acute promyelocytic leukemia associated with, 1430-1435
adjuvant, relapsed breast cancer and, 480
alternating radiotherapy and, in SCLC, 448
BMT plus, in inflammatory breast cancer, 1020-1021
BMT *v*, in acute myelogenous leukemia, 41-46
without BMT, in HD, 1086-1094
chronic, toxicity of, 1564
cisplatin, hypercholesterolemia following, 1386-1389
combination, *see* Combination chemotherapy
in combined modality therapy
for brain metastases, 1553-1560
for esophageal cancer, 1037-1043
compliance monitoring in, 1007-1013
for germ cell tumor, late effects of, 1375-1376
half-dose, in Wilms' tumor, 1305-1309
hepatic arterial infusion of, 1112-1118
high-dose consolidation, for stage IV breast cancer, 1743-1747
IL-3 following, 1131-1140
IL-3 plus GM-CSF following, 1452-1459
initial, in esophageal cancer, 1038
intrathecal, 143-148
late effects of, in rhabdomyosarcoma, 616-618
long-term effects of, in testicular cancer, 574-579
low-dose radiotherapy plus, in childhood HD, 1602-1608
quality-of-life assessment in, 1009
radiotherapy plus, *see* Chemoradiotherapy
radiotherapy *v*, in early-stage HD, 378-382
salvage
in HD, 203
in ovarian cancer, 513-514
salvage combination, in HD, 210-218
salvage intraperitoneal, in residual ovarian cancer, 1479-1484
second, in HD, 213
single-agent, in SCLC, 484-498
surgery plus, in stage IIIA NSCLC, 833-834
systemic adjuvant, in early-stage breast cancer, 357
Childhood cancer survivors
background characteristics of, 1399
economic sequelae for, 1397-1406
educational achievement by, 1399
employment history of, 1401
health history of, 1401
health insurance coverage of, 1402
income achievement by, 1399
life insurance coverage of, 1403
occupational achievement by, 1399
Children, acute promyelocytic leukemia in, microgranular variant of, 1413-1418
Chlorambucil, vincristine, procarbazine, prednisone regimen
in HD, 1252-1258
toxicity of, 1255
2-Chlorodeoxyadenosine
administration of, 1516-1517
bioavailability of, 1514-1518
bone marrow suppression of, 374-375
drug development priorities and, 1507-1510
infectious complications of, 375
for low-grade lymphocytic lymphomas, 371-377
pharmacokinetic parameters of, 1516-1517
pharmacokinetic study of, 365, 367

2-Chlorodeoxyadenosine (*Continued*)
preparation of, 1515
prolonged continuous infusion of, 365
in relapsed leukemia, 364-370
therapeutic effects of, 366-367
toxicity of, 367, 374
toxicity profile of, 368
Chlorozotocin, 5-FU plus, in islet cell cancer, 1914-1918
Cholesterol, serum levels of
following cisplatin therapy, 1386-1389, 1609-1614
following IL-3, 1138
Chromosome translocation, following 4-epi-doxorubicin, 1444-1451
Cisplatin
in chemoimmunotherapy, for melanoma, 1338-1343
in chemoradiotherapy, for limited-disease SCLC, 1230-1236
in combination chemotherapy, 913
drug delivery of, 1070
for gastric cancer, 536-540, 541-548
IL-3 plus GM-CSF following, 1452-1459
for NSCLC, 580-586
for osteogenic sarcoma, 13
for stage IV breast cancer, 1743-1747
for urothelial carcinoma, 1066-1073
toxicity of, 1067-1068
in combined modality therapy
for lymphoma, 1682-1689
for NSCLC, 1927-1932
concentration of, in neural tissue, 796-797
CPT-11 plus, in NSCLC, 1775-1780
cumulative doses of, 576
cyclophosphamide plus
in advanced ovarian cancer, 718-726
clinical response to, 722
efficacy of, 722-724
nausea and vomiting due to, 713
therapeutic index of, 706-717
toxicity of, 711-713
dosage of, tissue platinum levels and, 797-799
doxorubicin plus
hematologic toxicity of, 1587
nonhematologic toxicity of, 1587
for osteosarcoma, 1579-1591
toxicity of, 1586-1587
etoposide plus
dose intensity of, 287
in SCLC, 282-291
toxicity of, 287-288
5-FU plus
in head and neck cancer, 257-263, 1245-1251
nonhematologic toxicity of, 1248
toxicity of, 261
half-life for, 1004
hypercholesterolemia following, 1386-1389
interferon-alpha plus
for melanoma, 1574-1578
toxicities of, 1576
intracarotid
for anaplastic glioma, 452-458
toxicity of, 455-456
intrapleural, mitomycin plus, 1001-1006
Cisplatin (*Continued*)
leukemia following, 1446-1447
levels of, clinical neurotoxicity and, 800-801
long-term effects of, 574-579
neurotoxicity of, 795-803
for osteogenic sarcoma, 13
peptichemio plus
in neuroblastoma, 1870-1878
toxicity of, 1874
plasma lipid profiles following, 1609-1614
in postoperative combination chemotherapy, for gastric cancer, 1933-1942
in preoperative combination chemotherapy, for gastric cancer, 1933-1942
in testicular cancer, cardiovascular complications following, 760-765
toxicity of, 799-800
for urothelial carcinoma, 1066-1073
Cisplatin, cyclophosphamide, radiotherapy regimen
gastrointestinal toxicity following, 731
hematologic toxicity following, 730-731
infectious complications due to, 732
neurologic toxicity following, 731
in ovarian cancer, 727-734
survival following, 730
Cisplatin, doxorubicin, methotrexate regimen
brief intensive, for osteosarcoma, 1579-1591
hematologic toxicity of, 1587
nonhematologic toxicity of, 1587
toxicity of, 1586-1587
Cisplatin, etoposide, bleomycin regimen, for poorly differentiated carcinoma, 912-922
Cisplatin, vinblastine, bleomycin, doxorubicin regimen, in poorly differentiated carcinoma, 912-922
Cisplatin, vinblastine, fluorouracil regimen, combined modality therapy plus, in NSCLC, 1237-1244
Clinical oncologists, in cancer control, 164-168
Clinical trial(s)
meta-analyses in, 878-880
phase I, ethical issues in, 1810-1816
phase II
design of, 485
efficacy of, 484-498
patient selection in, 493
prognostic factors in, 485
in SCLC, 484-498
Clodronate, in bone metastases, 591-598
Coding, cranial irradiation dosing and, 810-817
Colorectal cancer
advanced
bolus 5-FU plus PALA in, 747-752
5-FU plus leucovorin in, 896-903
early chemotherapy in, 904-911
hepatic metastases of, floxuridine for, 1112-1118
methotrexate, fluorouracil, leucovorin regimen in, 904-911
Colposcopy, telephone counseling and, 330-333
Combination chemotherapy
in head and neck cancer, 1245-1251
intensification regimen for, 102-110
in triple-modality therapy, for NSCLC, 1237-1244

Combined modality therapy
of brain metastases, in ovarian cancer, 1553-1560
of inflammatory breast cancer, 1018-1020
in limited-disease SCLC, 1230-1236
for multiple myeloma, 1769-1774
for NHL, 1949-1954
in ovarian cancer, 1561-1568
in pediatric HD, 929-935
for primary CNS lymphoma, 635-643
of rectal cancer, 1218-1224
in rectal cancer downstaging, 79-84
in resistant NHL, 936-941
single agent *v*, in head and neck cancer, 257-263
triple, in NSCLC, 1237-1244
Complement-dependent cellular toxicity, 1470
Compliance, with chemotherapy, monitoring of, 1007-1013
Conditioning regimen, autologous *v* allogeneic BMT and, 1693
Corticotropin production, ectopic, SCLC and, 21-27
Cosmesis
arm edema and, 362
boost technique *v* reexcision and, 359
categorical variables influencing, 358-359
continuous variables and, 359
in early-stage breast cancer, 356-363
external radiation therapy and, 361
tamoxifen and, 362
CPT-11
cisplatin plus
hematologic toxicity of, 1777
in NSCLC, 1775-1780
dosing of, 1776
in relapsed SCLC, 1225-1229
toxicity of, 1227-1228, 1776-1777
treatment schedule of, 1226
worst toxicity of, 1227
Cranial irradiation
in acute lymphoblastic leukemia, 810-817
chemotherapy plus, for primary CNS lymphoma, 635-643
coding and, 810-817
delayed, in acute lymphoblastic leukemia, 1095-1102
intravenous, sex and, 810-817
prophylactic, brain metastases and, 1242
for SCLC brain metastases, 1499
verbal memory and, 810-817
C-reactive protein, following liposomal muramyl tripeptide, 1313
Cushing's syndrome
clinical features of, 23
SCLC and, 21-27
Cyclophosphamide
busulfan plus
for allogeneic BMT, 1492-1497
dose escalation of, 1493
for multiple myeloma, 1492-1497
toxicity of, 1493-1494
carboplatin plus
in advanced ovarian cancer, 718-726
clinical response to, 722
efficacy of, 722-724
nausea and vomiting due to, 713
therapeutic index of, 706-717
toxicity of, 707-708
Cyclophosphamide (*Continued*)
cardiac toxicity of, 995-1000
in chemoimmunotherapy, for breast cancer, 1540-1546
in chemoradiotherapy, for limited-disease SCLC, 1230-1236
cisplatin plus
in advanced ovarian cancer, 718-726
clinical response to, 722
efficacy of, 722-724
nausea and vomiting due to, 713
therapeutic index of, 706-717
toxicity of, 711-713
in combination chemotherapy
for lymphoblastic lymphoma, 1078-1085
for NHL, 1949-1954
for stage IV breast cancer, 1743-1747
in combined modality therapy
for multiple myeloma, 1769-1774
for pediatric solid tumors, 1857-1864
for resistant NHL, 936-941
doxorubicin plus
escalating doses of, 1540-1546
hematologic toxicity of, 1545
toxicity of, 1543-1544
high-dose, in combination chemotherapy, 102-110
leukemia following, 1444-1451
in LNH-84 regimen, for relapsing lymphomas, 1615-1623
pharmacokinetics of, 995-1000
tumor response to, 995-1000
Cyclophosphamide, cisplatin, radiotherapy regimen
gastrointestinal toxicity following, 731
hematologic toxicity following, 730-731
infectious complications due to, 732
neurologic toxicity following, 731
in ovarian cancer, 727-734
survival following, 730
Cyclophosphamide, doxorubicin, cisplatin regimen
compliance with, 1928
nonhematologic toxicity of, 1930
postoperative, in NSCLC, 1927-1932
survival following, 1929-1930
toxicity of, 1930
Cyclophosphamide, doxorubicin, etoposide regimen, IL-3 following, 1131-1140
Cyclophosphamide, doxorubicin, vincristine regimen
dose intensity of, 287
in SCLC, 282-291
toxicity of, 287-288
Cyclophosphamide, doxorubicin, vincristine, methotrexate, leucovorin regimen
in stage IV breast cancer, 1743-1747
toxicity of, 1745-1747
Cyclophosphamide, doxorubicin, vincristine, prednisone regimen, 644-646
in lymphoblastic lymphoma, 1078-1085
Cyclophosphamide, methotrexate, 5-FU regimen, in breast cancer, c-*erb*B-2 positivity and, 1049-1056
Cyclophosphamide, methotrexate, 5-FU, prednisone, tamoxifen regimen, in breast cancer, 1848-1856
Cyclophosphamide, methotrexate, 5-FU, prednisone, tamoxifen, halotestin regimen, in breast cancer, 1848-1856

Cyclophosphamide, thiotepa, autologous stem-cell rescue regimen
in stage IV breast cancer, 1743-1747
toxicity of, 1745-1747
Cyclophosphamide, thiotepa, carboplatin regimen
dosing of, 106
in breast cancer, 102-110
toxicity of, 104
Cyclophosphamide, thiotepa, carmustine regimen
in stage IV breast cancer, 1743-1747
toxicity of, 1745-1747
Cyclophosphamide, total body irradiation, BMT regimen, for lymphoblastic lymphoma, 644-646
Cyclosporine
dose escalation of, 1625
etoposide pharmacokinetic alteration by, 1635-1642
etoposide plus
drug resistance modulation by, 1624-1634, 1635-1642
hematologic toxicities of, 1627
leukopenia and, 1638
nausea following, 1627
nonhematologic toxicities of, 1628
pharmacokinetics of, 1635-1642
phase I trial of, 1624-1634, 1635-1642
toxicities of, 1627-1629
vomiting following, 1627
maximum-tolerated dose of, 1629
Cytarabine
in combined modality therapy, for primary CNS lymphoma, 635-643
daunorubicin plus, 43
high-dose, neurotoxicity due to, 948-953
interferon-alpha plus
in chronic myelogenous leukemia, 772-778
side effects of, 776-777
low-dose, interferon-alpha plus, 772-778
in LNH-84 regimen, for relapsing lymphomas, 1615-1623
mitoxantrone plus, 43
plus idarubicin or daunorubicin, in acute myelogenous leukemia, 1103-1111
Cytarabine, mitoxantrone, quinine regimen, in refractory acute leukemia, 1730-1736
Cytokine release, following IL-3, 1136-1137

Dacarbazine
in chemoimmunotherapy, for melanoma, 1338-1343
in combination chemotherapy, for childhood HD, 1602-1608
Dacarbazine, vincristine, bleomycin, lomustine, interferon-alpha regimen
for metastatic melanoma, 1919-1926
response of, 1923
toxicity of, 1923
Daunorubicin
in combination chemotherapy, for lymphoblastic lymphoma, 1078-1085
cytarabine plus, 43
in acute myelogenous leukemia, 1103-1111
toxicity of, 43
Daunorubicin, cytarabine, GM-CSF regimen
in chronic myelogenous leukemia, 398-405
side effects of, 403
toxicity of, 400-401
Daunorubicin, vincristine, cyclophosphamide, prednisolone regimen, for lymphoblastic lymphoma, 1078-1085
Daunorubicin, vincristine, cyclophosphamide, prednisolone, asparaginase regimen, for lymphoblastic lymphoma, 1078-1085
Deoxycoformycin pentostatin, *see* Pentostatin
1-Desamineo-8-D-arginine vasopressin, response to, in Wilms' tumor patients, 422-427
Diarrhea, irradiation-induced, sucralfate for, 969-975
Diaziquone, intrathecal
in refractory meningeal malignancies, 143-148
pharmacokinetics of, 144-145
response to, 145-146
toxicity of, 145
Dibromodulcitol
in chemoradiotherapy regimen, for recurrent glioma, 766-771
in combination chemotherapy, for nitrosourea resistance, 766-771
Dichloromethylene bisphosphonate, for bone metastases, 591-598
Diffuse large-cell lymphoma, MACOP-B regimen in, prognosis of, 219-227
DNA flow cytometry
in breast cancer, 1045, 688
in good-risk node-negative breast cancer, 428-432
in locally recurrent breast cancer, 1839-1847
prognostic value of, 1839-1847
results of, in locally recurrent breast cancer, 1841
DNA index
in acute lymphoblastic leukemia, 606-613
in good-risk node-negative breast cancer, 428-432
DNA ploidy, as prognostic factor, in breast cancer, 686-695
Doxorubicin
acute promyelocytic leukemia associated with, 1430-1435
cisplatin plus
for osteosarcoma, 1579-1591
hematologic toxicity of, 1587
nonhematologic toxicity of, 1587
toxicity of, 1586-1587
in combination chemotherapy
for breast cancer, 1848-1856
for gastric cancer, 536-540, 541-548
for HD, 1086-1094, 1252-1258
IL-3 following, 1131-1140
for lymphoblastic lymphoma, 644-646, 1078-1085
for NHL, 1949-1954
for poorly differentiated carcinoma, 912-922
for stage IV breast cancer, 1743-1747
for urothelial carcinoma, 1066-1073
in combined modality therapy, for NSCLC, 1927-1932
cyclophosphamide plus
escalating doses of, 1540-1546
hematologic toxicity of, 1545
toxicity of, 1543-1544
ICRF-187 plus, in breast cancer, 117-127
by infusion, 1540-1546
teniposide plus
in testicular relapse, 624-630
toxicity of, 627
whole-lung irradiation plus
for osteogenic sarcoma, 459-463
pulmonary function tests following, 459-463

Doxorubicin, bleomycin, vinblastine, dacarbazine regimen, in childhood HD, 1602-1608
Doxorubicin, cisplatin, methotrexate regimen
brief intensive, for osteosarcoma, 1579-1591
hematologic toxicity of, 1587
nonhematologic toxicity of, 1587
toxicity of, 1586-1587
Doxorubicin, cyclophosphamide, etoposide, cisplatin regimen, radiotherapy plus warfarin and, 1230-1236
Doxorubicin, cyclophosphamide, leukocyte alpha-interferon regimen, in breast cancer, 1540-1546
Doxorubicin, cyclophosphamide, vindesine, bleomycin, methylprednisolone, methotrexate regimen, in lymphoma, 1615-1623
Doxorubicin, methotrexate, cisplatin regimen, for osteogenic sarcoma, 13
Drug resistance
etoposide plus cyclosporine modulation of, 1624-1634, 1635-1642
quinine for, 1730-1736

EBV, *see* Epstein-Barr virus
Edema, arm, cosmesis and, 362
Ejaculatory dysfunction, following rhabdomyosarcoma therapy, 617
Elderly, etoposide, mitoxantrone, prednimustine regimen for, in NHL, 228-236
ELISA, *see* Enzyme-linked immunosorbent assay
Emesis
due to carboplatin plus cyclophosphamide, 713
due to cisplatin plus cyclophosphamide, 713
ondansetron for, 1969-1975
Enzyme-linked immunosorbent assay, for c-*erb*B-2 antigen, 1436-1443
Eosinophil chemotaxis, assay for, 1268-1269
Epidermal growth factor receptor
aromatase activity and, in breast cancer, 438-446
disease progression and, 531-532
expression of, 530-531
immunocytochemical assay for, 688
in ovarian cancer, 529-535
as prognostic factor
in breast cancer, 686-695
in ovarian cancer, 529-535
quantification of, 440
sample preparation for, 440
4-Epi-doxorubicin
chromosome translocation following, 1444-1451
leukemia following, 1444-1451
Epirubicin
dosing of, 825
high-dose, in NSCLC, 297-303
in mesothelioma, 824-828
toxicity of, 825-826
Esophageal cancer
combined modality therapy of, 1037-1043
interferon alfa-2a plus 5-FU in, 269-274
randomized trials in, 1031-1033
symptom relief in, 1039
therapy morbidity in, 1041-1042
Estradiol
aromatase activity and, in breast cancer, 438-446
tumor quantification of, 440

Estradiol receptor
quantification of, 440
sample preparation for, 440
Estramustine, vinblastine plus
hematologic toxicity of, 1757
in prostatic cancer, 1754-1761
therapeutic activity of, 1756-1757
toxicity of, 1757-1758
Etidronate disodium
in cancer-related hypercalcemia, 134-142
safety of, 138
Etoposide
acute promyelocytic leukemia associated with, 1430-1435
carboplatin plus
disease site and, 1600
for neuroblastoma, 1592-1601
phase II study of, 1074-1077
previous cisplatin dose and, 1599
previous treatment and, 1599
for recurrent malignant glioma, 1074-1077
response to, 1075
scheduling of, 1599
toxicity of, 1076
in chemoimmunotherapy, for germ cell cancer, 558-563
in chemoradiotherapy, for limited-disease SCLC, 1230-1236
cisplatin plus
dose intensity of, 287
in SCLC, 282-291
toxicity of, 287-288
in combination chemotherapy
for HD, 1086-1094
IL-3 following, 1131-1140
for NHL, 1949-1954
for poorly differentiated carcinoma, 912-922
for SCLC, 818-823
in combined modality therapy
for lymphoma, 1682-1689, 1712-1722
for resistant NHL, 936-941
cumulative doses of, 576
cyclosporine plus
drug resistance modulation by, 1624-1634, 1635-1642
hematologic toxicities of, 1627
leukopenia and, 1638
nonhematologic toxicities of, 1628
pharmacokinetics of, 1635-1642
phase I trial of, 1624-1634, 1635-1642
toxicities of, 1627-1629
G-CSF plus
for lymphoma, 1955-1962
for myeloma, 1955-1962
GM-CSF plus
for lymphoma, 1955-1962
for myeloma, 1955-1962
high-dose, 1957
antitumor effect of, 1959
nonhematologic toxicity of, 1958-1959
ifosfamide plus
in Ewing's sarcoma, 1737-1742
toxicity of, 1742

Etoposide (*Continued*)
in LNH-84 regimen, for relapsing lymphomas, 1615-1623
long-term effects of, 574-579
nausea following, 1627
oral
efficacy of, 293
in NSCLC, 292-296
pharmacokinetic studies of, 294
toxicity of, 293-294
pharmacokinetic parameters of, 1638
pharmacokinetics of, 1629-1630
cyclosporine alteration of, 1635-1642
plasma concentration-time plots of, 1637
total clearance of, 1638
vomiting following, 1627
Etoposide, doxorubicin, cisplatin regimen
in advanced gastric cancer, 515-516, 536-540
dosing schedule for, 537
in gastric cancer, 515-516, 536-540, 541-548
survival following, 546
toxicity of, 537-538, 544-545
Etoposide, ifosfamide, cisplatin regimen, IL-3 plus GM-CSF following, 1452-1459
Etoposide, mitoxantrone, prednimustine regimen
for elderly, in NHL, 223-236
toxicity of, 231
Etoposide, vinblastine, doxorubicin, prednisone regimen
in HD, 1252-1258
toxicity of, 1255
Ewing's sarcoma
etoposide plus ifosfamide in, 1737-1742
ifosfamide in, 1407-1412
Extensive intraductal component, relapsed breast cancer and, 474-475

Fadrozole
dosing of, 113
in metastatic breast cancer, 111-116
response to, 114
toxicity of, 113
Fever, risk assessment for, 316-322
Flow cytometry
in acute lymphoblastic leukemia, 608
in good-risk node-negative breast cancer, 428-432
Floxuridine
hepatic arterial infusion of, for hepatic metastases, 1112-1118
implanted pump for, complications of, 1114-1115
Floxuridine, cisplatin, sodium thiosulfate regimen
intraperitoneal, 1935
postoperative, in gastric cancer, 1933-1942
toxicity of, 1938
Fludarabine phosphate
activity of, 31
chemical structure of, 791
low-grade lymphoma and, 790-794
in lymphoma, 790-794
in previously treated NHL, 28-32
phase II trial of, 790-794
responses with, 30
lymphoma subtype and, 791
toxicity of, 30

Fluorouracil
bolus, PALA plus, 747-752
carboplatin plus
in head and neck cancer, 1245-1251
nonhematologic toxicity of, 1248
cardiac manifestations of, 1796
in chemoradiotherapy regimen
for rectal cancer, 549-557
for recurrent glioma, 766-771
chlorozotocin plus, in islet cell cancer, 1914-1918
cisplatin plus
in head and neck cancer, 257-263, 1245-1251
nonhematologic toxicity of, 1248
toxicity of, 261
clearance of
age and, 1171-1175
sex and, 1171-1175
in combination chemotherapy
for breast cancer, 1848-1856
c-*erb*B-2 positivity and, 1049-1056
for colorectal cancer, 904-911
for gastric cancer, 541-548
for nitrosourea resistance, 766-771
high-dose continuous infusion of, cardiotoxicity of, 1795-1801
interferon alfa-2a plus
dose attenuation schedule of, 271
in esophageal cancer, 269-274
leucovorin plus
in breast cancer, 1278-1283
in colorectal cancer, 896-903
in rectal cancer, 1218-1224
for rectal cancer radiation-induced downstaging, 79-84
preoperative *v* postoperative, 1218-1224
survival following, 900-901
toxicities of, 1281
tumor response to, 899-900
PALA plus, in advanced colorectal cancer, 747-752
pharmacokinetic survey and, 1171-1172
in triple-modality therapy, for NSCLC, 1237-1244
Fluorouracil, cisplatin, doxorubicin, cyclophosphamide regimen
in stage IV breast cancer, 1743-1747
toxicity of, 1745-1747
Fluorouracil, leucovorin, cisplatin regimen
preoperative, in gastric cancer, 1933-1942
toxicity of, 1936-1938
Forced expiratory volume following whole-lung irradiation plus doxorubicin, 460-462
Forced vital capacity, following whole-lung irradiation plus doxorubicin, 460-462
Friedman and Moore classification, of testicular cancer, 69
5-FU, *see* Fluorouracil
Functional residual capacity, following whole-lung irradiation plus doxorubicin, 460-462

Gastric cancer
etoposide, doxorubicin, cisplatin regimen in, 515-516, 536-540
methotrexate, 5-FU, doxorubicin, leucovorin regimen in, 541-548
pre- and postoperative chemotherapy in, 1933-1942
G-CSF, *see* Granulocyte colony-stimulating factor

Gemcitabine
cellular pharmacokinetics following, 409-411
in leukemia, 406-413
pharmacokinetic analysis of, 407
plasma pharmacokinetics following, 409
toxicity of, 408
tumor response to, 408
Gene, cancer-susceptibility, predictive testing in, 1203-1204
Gene therapy, 180-199
with TNF or IL-2 genes, protocol for, 195
with tumor-infiltrating lymphocytes transduced with TNF gene, 194
Germ cell cancer
carboplatin, etoposide, BMT regimen in, 558-563
cisplatin in, plasma lipids following, 1609-1614
Indiana classification of, 560
retinoids in, 852
Germ cell tumor
cisplatin chemotherapy for, hypercholesterolemia following, 1386-1389
postchemotherapy histology in, 572
Glioblastoma multiforme
iododeoxyuridine plus radiation for, 264-268
radiosurgery for, 1382
Glioma
anaplastic, intracarotid cisplatin in, 452-548
malignant, radiosurgery for, 1379-1385
recurrent, nitrosourea resistance in, 766-771
recurrent malignant, carboplatin plus etoposide for, 1074-1077
retinoids in, 852
Glycoprotein-72, tumor-associated
following interferon-gamma, 735-746
measurement of, 738
GM-CSF, *see* Granulocyte-macrophage colony-stimulating factor
Gonadal status, following rhabdomyosarcoma therapy, 618-619
Graft-versus-host disease
autologous *v* allogeneic BMT and, 1692-1693
BMT and, 1726
incidence of, age and, 1194-1195
prevention of, 1191-1200
prophylaxis of, 238
standard- *v* high-risk patients in, 1196
treatment of, 238
Granulocyte colony-stimulating factor
etoposide plus
for lymphoma, 1955-1962
for myeloma, 1955-1962
taxol plus, in refractory ovarian cancer, 1165-1170
Granulocyte-macrophage colony-stimulating factor
administration of, 391
antitumor response of, 1272
in chemoimmunotherapy, for Kaposi's sarcoma, 1344-1351
dosing effects of, 393-394
dosing regimen of, 1460-1469
effects of, in Kaposi's sarcoma, 1346
etoposide plus
for lymphoma, 1955-1962
for myeloma, 1955-1962
Granulocyte-macrophage colony-stimulating factor (*Continued*)
in HD, 390-397
hematologic recovery following, 1462-1463
hematologic toxicity due to, 467
IL-3 plus, following combination chemotherapy, 1452-1459
leukopenia following, 1463-1464
following MOPP regimen, 390-397
morbidity and, 1272
myeloprotection by, 1266-1277
repeated cycles of, effect of, 1464-1465
scheduling of, 1462
side effects of, 395-396, 1272-1273
subcutaneous *v* intravenous administration of, 394
supportive therapy with, 1461
thiotepa plus
marrow toxicity of, 1354-1355
pharmacokinetics of, 1355
phase I trial of, 1352-1358
toxicity of, 1355
thrombocytopenia following, 1463-1464
toxicity due to, 467
Granulocyte-macrophage colony-stimulating factor, carboplatin, peripheral-blood progenitor cell regimen, 464-473
Granulocytopenia
indium-111–labeled immunoglobulin G in, 61-68
supportive care in, 42
GVHD, *see* Graft-versus-host disease
Gynecologic cancer, retinoids in, 853

Halotestin, in combination chemotherapy, for breast cancer, 1848-1856
HAMA, *see* Human antimouse antibody
HD, *see* Hodgkin's disease
Head and neck cancer
carboplatin plus 5-FU in, 1245-1251
cisplatin plus 5-FU in, 1245-1251
combination *v* single agents in, 257-263
methotrexate in, 1245-1251
prognostic factors in, 260
retinoids in, 850-851
squamous-cell, 1245-1251
Health insurance coverage, of childhood cancer survivors, 1402
Health Status Classification
of brain tumor patients, 926
of childhood cancer patients, 925
Hearing function, following chemotherapy, 576-577
Hematopoietic progenitor cells, assay for, 1268
Hepatic arterial infusion, of floxuridine, for hepatic metastases, 1112-1118
Hepatic metastases
floxuridine for, 1112-1118
of colorectal cancer, floxuridine for, 1112-1118
progression to, 1114
HER-2, *see also* c-*erb*B-2
HER-2 oncoprotein, in breast cancer, 1044-1048
HER-2-*neu* oncogene
expression of, in breast cancer, 599-605
overexpression of
adjuvant therapy and, 602
as prognostic factor, 601-602
Histologic grade, relapsed breast cancer and, 476

HLA, *see* Human leukocyte agglutinin antigens
Hodgkin's disease
  ABMT timing in, 200-209
  chemotherapy without BMT, 1086-1094
  childhood, 1602-1608
  chlorambucil, vincristine, procarbazine, prednisone regimen in, 1252-1258
  early-stage, chemotherapy *v* radiotherapy in, 378-382
  etoposide, vinblastine, doxorubicin, prednisone regimen in, 1252-1258
  GM-CSF in, 390-397
  interval following, for breast cancer development, 1675
  low-dose radiotherapy plus chemotherapy in, 1602-1608
  MOPP regimen in, 378-382
  MOPP-ABV(D) regimen in, relapse following, 204
  pediatric
    chemoradiotherapy in, 929-935
    high- and low-dose radiotherapy in, 929-935
  prognostic factors in, 1255-1256
  radiation-associated breast cancer following, 1662-1665, 1674-1681
  radiotherapy *v* MOPP in, 378-382
  relapsed, 201
  salvage combination chemotherapy in, 210-218
  second treatment in, 213-214
  treatment for, 1675
  treatment strategy costs in, 206, 208
  vindesine, doxorubicin, carmustine, etoposide, methylprednisolone regimen in, 1086-1094
Hospitalization, duration of, following GM-CSF, 1464
Human antimouse antibody, in melanoma, 1334
Human antimouse antibody assay, 1471
  in monoclonal antibody L6 plus IL-2 trial, 1475
Human leukocyte agglutinin antigens
  alleles of, clinical response and, 1162
  melanoma vaccine and, 1158-1164
Hydrocortisone, aminoglutethimide plus
  in breast cancer, 984-989
  side effects of, 988
Hydroxyurea
  in chemoradiotherapy regimen, for recurrent glioma, 766-771
  in combination chemotherapy, for nitrosourea resistance, 766-771
Hyperbilirubinemia, in P-glycoprotein function inhibition, 1624-1634
Hypercalcemia
  cancer-related
    etidronate disodium in, 134-142
    pamidronate disodium in, 134-142
  prostatic cancer and, 499-505
  symptoms of, 137-138
Hypercholesterolemia, chemotherapy following, 1386-1389

ICRF-187
  cardiac toxicity of, 121-122
  dosing of, 118-119
  doxorubicin plus, in breast cancer, 117-127
  monitoring of, 119
Idarubicin, cytarabine plus, in acute myelogenous leukemia, 1103-1111
Ifosfamide
  antidiuretic effects of, 1721
  in combination chemotherapy
    IL-3 following, 1131-1140
    IL-3 plus GM-CSF following, 1452-1459
  etoposide plus
    in Ewing's sarcoma, 1737-1742
    toxicity of, 1742
  in Ewing's sarcoma, 1407-1412
  in LNH-84 regimen, for relapsing lymphomas, 1615-1623
  mesna plus, in ovarian cancer, 243-248
  toxicity of, 1410-1411
Ifosfamide, carboplatin, etoposide regimen
  acute toxicity of, 1718
  antitumor effects of, 1719
  with bone marrow rescue, 1712-1722
  diarrhea due to, 1718-1719
  dose escalation in, 1717
  hematologic toxicity of, 1719
  hepatic toxicity of, 1718
  high-dose, 1712-1722
  infectious complications of, 1719
  mucositis due to, 1718-1719
  neurologic toxicity of, 1718
  toxic deaths of, 1719
  toxicity of, 1717-1718
IL-2, *see* Interleukin-2
IL-3, *see* Interleukin-3
IL-6, *see* Interleukin-6
Immunocytochemical staining, with 21N antibody, 689
Immunofluorescence assay, in acute myeloid leukemia, 1420
Immunoglobulin G, indium-111–labeled, in granulocytopenia, 61-68
Immunologic cell typing, in acute lymphoblastic leukemia, 607-608
Immunophenotype(s)
  in acute myeloid leukemia, 1420
  correlation of, with clinical characteristics, 1421-1423
  of lymphoma, 1259-1265
Immunotherapy, 180-199
  chemo-, *see* Chemoimmunotherapy
  combination chemotherapy plus, in breast cancer, 1540-1546
  experimental leads for, 191
  high-dose IL-2 as, in NHL, 33-40
  with IL-2, 181
  with IL-2 plus interferon alfa, 191
  with IL-2 plus LAK cells, 182
  with IL-2 plus tumor-infiltrating lymphocytes, 186
  infused cell characteristics, 193
  of melanoma, HLA phenotype and, 1158-1164
  studies of, 180-185
Implanted pump, for floxuridine, complications of, 1114-1115
In situ carcinoma, HER-2-*neu* overexpression and, 601
Indiana classification system, of germ cell cancer, 560
Indium-111, neomycin phosphotransferase marker gene *v*, 190-191
Indomethacin
  effects of, 1146
  interleukin-1 alpha plus, 1145-1146
Infants
  delayed cranial irradiation in, 1100-1101
  leukemia in, 1095-1102
Infection, of venous catheters, 1943-1948
Infiltrating lobular histology, in relapsed breast cancer, 476-479

Insurance, for childhood cancer survivors, 1397-1406
Intelligence quotient
  cranial irradiation and, 814
  methotrexate dosing and, 813-814
  sex and, following leukemia therapy, 813-814
  following whole-brain irradiation, 1390-1396
Interferon, leukocyte alpha-
  in breast cancer, 1540-1546
  combination chemotherapy plus, 1540-1546
Interferon alfa, IL-2 plus, 191
Interferon alfa-2a
  in chemoimmunotherapy, for melanoma, 1338-1343
  dosing of, 415
  5-FU plus
    dose attenuation schedule of, 271
    in esophageal cancer, 269-274
  high-dose bolus IL-2 plus, 804-809
  IL-2 plus
    antibody analysis in, 416
    antitumor effects of, 806-807
    clinical responses to, 416-417
    dosing levels of, 806
    immunologic effects of, 807
    phase I trial of, 804-809
    in renal cell carcinoma, 414-421, 1124-1130
    supportive care following, 415-416
    toxicity of, 417-419, 806, 1127-1128
    treatment duration of, 416
  pentostatin plus
    administered doses of, 1910
    in mycosis fungoides, 1907-1913
    in Sézary syndrome, 1907-1913
    toxicity of, 1910-1911
Interferon alfa-2b
  immune changes following, 1153-1157
  in chronic myelogenous leukemia, 631-634
  preparation of, 631-632
Interferon-alpha
  in chemoimmunotherapy, for metastatic melanoma, 1919-1926
  cisplatin plus
    for melanoma, 1574-1578
    toxicities of, 1576
  cytarabine plus
    in chronic myelogenous leukemia, 772-778
    side effects of, 776-777
Interferon-alpha, zidovudine, GM-CSF regimen
  effects of, 1347-1348
  immonologic evaluations following, 1349
  for Kaposi's sarcoma, 1344-1351
  toxicity of, 1346-1347
  virologic evaluations following, 1348
Interferon gamma
  intraperitoneal administration of, 735-746
  following liposomal muramyl tripeptide, 1313
  measurement of, 738
Interferon gamma, TNF, melphalan regimen
  for melanoma, 52-60
  response to, 56-58
  for sarcoma, 52-60
  systemic side effects of, 55-56
  toxicity of, 55
Interleukin-1, production of, monitoring of, 1154
Interleukin-1 alpha
  antitumor effects of, 1148
  dose-limiting toxicity of, 1145-1146
  hematologic effects of, 1146-1147
  hemodynamic effects of, 1145
  IL-6 serum levels following, 1148
  indomethacin plus, 1145-1146
  laboratory changes following, 1147-1148
  maximum-tolerated dose of, 1145-1146
  pharmacokinetics of, 1148
  phase I trial of, 1141-1152
  toxicity of, 1144-1145
Interleukin-1 beta, monocyte assay for, 1269
Interleukin-2
  in chemoimmunotherapy, for melanoma, 1338-1343
  continuous infusion, 960-968
    dosing of, 754
    in metastatic renal cancer, 753-759
    toxicity management following, 754
    toxicity of, 755-758
  dosing of, 415
  high-dose bolus, interferon alfa-2a plus, 804-809
  interferon alfa plus, 191
  interferon alfa-2a plus
    antibody analysis in, 416
    antitumor effects of, 806-807
    clinical responses to, 416-417
    dosing levels of, 806
    immunologic effects of, 807
    in renal cell carcinoma, 414-421, 1124-1130
    phase I trial of, 804-809
    supportive care following, 415-416
    toxicity of, 417-419, 806, 1127-1128
    treatment duration of, 416
  LAK cells plus
    dosing of, 35, 279
    for murine tumors, 182
    hematologic toxicity of, 280
    immunologic monitoring of, 964
    in NHL, 33-40
    in renal cell carcinoma, 275-281, 960-968
    toxicity of, 37-38, 277-278, 280, 962-964, 966
  monoclonal antibody L6 plus
    phase I trial of, 1470-1478
    treatment plan for, 1472
  for murine tumors, 181
  production of, monitoring of, 1154
  studies of, 180-185
  subcutaneous
    in renal cell cancer, 1119-1123
    toxicity of, 1122
  toxicity of, 185, 1473-1474
  tumor-infiltrating lymphocytes plus, 186
Interleukin-3
  adverse effects of, 1133-1134
  following chemotherapy, 1131-1140
  cytokine release following, 1136-1137
  GM-CSF plus, following combination chemotherapy, 1452-1459
  hematologic effects of, 1134-1136

Interleukin-3 (*Continued*)
in relapsed SCLC, 1131-1140
serum lipids following, 1137-1138
Interleukin-4
antibodies, 1803-1804
antitumor effect of, 1804-1805
concomitant medications with, 1803
phase I evaluation of, 1802-1809
thrice-daily IV bolus of, 1802-1809
toxicity of, 1804-1805
Interleukin-6
following liposomal muramyl tripeptide, 1312
serum levels of, following interleukin-1 alpha, 1148
International Breast Cancer Study Group, 696-705
Intralymphatic extension, relapsed breast cancer and, 476
Iodine 131 metaiodobenzylguanidine
in chemoresistant neuroblastoma, 1889-1896
phase I-II study of, 1889-1896
response to, 1893
toxicity of, 1892-1893
Iododeoxyuridine, radiation plus, complications of, 266-267
Iododoxorubicin
metabolism of, 1185
pharmacodynamic evaluations of, 1184-1185
pharmacokinetic-pharmacodynamic relationships of, 1187
pharmacokinetics of, 1183-1190
toxicity of, 1187-1188
tumor penetration by, 1186-1187
urinary elimination of, 1185-1186
IQ, *see* Intelligence quotient
IQ score
following whole-brain irradiation, 1390-1396
predicting, 1392-1393
Islet cell cancer, chlorozotocin plus 5-FU in, 1914-1918
Isolation limb perfusion, TNF via, 52-60

Kaposi's sarcoma, interferon-alpha, zidovudine, GM-CSF regimen for, 1344-1351
Ki-67 antigen, in lymphoma, 1259-1265

LAK cells, *see* Lymphokine-activated killer cells
LDH level, in lymphoma, 1259-1265
Leucovorin
in combination chemotherapy
for colorectal cancer, 904-911
for gastric cancer, 541-548
for stage IV breast cancer, 1743-1747
5-FU plus
in breast cancer, 1278-1283
in colorectal cancer, 896-903
preoperative *v* postoperative, 1218-1224
in rectal cancer, 1218-1224
for rectal cancer radiation-induced downstaging, 79-84
survival following, 900-901
toxicities of, 1281
tumor response to, 899-900
in preoperative combination chemotherapy, for gastric cancer, 1933-1942
Leucyl-doxorubicin
pharmacodynamics of, 1903
pharmacokinetics of, 1897-1906
Leucyl-doxorubicin (*Continued*)
toxicity of, 1900
treatment schedule of, 1898
Leukemia
acute lymphoblastic
allogeneic BMT in, 237-242
B-lineage, 1879-1888
B-progenitor cell, 606-613
childhood, as secondary neoplasm, 156-163
cranial irradiation dosing in, 810-817
delayed cranial radiotherapy in, 1095-1102
intravenous methotrexate in, 810-817
neuropsychologic outcome in, 810-817
ploidy in, 606-613
polymerase chain reaction in, 1879-1888
relapse prediction in, 1879-1888
residual disease in, 1879-1888
risk classification in, 608
sex in, 810-817
testicular relapse in, 624-630
acute lymphocytic, survivors of
obesity in, 128-133
short stature in, 128
acute monocytic, following 4-epi-doxorubicin, 1444-1451
acute myelocytic, retinoids for, 849
acute myelogenous
BMT *v* chemotherapy in, 41-46
cytarabine plus idarubicin or daunorubicin in, 1103-1111
acute myeloid
allogeneic BMT in, 1723-1729, 1865-1869
B-lymphoid antigen in, 1421
cell-surface antigen expression in, 1419-1429
2-chlorodeoxyadenosine in, 364-370
cytarabine-associated neurotoxicity in, 948-953
high-dose cytarabine in, 948-953
T-lymphoid antigen in, 1421
acute promyelocytic
immunophenotypic data in, 1415
microgranular variant of, 1413-1418
presentation features in, 1416
retinoids for, 848-850
therapy-related, 1430-1435
chronic myelogenous
in accelerated and blastic phases, 398-405
accelerated-phase, 774-775
BMT in, 779-789
daunorubicin, cytarabine, GM-CSF regimen in, 398-405
interferon alfa-2b in, 631-634
interferon-alpha plus cytarabine in, 772-778
tumor necrosis factor in, 631-634
gemcitabine in, 406-413
hairy cell, tumor necrosis factor-alpha in, 954-959
in infants, 1095-1102
juvenile chronic myelogenous, retinoids in, 850
lymphoid, 2-chlorodeoxyadenosine in, 364-370
myelomonocytic, following 4-epi-doxorubicin, 1444-1451
refractory, quinine in, 1730-1736
following SCLC therapy, 1530-1531
Leukocyte alpha-interferon, in chemoimmunotherapy, for breast cancer, 1540-1546
Leukocyte count, in acute lymphoblastic leukemia, 606-613

Leukopenia
cyclosporine plus etoposide and, 1638
duration of, following GM-CSF, 1463-1464
Life insurance coverage, of childhood cancer survivors, 1403
Limbs, osteosarcoma of, brief adjuvant chemotherapy for, 1579-1591
Lipids
following cisplatin therapy, 1386-1389, 1609-1614
serum, *see* Serum lipids
Lipoprotein level, plasma, following cisplatin therapy, 1612
Liposome encapsulation, of muramyl tripeptide phosphatidylethanolamine, 1310-1316
LNH-84 regimen, BMT plus, in relapsing lymphomas, 1615-1623
Lomustine
in chemoimmunotherapy, for metastatic melanoma, 1919-1926
in chemoradiotherapy regimen, for recurrent glioma, 766-771
in combination chemotherapy, for nitrosourea resistance, 766-771
Ludwig Breast Cancer Study Group, 696-705
Lumpectomy
emotional adjustment and, 1292-1298
mastectomy *v*, in breast cancer, 1292-1298
psychologic measures in, 1294
psychologic well-being in, 1295-1297
radiation plus
improving outcome with, 349-351
mastectomy *v*, 976-983
Lung cancer
international staging system for, 830
non–small-cell
chemotherapy phase III trial in, 835-836
chemotherapy plus surgery in, 834
CPT-11 in, 16-20
CPT-11 plus cisplatin for, 1775-1780
future research strategies in, 834-835
high-dose epirubicin in, 297-303
mitomycin, vindesine, cisplatin regimen in, 580-586
multimodality therapy of, 829-838
oral etoposide in, 292-296
postoperative chemotherapy in, 1927-1932
stage III unresectable, 580-586
stage IIIa, 829-838
surgery phase III trial in, 836-837
triple-modality regimen in, 1237-1244
retinoids in, 851
small-cell
ACTH and, 21-27
alternating chemotherapy in, 282-291
alternating radiotherapy and chemotherapy in, 448
brain metastases from, 1498-1502
carboplatin, etoposide, vincristine regimen in, 818-823
competing risk events in, 447-451
complications during therapy of, 25
CPT-11 in, 1225-1229
Cushing's syndrome and, 21-27
cyclophosphamide, doxorubicin, vincristine regimen in, 282-291
diagnosis of, second primary malignancy following, 1525-1533
ectopic corticotropin production and, 21-27
etoposide plus cisplatin in, 282-291
IL-3 in, 1131-1140
Lung cancer (*Continued*)
limited, relative recurrence in, 447-451
limited-disease, 1230-1236
phase II trials in, 484-498
relapse-free survival in, 447-451
second primary malignancies in, 1511-1513, 1519-1524
single-agent chemotherapy in 484-498
therapy of, acute leukemia following, 1530-1531
thoracic irradiation in, 1781-1787
spinal cord compression and, 1781-1787
stage III
preoperative radiotherapy in, 832
radiotherapy in, 830-831
stage IIIA
neoadjuvant chemotherapy plus radiation in, 832-833
neoadjuvant chemotherapy plus surgery in, 833-834
surgery in, 831
Lung function, following chemotherapy, 576
Lymphocytes, tumor-infiltrating, *see* Tumor-infiltrating lymphocytes
Lymphokine-activated killer cells
IL-2 plus
dosing of, 35
for murine tumors, 182
hematologic toxicity of, 280
immunologic monitoring of, 964
in NHL, 33-40
in renal cell carcinoma, 275-281, 960-968
toxicity of, 37-38, 277-278, 280, 962-964, 966
preparation of, 277
studies of, 180-185
Lymphoma
AIDS-associated polyclonal EBV-negative, 383-389
B-cell, anti-CD37 imaging and, 1696-1711
diffuse large-cell, MACOP-B regimen in, 219-227
diffuse small cleaved-cell, immunobiologic subsets of, 1259-1265
fludarabine therapy of, 790-794
G-CSF plus etoposide for, 1955-1962
GM-CSF plus etoposide for, 1955-1962
immunophenotypes of, 1259-1265
low-grade
2-chlorodeoxyadenosine for, 371-377
fludarabine therapy of, 790-794
survival following, 942-947
survival predictors in, 944
lymphoblastic
in adults, 1078-1085
autologous BMT for, 644-646
cyclophosphamide, total body irradiation, BMT regimen for, 644-646
daunorubicin, vincristine, cyclophosphamide, prednisolone regimen in, 1078-1085
daunorubicin, vincristine, cyclophosphamide, prednisolone, asparaginase regimen in, 1078-1085
prognostic factors in, 1081-1083
non-Hodgkin's, *see* Non-Hodgkin's lymphoma
primary CNS
chemoradiotherapy for, 635-643
methotrexate, radiotherapy, cytarabine regimen in, 635-643
recurrence of, 637-638
prognostic factors in, 1620

Lymphoma (*Continued*)
relapsed, carmustine, etoposide, cisplatin, BMT regimen in, 1682-1689
relapsing, LNH-84 regimen plus BMT in, 1615-1623

MACOP-B, *see* Methotrexate, leucovorin, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin regimen
Macrophage colony-stimulating factor
clinical outcome with, 1647
hematologic effect of, 1646-1647
in metastatic cancer, 1643-1649
pharmacokinetics of, 1646-1647
toxicity of, 1645-1646
treatment duration with, 1644-1645
Marked mononuclear cell reaction, in relapsed breast cancer, 476-479
Marker
breast cancer, assays for, 1058-1059
serum, for breast cancer mucin, 1057-1065
Mastectomy
complications of, 980
emotional adjustment and, 1292-1298
lumpectomy plus radiation *v*, 976-983
lumpectomy *v*, 1292-1298
psychologic measures in, 1294
psychologic well-being in, 1295-1297
M-CSF, *see* Macrophage colony-stimulating factor
Mechlorethamine, in combination chemotherapy, for NHL, 1949-1954
Mechlorethamine, vincristine, procarbazine, prednisone regimen
administration of, 391
in childhood HD, 1602-1608
dosing of, 391
in early-stage HD, 378-382
GM-CSF following, 390-397
radiotherapy *v*, 378-382
Medical complications, risk assessment for, 319
Medroxyprogesterone acetate
in advanced breast cancer, 1176-1182
bioavailability of, 1179-1180
concentration of, disease response and, 1178
dosing of, 1181
side effects of, 1180
toxicity of, 1179
Melanoma
chemoimmunotherapy for, 1338-1343
cisplatin plus interferon-alpha for, 1574-1578
dacarbazine, vincristine, bleomycin, lomustine, interferon-alpha regimen for, 1919-1926
immunotherapy of, HLA phenotype and, 1158-1164
malignant, retinoids in, 851-852
technetium 99m-labeled monoclonal antibody in, 1301-1337
TNF, interferon gamma, melphalan regimen for, 52-60
tumor-infiltrating lymphocytes for, 189
vaccine for
clinical response to, 1160
HLA phenotype and, 1158-1164
lymphocyte phenotyping following, 1159
phenotyping cell lines in, 1159

Melphalan
in combined modality therapy, for multiple myeloma, 1769-1774
high-dose
clinical outcome following, 49-50
consolidation, 48-49
in multiple myeloma, 47-51
primary, 48
toxicity of, 49-50
prednisolone plus
dose intensity of, 336
in multiple myeloma, 334-342
Melphalan, interferon gamma, TNF regimen
for melanoma, 52-60
response to, 56-58
for sarcoma, 52-60
systemic side effects of, 55-56
toxicity of, 55
Memorial Sloan-Kettering, osteosarcoma chemotherapy at, 5-15
Meningeal malignancies, intrathecal diaziquone in, 143-148
Mesna
in combination chemotherapy, IL-3 following, 1131-1140
ifosfamide plus, in ovarian cancer, 243-248
Mesothelioma, malignant
epirubicin in, 824-828
following pleurectomy, 1001-1006
intrapleural cisplatin plus mitomycin for, 1001-1006
Metastatic cancer, M-CSF in, 1643-1649
Methotrexate
in acute lymphoblastic leukemia, 810-817
in combination chemotherapy
for breast cancer, 1848-1856
c-*erb*B-2 positivity and, 1049-1056
for NHL, 1949-1954
for osteogenic sarcoma, 13
for stage IV breast cancer, 1743-1747
in head and neck cancer, 1245-1251
high-dose, for osteogenic sarcoma, 13-14
intravenous, sex and, 810-817
IQ and, 813-814
in LNH-84 regimen, for relapsing lymphomas, 1615-1623
nonhematologic toxicity of, 1248
pharmacokinetics of, following carboxypeptidase-G2, 1359-1364
Methotrexate, doxorubicin, cisplatin regimen
brief intensive, for osteosarcoma, 1579-1591
hematologic toxicity of, 1587
nonhematologic toxicity of, 1587
toxicity of, 1586-1587
Methotrexate, fluorouracil, doxorubicin, leucovorin regimen
in gastric cancer, 541-548
survival following, 546
toxicity of, 544-545
Methotrexate, fluorouracil, leucovorin regimen
in colorectal cancer, 904-911
toxicity following, 908
Methotrexate, ifosfamide, etoposide, asparaginase, cytarabine regimen, in lymphoma, 1615-1623
Methotrexate, leucovorin, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin regimen, in diffuse large-cell lymphoma, 219-227

Methotrexate, radiotherapy, cytarabine regimen
in primary CNS lymphoma, 635-643
toxicity of, 639-640
Methotrexate, vinblastine, doxorubicin regimen, in urothelial carcinoma, 1066-1073
Methylprednisolone
in combination chemotherapy, for HD, 1086-1094
in LNH-84 regimen, for relapsing lymphomas, 1615-1623
MGI 209, for oral ulcer pain, 1963-1968
Microparticle enzyme immunoassay, for breast cancer mucin, 1057-1065
Mitomycin
area-under-the-curve for, 1004
half-life for, 1004
intrapleural cisplatin plus, for malignant mesothelioma, 1001-1006
Mitomycin, vindesine, cisplatin regimen
chemotherapy complications of, 582-583
clinical response to, 581
hematologic toxicity of, 582
nonhematologic toxicity of, 582
for NSCLC, 580-586
pathologic response to, 581
renal toxicity of, 582
surgical complications of, 581-582
survival following, 583
toxicity of, 581-582
Mitoxantrone
acute promyelocytic leukemia associated with, 1430-1435
in combination chemotherapy, for NHL, 228-236
cytarabine plus, 43
Mitoxantrone, cytarabine, quinine regimen
hematologic toxicity of, 1733
myelosuppression due to, 1732-1733
nonhematologic toxicity of, 1734
nonhematopoietic cytotoxicity due to, 1733
in refractory acute leukemia, 1730-1736
Mixed lymphocyte reaction, monitoring of, 1154
Monoclonal antibody(ies)
in acute myeloid leukemia phenotyping, 1420
anti-T12
in GVHD prevention, 1191-1200
toxicity associated with, 1194-1195
binding of, immunocytochemical analysis of, 737
generation of, for ELISA, 1437
in lesion radioimmunodetection, 1332-1334
99m-labeled, in cutaneous malignant melanoma, 1330-1337
Monoclonal antibody 2E11, in bone marrow tumor cell detection, 1534-1539
Monoclonal antibody HMB-45, 1331, 1334
Monoclonal antibody imaging, in cutaneous malignant melanoma, 1330-1337
Monoclonal antibody L6
IL-2 plus
phase I trial of, 1470-1478
treatment plan for, 1472
toxicity of, 1473
Monoclonal antibody MB-1
dosing of, 1702-1703
HAMA assay of, 1699
hematologic toxicity of, 1703
Monoclonal antibody MB-1 (*Continued*)
iodination of, 1697-1698
pharmacokinetics of, 1701-1702
preparation of, 1697
radiolabeled, administration of, 1698
toxicity of, 1699
in tumor imaging studies, 1698-1699
tumor responses to, 1704-1705
Monoclonal antibody MRK16, for P-glycoprotein detection, 1732
Monoclonal antibody NR-ML-05, 1330-1337
Monoclonal antibody S-100, 1334
Monocyte, peripheral-blood, as interleukin-1 beta assay, 1269
Monocyte activation, following liposomal muramyl tripeptide, 1313-1314
MOPP, *see* Mechlorethamine, vincristine, procarbazine, prednisone regimen
MOPP-ABV(D) regimen, in HD, relapse following, 204
MRK16 monoclonal antibody, for P-glycoprotein detection, 1732
MSKCC T10 study, 14
Mucin, breast cancer, microparticle enzyme immunoassay, 1057-1065
Multiattribute Health Status Classification System, 924
Multidrug resistance
etoposide plus cyclosporine modulation of, 1624-1634, 1635-1642
quinine for, 1730-1736
Multiple myeloma
busulfan plus cyclophosphamide in, 1492-1497
combination chemotherapy in, 334-342
combined modality therapy for, 1769-1774
evolution of, 588
hemibody radiotherapy plus chemotherapy in, 1769-1774
high-dose melphalan in, 47-51
melphalan plus prednisolone in, 334-342
prognosis for, 47
retinoids in, 850
Muramyl tripeptide phosphatidylethanolamine
clinical toxic effects of, 1311
C-reactive protein following, 1313
IL-6 following, 1312
interferon-gamma following, 1313
monocyte activation following, 1313-1314
neopterin following, 1313
in osteosarcoma, 1310-1316
tumor necrosis factor-alpha following, 1312
Murine tumor
IL-2 plus LAK cells for, 182
IL-2 therapy for, 181
Mycosis fungoides
interferon alfa-2a plus pentostatin in, 1907-1913
retinoids in, 850
Myelodysplastic syndrome, retinoids in, 849-850
Myeloid antigen expression, in childhood acute myeloid leukemia, 1421
Myeloma
allogeneic BMT in, 1492-1497
G-CSF plus etoposide for, 1955-1962
GM-CSF plus etoposide for, 1955-1962
high-dose busulfan for, 1569-1573
multiple, *see* Multiple myeloma
Myeloma protein level, radiotherapy and, 588

Myelomonocytic cell functions, GM-CSF and, 1273
Myelosuppression
due to IL-3, 1134-1136
due to mitoxantrone, cytarabine, quinine regimen, 1732-1733
radioimmunotherapy and, 1703

N-(phosphonacetyl)-L-aspartic acid, bolus 5-FU plus, 747-752
Natural-killer cell, activity of, antibody-dependent cellular toxicity and, 1475
Nausea
following carboplatin plus cylophosphamide, 713
following cisplatin plus cylophosphamide, 713
following cyclosporine plus etoposide, 1627
following etoposide, 1627
ondansetron for, 1969-1975
Neck cancer, *see* Head and neck cancer
Neomycin phosphotransferase marker gene, 190-191
Neopterin, following liposomal muramyl tripeptide, 1313
Nephrotoxicity, due to chemotherapy, 574-579
Neural tissue, platinum concentration in, 796-797
Neuroblastoma
chemoresistant, iodine 131 metaiodobenzylguanidine in, 1889-1896
etoposide plus carboplatin in, 1592-1601
incidence of, in North America, 323-329
Italian Cooperative Group staging for, 1871
pediatric, limited postoperative chemotherapy for, 1299-1304
peptichemio plus cisplatin in, 1870-1878
retinoids in, 852-853
surgical staging in, 1300
Neuroendocrine carcinoma, of prostate, hypercalcemia and, 499-505
Neurotoxicity
of cisplatin, 795-803
due to high-dose cytarabine, 948-953
sex and, in acute lymphoblastic leukemia, 810-817
Neutropenia, risk assessment for, 316-322
NHL, *see* Non-Hodgkin's lymphoma
Nitrosourea resistance, combination chemotherapy for, 766-771
Non-Hodgkin's lymphoma
in AIDS
immunophenotype of, 386-387
molecular classification of, 386
AIDS-associated polyclonal EBV-negative, 383-389
autologous *v* allogeneic BMT for, 1690-1695
2-chlorodeoxyadenosine for, 371-377
combined modality therapy in, 936-941
elderly patients with, combination chemotherapy for, 228-236
IL-2 plus LAK cells in, 33-40
prednisone, methotrexate, doxorubicin, cyclophosphamide, etoposide, mechlorethamine, vincristine, procarbazine regimen in, 1949-1954
previously treated, fludarabine in, 28-32
total body irradiation, etoposide, cyclophosphamide, BMT regimen in, 936-941
Nonseminomatous germ cell tumor(s)
clinical variables in, 89
disease extent summary measures of, 88
histopathology of, 89
markers in, 87-88
poor-risk features in, 90
Nonseminomatous germ cell tumor(s) (*Continued*)
prognostic factors in, 85-94
prognostic groups in, 90-91
stage I, 564-568
staging variables in, 87
of testis, surveillance for, 564-568
treatment of, 86
treatment response in, 87
North America, neuroblastoma incidence in, 323-329
NSCLC, *see* Lung cancer, non–small-cell
NSGCT, *see* Nonseminomatous germ cell tumors

Obesity, in childhood ALL survivors, 128-133
Oncologists, in cancer control, 164-168
Ondansetron, single- *v* multiple-dose, 1969-1975
Opioids
changes over time, 151
for pain, 149-155
pain variables and, 150
relative potencies of, 150
Oral ulcer, pain of, MGI 209 for, 1963-1968
Orchidectomy, for NSGCT, surveillance following, 564-568
Osteogenic sarcoma
chemotherapy protocol for, 10-11
cisplatin for, 13
dosing for, 14
early intensive therapy for, 14
histologic response to, 13
nonmetastatic, chemotherapy for, 5-15
preoperative chemotherapy for, 15
whole-lung irradiation plus doxorubicin for, 459-463
Osteosarcoma
brief adjuvant chemotherapy in, 1579-1591
doxorubicin plus cisplatin for, 1579-1591
liposomal muramyl tripeptide in, 1310-1316
at Memorial Sloan-Kettering, 5-15
methotrexate, doxorubicin, cisplatin regimen for, 1579-1591
multiagent adjuvant chemotherapy for, 1588
Ototoxicity, due to chemotherapy, 574-579
Ovarian cancer
advanced
carboplatin plus cyclophosphamide in, 718-726
cisplatin plus cyclophosphamide in, 718-726
cisplatin-based multimodality therapy of, 1561-1568
prognostic factors in, 532
taxol in, 1748-1753
brain metastases of, 1553-1560
carboplatin in, 520-528
carboplatin plus cyclophosphamide in, 706-717
cisplatin plus cyclophosphamide in, 706-717
cyclophosphamide, cisplatin, radiotherapy regimen in, 727-734
epidermal growth factor receptor in, 529-535
ifosfamide plus mesna in, 243-248
optimal treatment of, 683-685
platinum-resistant, 243-248
refractory, taxol in, 1165-1170
residual, salvage intraperitoneal chemotherapy for, 1479-1484
salvage chemotherapy in, 513-514
sialyl Tn in, 95-101

Ovarian cancer (*Continued*)
stages III and
carboplatin plus cyclophosphamide in, 706-717
cisplatin plus cyclophosphamide in, 706-717
ten-year outcome in, 1561-1568
P-glycoprotein
detection of, monoclonal antibody MRK16 for, 1732
inhibition of, hyperbilirubinemia and, 1624-1634
Pain
at admission, 151
of cancer, 1830-1832
opioids for, 149-155
variables in, 150
PALA, *see* N-(phosphonacetyl)-L-aspartic acid
Pamidronate disodium
in cancer-related hypercalcemia, 134-142
safety of, 138
Paratesticular tumor
chemotherapy of, late effects of, 616-618
radiotherapy of, late effects of, 616
surgery for, late effects of, 616
therapy of
ejaculatory dysfunction following, 617
late effects of, 614-623
Pelvic cancer, radiotherapy in, sucralfate and, 969-975
Pentostatin, interferon alfa-2a plus
administered doses of, 1910
in mycosis fungoides, 1907-1913
in Sézary syndrome, 1907-1913
toxicity of, 1910-1911
Peptichemio, cisplatin plus
in neuroblastoma, 1870-1878
toxicity of, 1874
Peripheral-blood progenitor cell
collection of, 466
impact of, on hematologic toxicity, 468
Peripheral-blood progenitor cell, carboplatin, GM-CSF regimen, 464-473
Phenobarbital, teniposide clearance and, 311-315
Phenotyping, in acute myeloid leukemia, 1420
Phenytoin, teniposide clearance and, 311-315
Plasmacytoma, solitary, of bone, 587-590
Pleurectomy, malignant mesothelioma following, 1001-1006
Ploidy
in acute lymphoblastic leukemia, 606-613
in good-risk node-negative breast cancer, 428-432
Polymerase chain reaction, in acute lymphoblastic leukemia, 1879-1888
Prednimustine, in combination chemotherapy, for NHL, 228-236
Prednisolone
in combination chemotherapy, for lymphoblastic lymphoma, 1078-1085
melphalan plus
dose intensity of, 336
in multiple myeloma, 334-342
Prednisone
in combination with chemotherapy
for breast cancer, 1848-1856
for childhood HD, 1602-1608
for early-stage HD, 378-382
Prednisone (*Continued*)
for HD, 1252-1258
for lymphoblastic lymphoma, 644-646, 1078-1085
in combined modality therapy, for multiple myeloma, 1769-1774
Prednisone, methotrexate, doxorubicin, cyclophosphamide, etoposide, mechlorethamine, vincristine, procarbazine regimen, in NHL, 1949-1954
Procarbazine
in chemoradiotherapy regimen, for recurrent glioma, 766-771
in combination chemotherapy
for childhood HD, 1602-1608
for early-stage HD, 378-382
for HD, 1252-1258
for NHL, 1949-1954
for nitrosourea resistance, 766-771
Progesterone receptor level, in metastatic breast cancer, 1284-1291
Prognostic factor(s)
in acute lymphoblastic leukemia, 606-613
in advanced ovarian cancer, 532
in allogeneic BMT, 784
bone marrow tumor cell detection as, 1534-1539
in breast cancer, 679-682, 686-695, 1046
c-*erb*B-2 as, in breast cancer, 1049-1056
extensive intraductal component as, in relapsed breast cancer, 476
in good-risk node-negative breast cancer, 428-432
in HD, 1255-1256
in head and neck cancer, 260
HER-2 as, in breast cancer, 1044-1048
HER-2-*neu* overexpression as, 601
histologic grade as, in relapsed breast cancer, 476
infiltrating lobular histology as, in relapsed breast cancer, 476-479
in inflammatory breast cancer, 1017
intralymphatic extension as, in relapsed breast cancer, 476
in lymphoblastic lymphoma, 1081-1083
in lymphoma, 1259-1265
in MACOP-B treated diffuse large-cell lymphoma, 219-227
marked mononuclear cell reaction as, in relapsed breast cancer, 476-479
in node-negative breast cancer, 696-705
in NSGCT, 85-94
in ovarian cancer, 529-535, 95-101
in phase II trials, 485
prostate-specific antigen as, 1208-1217
in relapsing lymphomas, 1620
S-phase fraction as, 428-432
sialyl Tn as, in ovarian cancer, 95-101
in soft tissue sarcoma, 1317-1329
in testicular cancer, 1766
tumor necrosis as, in relapsed breast cancer, 476
young age as, in relapsed breast cancer, 476-477
Prostate-specific antigen
determination of, 1209
increase in, patterns of, 1214
prostatic cancer recurrence and, 1211-1213
following radiotherapy, 1208-1217
as tumor marker, 1205-1207
Prostatic cancer
estramustine plus vinblastine in, 1754-1761
hormone-refractory, suramin in, 881-889

Prostatic cancer (*Continued*)
hypercalcemia and, 499-505
neuroendocrine, hypercalcemia and, 499-505
prostate-specific antigen levels in, 1208-1217
recurrence of
local *v* metastatic, 1214
prostate-specific antigen levels and, 1211-1213
retinoids in, 852
serum markers in, 1213
Pulmonary function, following chemotherapy, 576
Pulmonary function test, following whole-lung irradiation plus doxorubicin, 459-463
Pulmonary toxicity, due to chemotherapy, 574-579
Pump, implanted, for floxuridine, complications of, 1114-1115
Purine analogs
clinical results with, 353
therapeutic contest of, 352-355

Quality of life
assessment of, 1827-1829
in breast cancer chemotherapy, 1833-1838
Quality-of-life scores
changes in, 1835
evaluation of, 1833-1834
in breast cancer chemotherapy, 1833-1838
prognostic value of, 1834
survival prediction by, 1833-1838
Quinine
for acute multidrug resistance, 1730-1736
dosing of, 1731
in refractory acute leukemia, 1730-1736
serum concentration of, 1731-1732
serum levels of, 1733-1734

Radiation
in combined modality therapy, for rectal cancer downstaging, 79-84
complications of, 980
conservative surgery plus, in early-stage breast cancer, 356-363
external, cosmesis and, 361
iododeoxyuridine plus, complications of, 266-267
lumpectomy plus
improving outcome with, 349-351
*v* mastectomy, 976-983
technique for, in early-stage breast cancer, 356-363
whole-abdominal, in advanced ovarian cancer, 727-734
whole-brain, IQ score following, 1390-1396
Radioimmunodetection, monoclonal antibodies for, 1331
Radioimmunoprecipitation, for c-*erb*B-2, 1437
Radioimmunotherapy
myelosuppression and, 1703
toxicities associated with, 1704
Radioimmunotherapy imaging, in B-cell lymphoma, 1696-1711
Radiosurgery
applications for, 1373-1374
for glioblastoma multiforme, 1382
for malignant glioma, 1379-1385
morbidity associated with, 1384
stereotactic brachytherapy and, 1384

Radiotherapy
acute promyelocytic leukemia associated with, 1430-1435
alternating chemotherapy and, in SCLC, 448
chemotherapy and, in SCLC, 1526
chemotherapy *v*, in early-stage HD, 378-382
combination chemotherapy plus, in limited-disease SCLC, 1230-1236
in combined modality therapy
for brain metastases, 1553-1560
for esophageal cancer, 1037-1043
for primary CNS lymphoma, 635-643
conservative surgery plus, breast cancer relapse following, 474-483
consolidation hemibody, in multiple myeloma, 1769-1774
diarrhea due to, sucralfate for, 969-975
dose of, clinical outcome and, 588
doxorubicin plus
for osteogenic sarcoma, 459-463
pulmonary function tests following, 459-463
in Ewing's sarcoma, 1409
extended-field, in early-stage HD, 378-382
four-field technique of, 1209
high- and low-dose, in pediatric HD, 929-935
of inflammatory breast cancer, 1017-1018
initial, in esophageal cancer, 1038
late effects of, in rhabdomyosarcoma, 616
low-dose, in childhood HD, 1602-1608
myeloma protein level and, 588
neoadjuvant chemotherapy plus, in stage IIIA NSCLC, 832-833
postoperative 5-FU plus leucovorin and, 1218-1224
preoperative 5-FU plus leucovorin and, 1218-1224
preoperative, in stage III NSCLC, 832
prostate-specific antigen following, 1208-1217
reduced chemotherapy plus, in childhood HD, 1602-1608
in SCLC, 890-895
for solitary bone plasmacytoma, 587-590
in stage III NSCLC, 830-831
survival following, for solitary bone plasmacytoma, 588-589
targeting, in chemoresistant neuroblastoma, 1889-1896
in triple-modality therapy, for NSCLC, 1237-1244
toxicity of, 1220, 1565
vincristine, melphalan, cyclophosphamide, prednisone regimen plus, 1769-1774
Radiotherapy, cisplatin, cyclophosphamide regimen
gastrointestinal toxicity following, 731
hematologic toxicity following, 730-731
infectious complications due to, 732
neurologic toxicity following, 731
in ovarian cancer, 727-734
survival following, 730
Radiotherapy, fluorouracil, semustine regimen
disease recurrence following, 553-554
mortality following, 554-555
in rectal cancer, 549-557
toxicity of, 552-553
Rectal cancer
chemoradiotherapy in, 549-557
combined modality therapy of, 79-84, 1218-1224
5-FU plus leucovorin in, for radiation-induced downstaging, 79-84

Rectal cancer (*Continued*)
postoperative 5-FU plus leucovorin in, 1218-1224
preoperative 5-FU plus leucovorin in, 1218-1224
radiotherapy, 5-FU plus, semustine regimen in, 549-557
semustine in, 549-557
Relapse, definition of, 1683
Renal cell carcinoma
IL-2 plus interferon alfa-2a in, 414-421, 1124-1130
IL-2 plus LAK cells in, 275-281, 960-968
interferon alfa-2b in, 1153-1157
metastatic
active outpatient regimen in, 414-421
continuous infusion IL-2 in, 753-759
subcutaneous IL-2 in, 1119-1123
Renal function, following chemotherapy, 576
Residual volume, following whole-lung irradiation plus doxorubicin, 460-462
Response, definition of, 1683
Retinoic acid
apoptosis and, 846-847
in combination, for differentiation, 845-846
differentiation induction by, 843-844
direct growth inhibition by, without differentiation, 844-845
gene transcription changes and, 842-843
nuclear receptors of, 841-842
paracrine-mediated growth inhibition and, 845
preclinical studies of, 843-847
Retinoids
absorption of, 839
in acute myelocytic leukemia, 849
in acute promyelocytic leukemia, 848-850
in basal cell carcinoma, 851
in bladder cancer, 853
in breast cancer, 852
in cancer therapy, 839-864
cellular mechanisms of, 841
clinical toxicities of, 847-848
clinical toxicity incidence, 847
cytoplasmic binding proteins of, 840-841
future directions in, 853-854
in germ cell tumors, 852
in gliomas, 852
in gynecologic cancer, 853
in head and neck cancer, 850-851
hematopoiesis and, 840
for hematopoietic malignancies, 848-850
immune function and, 840
in juvenile chronic myelogenous leukemia, 850
in lung cancer, 851
in malignant melanoma, 851-852
metabolism of, 840
morphogenetic role of, 840
in multiple myeloma, 850
in mycosis fungoides, 850
in myelodysplastic syndrome, 849-850
in neuroblastoma, 852-853
normal physiology of, 839-840
pharmacokinetics of, 847
in prostatic cancer, 852
in sarcomas, 852
for specific malignancies, 848
Retinoids (*Continued*)
structure of, 839-840
synthesis of, 840
transport of, 839-840
Retroperitoneal lymph node dissection, postchemotherapy, in testicular cancer, 569-573
Rhabdomyosarcoma
paratesticular, therapy effects in, 614-623
treatment regimens for, 615
RNA blot analysis, messenger, 955

S-phase fraction, in good-risk node-negative breast cancer, 428-432
Sarcoma
osteogenic, *see* Osteogenic sarcoma
retinoids in, 852
soft tissue
clinicopathologic staging for, 1317-1329
distant metastasis development in, 1319-1323
local recurrence in, 1323-1324
metastasis development in, 1324
of extremity, 1317-1329
postmetastasis survival in, 1324-1325
tumor mortality in, 1319-1323
TNF, interferon gamma, melphalan regimen for, 52-60
Scintigraphy, of indium-111–labeled immunoglobulin G, 61-68
SCLC, *see* Lung cancer, small-cell
Second malignancy
acute lymphoblastic leukemia as, 156-163
following rhabdomyosarcoma therapy, 619
following SCLC diagnosis, 1525-1533
in SCLC, 1511-1513, 1519-1524
Semustine, in chemoradiotherapy, for rectal cancer, 549-557
Serum lipids, following IL-3, 1137-1138
Sex
5-FU clearance and, 1171-1175
neurotoxicity and, in acute lymphoblastic leukemia, 810-817
Sézary syndrome, interferon alfa-2a plus pentostatin in, 1907-1913
Short stature, in childhood ALL survivors, 128-133
Sialyl Tn, in ovarian cancer, 95-101
Sodium thiosulfate, in postoperative combination chemotherapy, for gastric cancer, 1933-1942
Solid tumors, busulfan, cyclophosphamide, BMT regimen for, 1857-1864
Spinal cord compression
lung cancer and, 1781-1787
symptoms of, 1783
treatment of, 1783-1784
Stereotactic brachytherapy, radiosurgery and, 1384
Sucralfate
administration of, 970
following radiotherapy, 969-975
Suramin, 875-877
concentration of, 1791
in hormone-refractory prostatic cancer, 881-889
loading regimens of, 1789
pharmacokinetic data for, 1789
scheduling of, 1788-1794
toxicities of, 886
Surgery
in combined modality therapy
for brain metastases, 1553-1560
for esophageal cancer, 1037-1043

Surgery (*Continued*)
conservative
breast cancer relapse following, 474-483
radiotherapy plus, in early-stage breast cancer, 356-363
in Ewing's sarcoma, 1408-1409
in inflammatory breast cancer, 1017
late effects of, in rhabdomyosarcoma, 615-616
mastectomy *v* lumpectomy, in breast cancer, 1292-1298
neoadjuvant chemotherapy plus, in stage IIIA NSCLC, 833-834
postchemotherapy retroperitoneal, in testicular cancer, 569-573
radio, *see* Radiosurgery
in rectal cancer, 5-FU plus leucovorin prior to, 1218-1224
in stage IIIA NSCLC, 831
in triple-modality therapy, for NSCLC, 1237-1244
Surgical staging, in pediatric neuroblastoma, 1300
Surveillance, for stage I testicular cancer, 1762-1768
Survivors, of cancer, classifying health status of, 923-928

T lymphocyte, CD6-positive
in GVHD prevention, 1191-1200
toxicity associated with, 1194-1195
TAG12, 1534-1539
Tamoxifen
in combination chemotherapy, for breast cancer, 1848-1856
cosmesis and, 362
estrogenic metabolites of, 990-994
levels of, in tamoxifen-resistant tumors, 304-310
in metastatic breast cancer, progesterone receptor level following, 1284-1291
resistance to, 304-310, 990-994
Taxol
in advanced ovarian cancer, 1748-1753
clinical response to, 1750, 1752
dose-limiting toxicity of, 1167-1169
dosing of, 1166
G-CSF plus, in refractory ovarian cancer, 1165-1170
intraperitoneal
efficacy of, 1487-1488
hematologic toxicity of, 1487
local toxicity associated with, 1487
pharmacokinetic analysis of, 1486, 1488-1489
phase I trial of, 1485-1491
treatment plan with, 1486
non–dose-limiting toxicity of, 1166-1167
ovarian cancer response to, dosing of, 1169
phase II study of, in advanced ovarian adenocarcinoma, 1748-1753
preparation of, 1749
toxicity of, 1751
T-cell lineage, in lymphoma, 1259-1265
Telephone counseling, colposcopy and, 330-333
Teniposide
anticovulsant therapy and, 311-315
doxorubicin plus
in testicular relapse, 624-630
toxicity of, 627
pharmacokinetics of, 311-312
Teratoma
testicular, surveillance for, 1762-1768
undifferentiated malignant, in testicular cancer, 569-573
Testicle, irradiation of, 625

Testicular cancer
British classification of, 70
chemotherapy of, long-term effects of, 574-579
cisplatin in
hypercholesterolemia following, 1386-1389
plasma lipids following, 1609-1614
cisplatin-based chemotherapy in, cardiovascular complications following, 760-765
Friedman and Moore classification of, 69
immunohistochemistry and serum tumor marker correlation in, 74-75
metastatic node of, histology of, 73
pathologic review in, 69-78
postchemotherapy retriperitoneal surgery for, 569-573
predictive factors in, 571
prelymphadenectomy serum AFP levels in, 75
prognostic factors in, 1765-1766
relapsed, 1765
BMT for, 629
teniposide plus doxorubicin for, 624-630
treatment schema for, 626
stage I
primary tumor histology in, 71-72
surveillance for, 1762-1768
stage II of, primary tumor histology in, 72
staging of, 569-570
tumor recurrence in, 75
Testicular Cancer Intergroup Study, 69-78
Theraccine
clinical response to, 1160
HLA phenotype and, 1158-1164
lymphocyte phenotyping following, 1159
melanoma cell line phenotype in, 1161-1162
phenotyping cell lines in, 1159
Thioguanine
in chemoradiotherapy regimen, for recurrent glioma, 766-771
in combination chemotherapy, for nitrosourea resistance, 766-771
Thiotepa
in combination chemotherapy
for breast cancer, 102-110, 1848-1856
for stage IV breast cancer, 1743-1747
GM-CSF plus
marrow toxicity of, 1354-1355
pharmacokinetics of, 1355
phase I trial of, 1352-1358
toxicity of, 1355
Third National Wilms' Tumor Study, 1305-1309
Thoracic irradiation
chemotherapy plus, in SCLC, 892
mortality associated with, 894
in SCLC, 890-895
2-year survival in, 893
Thrombocytopenia
duration of, following GM-CSF, 1463-1464
peripheral-blood progenitor cell infusion and, 471-472
T-lymphoid antigen, in acute myeloid leukemia, 1421
TNF, *see* Tumor necrosis factor
Topotecan
administration of, 648
dosage of, 648

Topotecan (*Continued*)
follow-up studies with, 648-649
hematologic toxicity of, 650-651
nonhematologic toxicity of, 651-652
pharmacologic study of, 647-656
pharmacokinetics of, 652-653
pharmacologic analyses of, 649
phase I trial of, 647-656
responses to, 652
Total body irradiation, in combined modality therapy, for lymphoblastic lymphoma, 644-646
Total body irradiation, etoposide, cyclophosphamide, BMT regimen, in resistant NHL, 936-941
Total lung capacity, following whole-lung irradiation plus doxorubicin, 460-462
Toxicity, criteria for, autologous BMT and, 1715-1716
Triglyceride level, plasma, following cisplatin therapy, 1612
Tumor necrosis, relapsed breast cancer and, 476
Tumor necrosis factor
assay for, 632, 955
in chronic myelogenous leukemia, 631-634
via isolation perfusion, 52-60
Tumor necrosis factor-alpha
in hairy cell leukemia, 954-959
following liposomal muramyl tripeptide, 1312
serum levels of, 956
Tumor necrosis factor, interferon gamma, melphalan regimen
for melanoma, 52-60
for sarcoma, 52-60
response to, 56-58
systemic side effects of, 55-56
toxicity of, 55
Tumor-infiltrating lymphocytes, 185-189
genetic modifications of, 193
IL-2 plus, 186
for melanoma, 189
TNF-gene modified, administration of, 194
in vitro studies of, 188

Urothelial carcinoma
cisplatin in, 1066-1073
methotrexate, vinblastine, doxorubicin regimen in, 1066-1073

Vaccine, for melanoma
clinical response to, 1160
HLA phenotype and, 1158-1164
lymphocyte phenotyping following, 1159
phenotyping cell lines in, 1159
Venous catheter, complications with, 1943-1948
Verbal memory, cranial irradiation dosing and, 810-817
Vinblastine
in combination chemotherapy
for childhood HD, 1602-1608
for HD, 1252-1258
Vinblastine (*Continued*)
for poorly differentiated carcinoma, 912-922
for urothelial carcinoma, 1066-1073
cumulative doses of, 576
estramustine plus
hematologic toxicity of, 1757
in prostatic cancer, 1754-1761
therapeutic activity of, 1756-1757
toxicity of, 1757-1758
long-term effects of, 574-579
in triple-modality therapy, for NSCLC, 1237-1244
Vinblastine, doxorubicin, thiotepa, halotestin, tamoxifen regimen, in breast cancer, 1848-1856
Vincristine
in chemoimmunotherapy, for metastatic melanoma, 1919-1926
in combination chemotherapy
for childhood HD, 1602-1608
for early-stage HD, 378-382
for HD, 1252-1258
for lymphoblastic lymphoma, 1078-1085, 644-646
for NHL, 1949-1954
for SCLC, 818-823
for stage IV breast cancer, 1743-1747
Vincristine, ifosfamide, mesna, carboplatin regimen, IL-3 following, 1131-1140
Vincristine, melphalan, cyclophosphamide, prednisone regimen, radiotherapy plus, in multiple myeloma, 1769-1774
Vindesine
in combination chemotherapy, for NSCLC, 580-586
in LNH-84 regimen, for relapsing lymphomas, 1615-1623
Vindesine, doxorubicin, carmustine, etoposide, methylprednisolone regimen, in HD, 1086-1094
Vomiting
following carboplatin plus cylophosphamide, 713
following cisplatin plus cylophosphamide, 713
following cyclosporine plus etoposide, 1627
following etoposide, 1627
ondansetron for, 1969-1975
Von Willebrand disease, acquired, in Wilms' tumor patients, 422-427

Warfarin, chemoradiotherapy plus, in limited-disease SCLC, 1230-1236
Wilms' tumor
half-dose chemotherapy in, 1305-1309
patients with, acquired von Willebrand disease in, 422-427

Zidovudine, in chemoimmunotherapy, for Kaposi's sarcoma, 1344-1351